Clinical Annotation ID	Evidence ID	Evidence Type	Evidence URL	PMID	Summary	Score
1445117525	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445117525	1444974972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444974972	18212565	Allele T is associated with increased likelihood of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.25
1183705788	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705788	1447635152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635152	17081152	Allele C is associated with Malignant Hyperthermia as compared to allele T.	0.0
1183705788	1447681227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447681227	10097181	Genotype CT is associated with Malignant Hyperthermia and Myopathy, Central Core as compared to genotype TT.	0.0
1183705788	1447961009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961009	25989378	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele T.	0.25
1445400186	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400186	1184511797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511797	1354642	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele G.	0.0
1445400186	1444697813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697813	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1444697969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697969	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1445400662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400662	25989378	Genotypes AG + CG are associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400186	1445400809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400809	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447672542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672542	18564801	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400186	1447674350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674350	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400186	1447948045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948045	19346234	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447960710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960710	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447987329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987329	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400186	1449275206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275206	21804810	Allele C is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele G.	0.25
1139506787	1183689160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689160	23371292	CYP2A6 poor metabolizer genotype is associated with increased ratio of cotinine formation to removal when exposed to nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1183689165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689165	23371292	CYP2A6 poor metabolizer genotype is associated with decreased ratio of plasma cotinine to urinary TNE when exposed to nicotine in smokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1183703333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703333	24448396	CYP2A6 poor metabolizer genotype is associated with decreased metabolism of nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1451663080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451663080	15592323	Genotypes CT + TT are associated with decreased metabolism of nicotine as compared to genotype CC.	0.0
1139506787	1451667320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451667320	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1139506787	1451672860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672860	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1139506787	981201935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981201935	12445030	CYP2A6 *4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	827698978	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698978	15900015	CYP2A6 *1/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.0
1139506787	1447982613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447982613	27035242	CYP2A6 *4/*17 + *9/*26 are associated with decreased metabolism of nicotine.	0.125
1139506787	1450809796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809796	15861035	CYP2A6 *2 + *4 + *9 + *12 are associated with decreased clearance of cotinine and nicotine in healthy individuals as compared to CYP2A6 *1.	2.25
1139506787	1450824161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824161	27599351	CYP2A6 *1/*2 + *1/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	0.0
1139506787	827824861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824861	18360915	CYP2A6 *20 + *26 + *24+ *9 + *27 + *17 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	2.5
1139506787	981344956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344956	22569203	CYP2A6 *4 + *10 + *9 is associated with decreased plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT) when exposed to nicotine in healthy individuals as compared to CYP2A6 *1.	2.75
1139506787	827824877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824877	18360915	CYP2A6 *28 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	1.5
1139506787	1451409603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409603	31959879	CYP2A6 *1/*12 is associated with decreased concentrations of 3-hydroxycotinine as compared to CYP2A6 *1/*1.	1.25
1139506787	1451662800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451662800	10448083	CYP2A6 *4/*4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	1451662880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451662880	11237731	CYP2A6 *7 is associated with decreased metabolism of coumarin or nicotine as compared to CYP2A6 *1.	0.0
1139506787	827827654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827654	15993850	CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1.	This annotation is not used for clinical annotation scoring. In vitro study
1139506787	1451664820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451664820	17112802	CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12 are associated with decreased clearance of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	1.75
1139506787	1451664980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451664980	17220563	CYP2A6 *1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	1.5
1139506787	1451665040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665040	17220563	CYP2A6 *4/*7 + *4/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	This annotation is not used for clinical annotation scoring. VA 1451664980 is from the same paper and has been attached to the same clinical annotations.
1139506787	1451665780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665780	19279561	CYP2A6 *1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*9 + *1/*12.	This annotation is not used for clinical annotation scoring. Score covered by other VA on this paper.
1139506787	1451666180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666180	19365400	CYP2A6 *1/*35 + *9/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	2.75
1139506787	1451666225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666225	19365400	CYP2A6 *35/*35 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	0.0
1139506787	1451666260	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666260	19365400	CYP2A6 *17 + *35 are associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.	0.0
1139506787	1451666264	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666264	19365400	CYP2A6 *24 is not associated with catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.	-0.0
1139506787	827699021	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699021	15900015	CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.	0.0
1139506787	981201993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981201993	11779172	CYP2A6 *4/*4 + *4/*7 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	827827639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827639	15993850	CYP2A6 *1/*20 + *17/*20 are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	0.0
1139506787	827699412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827699412	12844137	CYP2A6 *4/*9 + *9/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 + *1/*4 + *1/*9.	2.5
1139506787	1451822580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451822580	16952495	CYP2A6 *2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	827827796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827796	17267622	CYP2A6 *1x2 is associated with increased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	1451663040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451663040	15265511	CYP2A6 *4/*4 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1 + *1/*46 + *1/*4.	0.125
1139506787	1451665280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665280	19279561	CYP2A6 *1/*46 + *46/*46 are associated with increased metabolism of nicotine as compared to CYP2A6 *1/*1.	This annotation is not used for clinical annotation scoring. Score covered by other VAs from paper
1139506787	1451675720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451675720	21597399	CYP2A6 *1 + *46 + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4.	2.5
1139506787	1451675840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451675840	21597399	CYP2A6 *1 + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *46.	This annotation is not used for clinical annotation scoring. Score for this paper comes from another VA.
1139506787	1451665300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665300	19279561	CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 (assigned as intermediate and low activity phenotype) are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 +*1/*46 + *46/*46 (assigned as normal metabolizer phenotype) .	2.5
1139506787	827705098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827705098	17522595	CYP2A6 *1/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	1448601760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601760	28181923	CYP2A6 *46/*46 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	2.0
1139506787	827705096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827705096	17522595	CYP2A6 *46/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.	1.5
1451434920	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434920	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434920	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434920	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434920	1448256010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256010	27427311	Allele G is associated with risk of Ototoxicity when treated with amikacin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434920	1451436542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436542	10661905	Allele G is associated with increased risk of Ototoxicity when treated with amikacin.	0.25
1445400222	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400222	1447673616	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673616	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele G.	0.0
1445400222	1447674780	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674780	9497245	Genotype GT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1445400222	1445296846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296846	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400222	1445297377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297377	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400222	1447674004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674004	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447674304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674304	10051009	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447675311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675311	17710899	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400222	1447675326	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675326	9389851	Genotype GT is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to genotype GG.	0.0
1445400222	1447948052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948052	19346234	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447952500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952500	16163667	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400222	1447960973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960973	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183689931	1448613202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613202	28112181	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.25
1183689931	982031594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031594	23778326	Genotype AG is not associated with tacrolimus dose-adjusted blood concentration when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-1.0
1183689931	1184470301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470301	24658827	Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1183689931	1185023357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023357	25271728	Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.5
1183689931	1448112417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112417	27314545	Genotype AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype GG.	0.0
1183689931	1183684149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684149	24052064	Genotype AG is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.25
1183689931	1183684036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684036	21903774	Genotype GG is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	2.5
1183689931	1184753642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753642	25141896	Genotypes AA + AG is not associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	-0.75
1183689931	1449171296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171296	29160300	Allele A is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	0.0
1183689931	1184753631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753631	25141896	Genotypes AA + AG is associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	1.25
1183689931	1449163578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163578	29318894	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	This annotation is not used for clinical annotation scoring. No direction given by the authors
1183689931	1451415506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415506	32843687	Allele A is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	1.75
1183689931	1451714346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451714346	33512723	Genotypes AA + AG are associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.5
1183689931	1184470941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470941	24522145	CYP3A4 *1/*1 is not associated with clearance of everolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*22 + *22/*22.	-1.0
1183689931	1185234460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234460	25287072	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.25
1183689931	1444706019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706019	25588704	CYP3A4 *1/*22 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.5
1183689931	1444934293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934293	26067485	CYP3A4 *22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation.	-1.5
1183689931	1448358561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358561	27653228	CYP3A4 *1/*1 are associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*22 + *22/*22.	1.0
1183689931	1448568158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568158	28044353	CYP3A4 *1/*22 + *22/*22 are not associated with metabolism of tacrolimus in children with liver transplantation as compared to CYP3A4 *1/*1.	-0.75
1183689931	1448602351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602351	28050888	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1448603912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603912	28229376	CYP3A4 *1/*22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-0.75
1183689931	1448603998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603998	28229376	CYP3A4 *1/*1 is not associated with trough concentration of tacrolimus in children with Kidney Transplantation as compared to CYP3A4 *1/*22.	-0.75
1183689931	1448641138	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448641138	28342282	CYP3A4 *1/*22 is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A4 *1/*1.	-0.125
1183689931	1448994572	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994572	28704257	CYP3A4 *1/*22 (assigned as poor metabolizers phenotype) is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.25
1183689931	1449161538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161538	29256966	CYP3A4 *1/*20 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.	1.25
1183689931	1449161549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161549	29256966	CYP3A4 *1/*22 + *22/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.	1.25
1183689931	1451118280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118280	31513279	CYP3A4 *22 is associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1183699824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699824	23588314	CYP3A4 *22 is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	-1.0
1183689931	1451250880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451250880	24444408	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1185234509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234509	25287072	CYP3A4 *1/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.75
1183689931	1448635420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635420	28603840	CYP3A4 *22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	-1.25
1183689931	1185234522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234522	25287072	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.25
1183689931	1183698704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698704	23557867	CYP3A4 *1/*18 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.0
1183689931	1449165805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165805	28945481	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*18 + *18/*18.	2.25
1183689931	1447946656	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946656	26770526	CYP3A4 *18 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	2.0
1183689931	1183689729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689729	24189425	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36.	2.25
1183689931	1183689778	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689778	24189425	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.75
1183689931	981843814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981843814	23459029	CYP3A4 *1/*36 + *36/*36 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.5
1183689931	1445584912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584912	26228923	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.0
1183689931	1450928466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928466	31401678	CYP3A4 *36 is not associated with concentrations of tacrolimus in children with proteinuria as compared to CYP3A4 *1/*1.	-1.25
1183689931	1447520683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520683	26227094	CYP3A4 *36 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.25
1183689931	827812461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812461	21635144	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.0
1183689931	1447679078	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679078	26521259	CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.	-0.125
1445400247	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400247	1445296980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296980	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400247	1445297386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297386	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1445400247	1447521378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521378	25611019	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1445400247	1447673898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673898	10484775	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to allele C.	0.0
1445400247	1447673930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673930	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.25
1445400247	1447674392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674392	10612851	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445400247	1447952543	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952543	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445400247	1447960997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960997	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400247	1449275158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275158	29608462	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183701210	827919462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919462	21545408	HLA-A *33:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1183701210	1184747209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747209	21301380	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
1183701210	1184755056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755056	15743917	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1183701210	1184756745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756745	21393610	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
1183701210	1184756788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756788	21393610	HLA-A *33:03 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.5
1183701210	1451721639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451721639	35187976	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	0.0
1183701210	1184467904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467904	21912425	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	0.0
1445400887	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400887	1445124465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124465	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400887	1445297250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297250	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400887	1445297422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297422	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400887	1447522099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522099	19191329	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400887	1447673046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673046	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400887	1447675954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675954	21455645	Genotype AG is associated with risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400887	1447947721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947721	23736090	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to desflurane as compared to genotype GG.	0.0
1445400887	1447960689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960689	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705797	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705797	1447674786	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674786	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705797	1445400831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400831	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705797	1447674039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674039	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705797	1447674469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674469	9497245	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1445400894	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400894	1445124420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124420	25256590	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1445296975	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296975	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1445400849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400849	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447634953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634953	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447672297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672297	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447672461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672461	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1445400894	1447672539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672539	19513315	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to enflurane and succinylcholine as compared to allele G.	0.25
1445400894	1447673865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673865	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447673900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673900	15108991	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447675323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675323	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447675740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675740	8220422	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1445400894	1447947742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947742	21965348	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400894	1447952537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952537	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447960614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960614	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447960991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960991	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1447987537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987537	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
655385400	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
655385400	981239905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239905	22871975	Allele C is not associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to allele T.	-1.5
655385400	1448257102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257102	27488389	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.75
655385400	981477999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477999	23132553	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.	1.5
655385400	981481812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481812	20833655	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	981481830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481830	20833655	Allele T is associated with increased dose of warfarin as compared to allele C.	2.25
655385400	981483967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483967	20653676	Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.	2.0
655385400	981489956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981489956	21084764	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	2.0
655385400	981500599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500599	21127708	Allele C is not associated with dose of warfarin in people with Myocardial Infarction as compared to allele T.	-1.5
655385400	981502925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502925	23215885	Allele T is associated with a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans when treated with warfarin as compared to allele C.	1.75
655385400	981502959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502959	23215885	Allele T is not associated with therapeutic warfarin dose requirement in African-Americans when treated with warfarin as compared to allele C.	-1.75
655385400	981754851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754851	23061746	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	2.0
655385400	982037942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037942	20072124	Allele T is not associated with decreased dose of warfarin as compared to allele C.	-1.5
655385400	982047993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047993	22130800	Genotype CC is not associated with dose of warfarin in children as compared to genotype TT.	-0.75
655385400	769246303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769246303	20442691	Genotype CC is associated with decreased dose of warfarin as compared to genotype CT.	2.0
655385400	827641885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641885	19300499	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	827813045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813045	19741565	Allele C is not associated with stable warfarin dose univariately when treated with warfarin as compared to allele T.	-1.75
655385400	827925134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925134	22528326	Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC.	2.5
655385400	978614465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614465	22676192	Allele T is associated with dose of warfarin.	0.0
655385400	655388324	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388324	20182420	Genotype CC is not associated with decreased required dose of warfarin as compared to genotypes CT + TT.	-0.5
655385400	699638607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638607	18250228	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	3.25
655385400	608431751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431751	19794411	Allele C is associated with dose of warfarin.	0.0
655385400	769182565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182565	21383771	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.5
655385400	827864558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864558	21228733	Allele C is not associated with decreased dose of warfarin as compared to allele T.	-0.5
655385400	1183697697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697697	23990957	Genotypes CC + CT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype TT.	2.25
655385400	1183700033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700033	19207028	Allele T is associated with increased dose of warfarin as compared to allele C.	2.5
655385400	1183700228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700228	19297519	Allele T is associated with increased dose of warfarin as compared to allele C.	2.0
655385400	1183701528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701528	20421126	Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele T.	2.5
655385400	1183704839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704839	24019055	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	3.0
655385400	1183934923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183934923	22010099	Genotype TT is associated with higher mean warfarin daily dose requirement when treated with warfarin in children as compared to genotypes CC + CT.	0.0
655385400	1184472389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472389	20128861	Allele T is not associated with dose of warfarin as compared to allele C.	-1.5
655385400	1184482772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482772	23949431	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	2.75
655385400	1184483813	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483813	23104259	Genotype TT is associated with increased dose of warfarin as compared to genotype CC.	2.25
655385400	1184510039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510039	22549502	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655385400	1184510136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510136	22192158	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	1.75
655385400	1184510155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510155	22172097	Genotype CT is associated with increased dose of warfarin as compared to genotype CC.	2.0
655385400	1184511577	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511577	25042728	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	2.0
655385400	1184511955	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511955	24029542	Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC.	1.0
655385400	1184654456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654456	24330000	Allele T is not associated with increased dose of warfarin in children with Heart Diseases as compared to allele C.	-1.5
655385400	1184748929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748929	25084205	Allele T is associated with increased dose of warfarin.	2.0
655385400	1184756280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756280	25126975	Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele T.	3.0
655385400	1185235744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235744	24601977	Allele C is not associated with dose of warfarin in children as compared to allele T.	-1.25
655385400	1444694633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694633	25594941	Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC.	-1.5
655385400	1445296694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296694	26024874	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	3.5
655385400	1446765933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765933	26257249	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.5
655385400	1447680563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680563	26739746	Allele T is associated with dose of warfarin as compared to allele C.	0.0
655385400	1447952609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952609	26877068	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	3.0
655385400	1447983837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983837	27073641	Allele T is associated with increased dose of warfarin as compared to allele C.	1.0
655385400	1448108296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108296	27262824	Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC.	-0.25
655385400	1448109663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109663	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
655385400	1448268037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268037	22534826	Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes CC + CT.	2.25
655385400	1448275984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448275984	21326313	Genotype CC is associated with decreased dose of warfarin as compared to genotype TT.	0.0
655385400	1448276458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276458	21725053	Allele T is associated with dose of warfarin.	0.0
655385400	1448431513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431513	26223945	Genotypes CC + CT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.	2.5
655385400	1448602262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602262	27938396	Genotypes CT + TT is not associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.	-1.5
655385400	1448615563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615563	28429387	Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	3.0
655385400	1448624178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624178	28550460	Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.	2.0
655385400	1448633907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633907	28620303	Allele T is associated with increased dose of warfarin as compared to allele C.	3.0
655385400	1449005167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005167	29054760	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655385400	1449005218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005218	28262345	Genotypes CC + CT are associated with decreased dose of warfarin as compared to genotype TT.	2.0
655385400	1449190771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190771	29432897	Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
655385400	1449191473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191473	29252193	Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.5
655385400	1449192000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192000	29201113	Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.5
655385400	1449251596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449251596	28049362	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
655385400	1449259246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449259246	27617219	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	1449269209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269209	28973620	Allele T is associated with dose of warfarin as compared to allele C.	0.0
655385400	1449575733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575733	29875668	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
655385400	1450186421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450186421	30506689	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.	1.75
655385400	1450370810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370810	30821933	Allele T is not associated with dose of warfarin as compared to allele C.	-1.0
655385400	827783872	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783872	21174619	CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1.	2.25
655385400	1447682700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682700	26745506	CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.	2.25
655385400	1448276515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276515	26710337	CYP4F2 *3 is associated with dose of warfarin.	0.0
1445400910	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400910	1447673436	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673436	9334205	Allele C is associated with increased sensitivity to caffeine or halothane as compared to allele T.	0.0
1445400910	1447674665	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674665	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1445400910	1445296822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296822	20681998	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele T.	0.25
1445400910	1447674897	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674897	9066328	Genotypes CC + CT are associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype TT.	0.0
1445400910	1447675104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675104	17710899	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype TT.	0.25
1445400910	1447952457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952457	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype TT.	0.25
1183960790	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960790	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960790	1449191784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191784	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960790	1183960714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960714	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981202609	1451258120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451258120	24967362	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	3.0
981202609	769153041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769153041	20847201	Allele C is associated with decreased risk of Disease Activity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.5
981202609	769173673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173673	19193698	Allele C is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.25
981202609	1448266203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266203	27676277	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
981202609	1448589833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448589833	27992285	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	1.625
1449157773	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449157773	1449157754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157754	28527222	Allele A is associated with Malignant Hyperthermia when treated with halothane and succinylcholine as compared to allele G.	0.25
1449157773	1449157786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157786	28326467	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449157843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157843	27663056	Allele A is associated with Rhabdomyolysis and Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160134	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160899	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160930	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160942	25960145	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160948	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160954	19346234	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160960	21455645	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160966	21965348	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449161016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161016	24433488	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705802	1447674795	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674795	9497245	Genotype AG is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705802	1184510579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510579	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705802	1444697633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697633	25466363	Allele A is associated with increased risk of Malignant Hyperthermia, Brain Edema and Brain Ischemia as compared to allele G.	0.25
1183705802	1444697831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697831	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1444697995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697995	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1445124450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124450	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1445198675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445198675	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705802	1445297032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297032	20681998	Allele A is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele G.	0.25
1183705802	1447672429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672429	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447672492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672492	25735680	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447672839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672839	11668625	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447674045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674045	10484775	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447674364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674364	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1447674556	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674556	9497245	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.0
1183705802	1447675343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675343	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1447948701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948701	16244001	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype GG.	0.0
1183705802	1447948711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948711	12709367	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447952506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952506	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype GG.	0.25
1183705802	1447960725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960725	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447960979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960979	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705802	1447961278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961278	19191333	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447987489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987489	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
981239773	981240106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240106	22863269	Genotype GG is associated with lack of treatment response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.	2.0
981239773	981344120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344120	22345656	Genotype TT is not associated with virological response (early, end-of-treatment and sustained virological response) in HCV-5 infected chronic hepatitis C patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotypes GG + GT.	-0.25
981239773	981352170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352170	22438096	Genotype TT is associated with increased response (SVR) in HCV genotype 1 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981352176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352176	22438096	Genotype TT is not associated with increased response (SVR) in HCV genotype 2 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.25
981239773	981352194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352194	22438096	Genotype TT is associated with increased response (SVR) to interferon monotherapy in HCV genotype 1 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981352203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352203	22438096	Genotype TT is not associated with increased response (SVR) to interferon monotherapy in HCV genotype 2 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.75
981239773	981419788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419788	21374656	Genotype TT is associated with rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.75
981239773	981419798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419798	21374656	Genotype TT is not associated with sustained virological response (SVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.75
981239773	981419920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419920	21145807	Genotype TT is not associated with sustained virological response (SVR) rate in HCV genotype 3 patients when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.25
981239773	981419932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419932	21145807	Genotype TT is associated with faster viral elimination (early virologic response) at week 2 or week 4 of antiviral treatment in HCV genotype 3 patients when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	0.0
981239773	981419944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419944	21068134	Genotype TT is associated with sustained virological response (SVR) and changes in viral load after 4 weeks of treatment when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	981479632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479632	21503910	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	981479639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479639	21503910	Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	2.75
981239773	981479677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479677	21739446	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981479690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479690	21739446	Genotype TT is not associated with resistance to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-0.5
981239773	981481540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481540	21048934	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	981481554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481554	21321200	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	2.25
981239773	981481560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481560	21321200	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	2.25
981239773	981481567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481567	21254157	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	981483529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483529	21360545	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.0
981239773	981483541	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483541	21112660	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.0
981239773	981483548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483548	21112660	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	981501236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501236	23133602	Allele T is associated with increased response (SVR and RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G.	2.75
981239773	981934519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934519	23142377	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	1.0
981239773	982031621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031621	21390311	Genotype TT is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.75
981239773	769248378	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769248378	19749757	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	0.0
981239773	827815352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815352	21745312	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	1184136190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136190	24355007	Genotypes GG + GT are associated with increased risk of treatment failure when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.0
981239773	1184136365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136365	24308755	Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.25
981239773	1444668499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668499	24102823	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	1444668556	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668556	24768758	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.5
981239773	1444705115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705115	22328925	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Hepatitis C, HIV Infections and HIV Infections as compared to genotypes GG + GT.	3.0
981239773	1444705133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705133	21466653	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	1.5
981239773	1444705147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705147	21466653	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	1444705254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705254	20060832	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	0.0
981239773	1444705262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705262	20060832	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C.	0.0
981239773	1444705281	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705281	21911885	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1444705313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705313	20434452	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	1444705520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705520	21346780	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.5
981239773	1444705578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705578	19749758	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	0.0
981239773	1444705585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705585	19749758	Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	0.0
981239773	1444705593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705593	19749758	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	0.0
981239773	1444705817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705817	21987611	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT.	2.25
981239773	1444706377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706377	21112657	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.75
981239773	1444706671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706671	22301466	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1444706848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706848	21907615	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.75
981239773	1444707045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707045	21384511	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1444707052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707052	23730840	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT.	1.75
981239773	1444843486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843486	26075078	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1444843578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843578	23281610	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	3.0
981239773	1444843741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843741	26003758	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1445296333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296333	24929144	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1445296808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296808	25278709	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	3.0
981239773	1447676959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676959	25852275	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.25
981239773	1447682270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682270	26825765	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G.	1.5
981239773	1447948073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948073	26699619	Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1447948089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948089	26699619	Genotype TT is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-2.0
981239773	1447951892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951892	26334898	Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.	2.0
981239773	1448995614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995614	21931540	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T.	0.0
981419263	PA166105008	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105008		Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B	100
981419263	PA166265162	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265162		Annotation of DPWG Guideline for carbamazepine and HLA-B	100
981419263	PA166104780	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104780		Annotation of FDA Label for carbamazepine and HLA-B	100
981419263	981349387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349387	18637831	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	2.75
981419263	981349402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349402	15057820	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	981349415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349415	16538176	HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	3.0
981419263	981482101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482101	23132554	HLA-B *15:02:01 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.	1.75
981419263	981859096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859096	17509004	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.	2.75
981419263	981859117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859117	22500513	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	0.25
981419263	994166507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/994166507	23588310	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	2.5
981419263	1183680856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680856	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1183702071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702071	24336023	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
981419263	1183702087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702087	24336023	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	1.75
981419263	1183702093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702093	24336023	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	1.375
981419263	1184407607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407607	19915237	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.5
981419263	1184412194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184412194	20345939	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1184421854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184421854	20833111	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.25
981419263	1184466792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466792	21204807	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184466803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466803	21244392	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184466880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466880	21397523	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1184466899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466899	21424386	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184466933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466933	21676164	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.	2.75
981419263	1184467933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467933	21917426	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
981419263	1184467942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467942	21917426	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	3.25
981419263	1184468042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468042	22053601	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	2.0
981419263	1184468294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468294	22348435	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184468301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468301	22348435	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184468322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468322	23884208	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.0
981419263	1184468379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468379	24225276	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.	1.0
981419263	1184468423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468423	24268988	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184469071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469071	24496695	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	2.5
981419263	1184469086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469086	24394201	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.5
981419263	1184469104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469104	24399721	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1184469192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469192	24322785	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	4.0
981419263	1184469237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469237	24322785	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-3.5
981419263	1184987994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987994	23551241	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.	-1.25
981419263	1184988662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988662	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.75
981419263	1185003386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003386	25266342	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.625
981419263	1185003427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003427	25305458	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.5
981419263	1444707937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707937	25938071	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
981419263	1444707960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707960	25938071	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1446895471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895471	26319500	HLA-B *15:02:01 is associated with Epidermal Necrolysis, Toxic when treated with carbamazepine.	0.25
981419263	1446902307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902307	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1447959759	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959759	27020614	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine in children with schizencephaly.	0.25
981419263	1447980932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447980932	27096699	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.	2.75
981419263	1447983639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447983639	23712814	HLA-B *15:02:01 is associated with risk of Stevens-Johnson Syndrome when treated with carbamazepine in women with Epilepsy.	0.25
981419263	1448261069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261069	25355835	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	2.5
981419263	1448525687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525687	27888155	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.75
981419263	1448635647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635647	28570299	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine.	3.25
981419263	1449004794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004794	29053440	HLA-B *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.5
981419263	1449147028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449147028	29076187	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	0.25
981419263	1184755407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755407	19018717	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	This annotation is not used for clinical annotation scoring. No patients had the allele.
981419263	1451305960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451305960	33356553	HLA-B *15:02:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	981349408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349408	16415921	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	0.25
981419263	1451431060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451431060	33910375	HLA-B *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	-1.0
981419263	1451504120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504120	34553372	HLA-B *15:11:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	2.25
981419263	1451641160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641160	34350628	HLA-B *15:11:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
981419263	1451641227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641227	34350628	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1451780623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451780623	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.	3.75
981202714	769170910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170910	12623934	Allele T is associated with decreased absolute mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.25
981202714	1451341865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451341865	23863317	Genotypes GT + TT is associated with increased response to hydrochlorothiazide as compared to genotype GG.	1.0
981202714	827921263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921263	14553962	Allele T is not associated with response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.	-2.0
981202714	827923882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923882	9149697	Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG.	2.25
981202714	827923903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923903	10523341	Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.75
981202714	827923924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923924	11882573	Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.75
981202714	827924535	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924535	19057513	Allele T is associated with decreased reduction in ambulatory SBP when treated with hydrochlorothiazide in men with Hypertension as compared to allele G.	0.0
981202714	827924748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924748	18591455	Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	3.0
981204044	PA166104938	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104938		Annotation of DPWG Guideline for acenocoumarol and VKORC1	100
981204044	1184754659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754659	23774941	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	0.0
981204044	1444699595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699595	25519826	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.5
981204044	1444705565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705565	23481074	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.0
981204044	1444705842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705842	24956252	Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	3.0
981204044	1444706967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706967	19277427	Genotype TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	1444707179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707179	16611310	Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	981502435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502435	19875892	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	2.25
981204044	981859299	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981859299	22486182	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.25
981204044	981940056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940056	19018719	Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.	2.25
981204044	981954427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954427	22629463	Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.	1.5
981204044	982006724	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006724	23159639	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	3.25
981204044	982006735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006735	23159639	Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.	3.25
981204044	982010028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010028	22486182	Genotype TT is not associated with dose of acenocoumarol as compared to genotype CT.	-1.25
981204044	982010039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010039	22486182	Genotype CC is associated with increased dose of acenocoumarol as compared to genotype CT.	0.0
981204044	982015093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015093	23473641	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	2.5
981204044	982031288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031288	23651023	Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	982031298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031298	23651023	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	827814729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814729	21148049	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.5
981204044	1183680104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680104	24108193	Genotype TT is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotype CC.	2.5
981204044	1184511557	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511557	25042728	Genotypes CT + TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.75
981204044	1448255537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255537	27335128	Genotypes CT + TT are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to genotype CC.	2.0
981204044	1448259259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259259	21636598	Allele T is associated with dose of acenocoumarol or phenprocoumon.	0.0
981204044	1448259324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259324	22911785	Allele T is associated with dose of acenocoumarol.	2.5
981204044	1448259376	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259376	25089947	Genotype CC is associated with increased dose of acenocoumarol in people with Atrial Fibrillation or venous thromboembolism as compared to genotypes CT + TT.	2.0
1447673669	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673669	1447672449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672449	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1447673669	1447952524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952524	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447673759	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673759	1447640254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447640254	19685112	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele C.	0.25
1447673759	1447641258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447641258	19685112	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447644525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644525	16621918	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447645111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645111	16621918	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447673056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673056	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447952930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952930	16732084	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447673759	1449157821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157821	27918309	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to rocuronium and sevoflurane as compared to allele C.	0.25
1447673778	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673778	1447521640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521640	21282829	Allele A is associated with Malignant Hyperthermia and Myopathy, Central Core.	0.0
1447673778	1447645202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645202	16621918	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447673778	1447649057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447649057	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447673778	1447673076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673076	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447673778	1447673879	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673879	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447673778	1447675488	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675488	25960145	Genotype AG is associated with increased risk of Cryptorchidism and Malignant Hyperthermia as compared to genotype GG.	0.0
1447673778	1447675503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675503	25960145	Genotype AG is associated with increased risk of king denborough syndrome, Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1447673778	1447960872	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960872	17483490	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
981475450	1447673749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673749	15737014	Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.	0.25
981475450	981417754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417754	21233402	Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	3.0
981475450	981417766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417766	18596266	Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	2.5
981475450	981475241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475241	18093943	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475253	17085664	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475286	20129249	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475298	19381876	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475337	21430269	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475352	22215752	Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
981475450	981475378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475378	21248300	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.0
981475450	981475801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475801	21921847	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.	0.25
1183705807	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705807	1447674808	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674808	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705807	1184510583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510583	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705807	1444697837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697837	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1444698000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698000	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1445400684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400684	12220451	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447521869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521869	19919814	Allele T is associated with Malignant Hyperthermia and multi-core congenital myopathy as compared to allele C.	0.0
1183705807	1447634887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634887	17081152	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447644820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644820	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447672437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672437	12059893	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705807	1447672498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672498	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447672579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672579	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705807	1447673805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673805	10484775	Genotype CG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705807	1447673851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673851	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674091	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447674246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674246	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674371	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674570	9497245	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype CC.	0.0
1183705807	1447675422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675422	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia, Myopathy, Central Core and Rhabdomyolysis as compared to genotype CC.	0.0
1183705807	1447948638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948638	16244001	Genotype CG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype CC.	0.0
1183705807	1447952512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952512	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447960682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960682	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447960985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960985	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705807	1447987507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987507	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1449160096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160096	25268394	Allele T is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele C.	0.25
1451243980	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1451243980	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1451243980	1451289240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451289240	25889207	Allele C is not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele T.	-1.5
1451243980	1183634232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634232	24080498	Genotypes CC + CT are not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to genotype TT.	-1.75
1451243980	1184473287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473287	24517233	Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections.	2.0
1451243980	1448636199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636199	28692529	Genotype CC is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1451243980	1448993810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993810	26715213	Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.	3.5
1451243980	827707534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707534	21862974	CYP2B6 *6/*6 is associated with increased risk of drug-induced liver injury when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.5
1451243980	1184168515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168515	23734829	CYP2B6 *1 is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV as compared to CYP2B6 *6.	-1.5
1451243980	1448993721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993721	22808112	CYP2B6 *6 is associated with increased risk of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.25
1451243980	1448993746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993746	27333947	CYP2B6 *6/*6 is associated with increased risk of Long QT Syndrome when exposed to efavirenz in healthy individuals as compared to CYP2B6 *1/*1.	1.75
1451243980	1448994067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994067	17686225	CYP2B6 *2/*2 is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.25
1451243980	1449156721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156721	23640958	CYP2B6 *6 + *38 are associated with increased risk of Neurotoxicity Syndromes when treated with efavirenz as compared to CYP2B6 *1/*1.	0.0
1451243980	1449156770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156770	24359841	CYP2B6 *6/*6 is associated with increased likelihood of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1183705817	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705817	1447674814	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674814	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705817	1445297016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297016	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705817	1445297398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297398	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705817	1447645310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645310	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705817	1447672858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672858	11668625	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705817	1447673872	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673872	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705817	1447674260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674260	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705817	1447674312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674312	10051009	Allele T is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to allele C.	0.0
1183705817	1447944287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944287	9450902	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.25
1183705817	1447952558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952558	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705822	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705822	1184511833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511833	10888602	Allele T is associated with risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705822	1447675399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675399	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705822	1447675494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675494	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705822	1447952564	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952564	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705822	1447960630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960630	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705822	1447987628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987628	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705827	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705827	1447521586	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447521586	22415532	Allele A is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.	0.0
1183705827	1447521594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521594	22415532	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele G.	0.25
1183705827	1447672311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672311	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705827	1447672593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672593	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705827	1447952283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952283	9450902	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1183705827	1447960758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960758	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705827	1447961050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961050	14985404	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane as compared to allele G.	0.0
1183705827	1447987608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987608	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400232	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400232	1447644914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644914	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1444697843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697843	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1445297273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297273	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	0.0
1445400232	1447674408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674408	11525881	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1445400232	1447674416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674416	11525881	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400232	1447675461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675461	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400232	1447952518	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952518	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400232	1447952711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952711	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1445400232	1447960739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960739	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1447987517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987517	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183888969	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183888969	PA166104867	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104867		Annotation of FDA Label for telaprevir and IFNL3	100
1183888969	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183888969	981483885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483885	21246582	Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
1183888969	1183888950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888950	24117654	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183888969	1183888954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888954	23321318	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	-2.0
1183888969	1444665865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665865	25393304	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.75
1183888969	1444704894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704894	20648473	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.25
1183888969	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1183888969	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183888969	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183960318	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960318	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960318	982009662	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982009662	23027855	Allele A is associated with increased activity of CFTR when treated with ivacaftor in CFBEo- cells.	0.0
1183960318	1183960311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960311	24081349	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960318	1449191831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191831	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960318	1449192774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192774	28371569	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960318	1183960686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960686	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183617854	PA166105000	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105000		Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6	100
1183617854	1446905865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905865	12360109	CYP2C19 *2/*2 is associated with decreased clearance of doxepin in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183624491	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183624491	PA166104958	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104958		Annotation of DPWG Guideline for pantoprazole and CYP2C19	100
1183624491	1450807008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807008	9433390	Genotypes *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to genotypes *1/*1 + *1/*2 + *1/*3.	0.75
1183624491	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183624491	827789167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827789167	19785625	CYP2C19 *1/*2 is associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183624491	982047471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047471	18664620	CYP2C19 *2/*2 is associated with decreased clearance of pantoprazole in children as compared to CYP2C19 *1/*1.	1.0
1183624491	1447947227	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947227	20223877	CYP2C19 *1/*1 + *1/*17 is associated with increased metabolism of pantoprazole in children as compared to CYP2C19 *1/*2 + *2/*17.	1.5
1183624491	1447947314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947314	22418828	CYP2C19 *17 is associated with increased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1.	1.0
1183624491	1447947325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947325	22418828	CYP2C19 *1/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183624491	1447947333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947333	22418828	CYP2C19 *2/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183624491	1450808617	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808617	11240974	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1451357200	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451357200	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451357200	1451228540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451228540	29950617	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.	3.0
1451357200	1451356526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451356526	20347093	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.25
1451357200	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451357200	1183689628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689628	23708174	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.	-2.0
1451357200	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451357200	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451357200	1448821127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821127	28812116	Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.	3.25
1449156175	1184407551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407551	19104471	HLA-C *04:01:01:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.	-1.75
1449156175	1184482759	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184482759	24911354	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.25
1449156175	1185001907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001907	19845952	HLA-C *04:01:01:01 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV.	0.0
1449156175	1185002071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002071	21505298	HLA-C *04:01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.	3.5
1449156175	1185002228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002228	21902584	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1449156175	1185002808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002808	23362284	HLA-C *04:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	3.5
1449156175	1185002850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002850	23362284	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1449156175	1444697789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697789	25714001	HLA-C *04:01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.	1.0
1449156175	1448925862	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925862	28819312	HLA-C *04:01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	3.5
613978931	1447678164	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678164	26555147	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	2.0
613978931	1447678392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678392	26314341	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	0.0
613978931	981500472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500472	22292851	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
613978931	982023304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023304	22591328	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
613978931	827823984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823984	22188362	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	2.5
613978931	827823998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823998	22188362	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.5
613978931	613978592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978592	15805193	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
1451237200	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451237200	PA166104952	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104952		Annotation of DPWG Guideline for mercaptopurine and TPMT	100
1451237200	1184348827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348827	1960624	TPMT poor metabolizer phenotype is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1451237200	1444705000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705000	25347948	TPMT intermediate metabolizer phenotype is associated with increased likelihood of treatment modification when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT normal metabolizer phenotype.	0.875
1451237200	1444703337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703337	25624441	Genotype CC is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	2.5
1451237200	1447682783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682783	26503813	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.25
1451237200	1449311061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311061	29683944	Genotype TT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	-0.25
1451237200	1449311070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311070	29683944	Genotype GG is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CG.	-0.25
1451237200	981501231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501231	23029095	TPMT *1/*1 is associated with increased dose of mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*3A.	0.0
1451237200	1184134029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134029	20175817	TPMT *2 + *3A + *3B + *3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	0.0
1451237200	1184134089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134089	16202677	TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.5
1451237200	1184134384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134384	17164697	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	0.0
1451237200	1184169832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169832	18987660	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.75
1451237200	1184282060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184282060	20153897	TPMT *1/*3C + *1/*2 + *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.25
1451237200	1184348438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348438	12142782	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184348458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348458	12142782	TPMT *1/*3C is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184467037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467037	9510461	TPMT *3A/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184467044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467044	9510461	TPMT *3A/*3A is associated with decreased dose of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184518608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184518608	21319286	TPMT *1/*3A + *1/*3C + *3A/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1451237200	1184521242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184521242	18467186	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.25
1451237200	1333193294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193294	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	-3.5
1451237200	1448256071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256071	27452984	TPMT *1/*3A is associated with increased likelihood of dose reduction when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.25
1451237200	1448260658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260658	27577869	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1451237200	1448576445	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576445	28146264	TPMT *1/*2 + *1/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1451237200	1449750276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750276	29720126	TPMT *1/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	0.0
1451237200	1356539101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1356539101	25441457	TPMT *1/*3C is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1451237200	1353450854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1353450854	25441457	TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1184661194	982010069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010069	22486182	Genotypes CT + TT are not associated with dose of acenocoumarol as compared to genotype CC.	-1.5
1184661194	981477999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477999	23132553	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.	1.5
1184661194	981954447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954447	22629463	Genotype CC is not associated with decreased dose of acenocoumarol as compared to genotypes CT + TT.	-1.5
1184661194	982010017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010017	22486182	Genotype TT is associated with increased dose of acenocoumarol as compared to genotype CT.	2.0
1184661194	982015210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015210	23510058	Genotype TT is not associated with increased dose of acenocoumarol as compared to genotypes CC + CT.	-1.75
1184661194	655388274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388274	19270263	Genotype CC is associated with decreased dosage requirement when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes CT + TT.	1.75
1184661194	1184511581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511581	25042728	Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC.	2.75
1184661194	1444699605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699605	25519826	Allele T is associated with increased dose of acenocoumarol as compared to allele C.	2.0
1184661194	1444705851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705851	24956252	Genotypes CT + TT are associated with increased dose of acenocoumarol as compared to genotype CC.	3.0
1184661194	1444706936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706936	19578179	Allele T is associated with increased dose of acenocoumarol as compared to allele C.	0.0
1184661194	1444708148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708148	24927344	Genotypes CT + TT is not associated with dose of acenocoumarol as compared to genotype CC.	-1.5
1184661194	1448259328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259328	22911785	Allele T is associated with dose of acenocoumarol.	2.5
1184661194	1449188284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188284	29479633	Allele T is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele C.	2.5
1184661194	1449190771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190771	29432897	Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
1184661194	1450186421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450186421	30506689	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.	1.75
1451275020	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451275020	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451275020	1450950160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450950160	9323575	Genotypes CT + TT are associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	827824632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824632	18600527	Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	1.0
1451275020	827825063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825063	16151913	Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.125
1451275020	827827351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827351	10071185	Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.125
1451275020	827892647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892647	17064846	Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.75
1451275020	1450945160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450945160	9472650	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450945204	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450945204	9472650	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450949680	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450949680	11895907	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450950020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950020	11988088	Genotype CT is associated with increased likelihood of Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.0
1451275020	1450950560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450950560	11953843	Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.0
1451275020	1450950647	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450950647	11953843	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951280	9470816	Genotype TT is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.0
1451275020	1450951440	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951440	28929491	Genotype CT is associated with decreased enzyme activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951521	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951521	8698850	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951541	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951541	26804652	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450952584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952584	10803677	Genotype CT is not associated with decreased activity of DPYD.	-0.0
1451275020	1450953420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953420	16361556	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450955720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955720	20803296	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450960760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960760	9439663	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1451275020	1450964980	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964980	31745289	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1451275020	1445400130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445400130	26216193	Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	2.0
1451275020	1447987751	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987751	23328581	Genotype TT is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype CC.	0.0
1451275020	1448267629	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267629	25410891	Allele T is not associated with activity of DPYD.	-0.0
1451275020	1448605295	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605295	28295243	Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC.	0.0
1451275020	1449165541	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449165541	26967565	Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC.	0.0
655385392	1451589740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589740	31114289	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AC + CC.	2.25
655385392	982038217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038217	21176721	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.5
655385392	981858915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858915	23183958	Genotype GG is associated with increased dose of warfarin in children as compared to genotypes AA + AG.	2.0
655385392	982034232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034232	16270629	Allele A is associated with decreased dose of warfarin as compared to allele G.	0.0
655385392	982035655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035655	18030307	Allele A is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele G.	2.25
655385392	982043321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043321	16821005	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	1.5
655385392	982043330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043330	17031720	Genotype AG is associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.0
655385392	982043353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043353	18240904	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.0
655385392	982045597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045597	18855533	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	0.0
655385392	982045763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045763	19077919	Allele A is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to allele G.	2.5
655385392	982045796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045796	19077919	Genotype AG is associated with a lower risk of time to first INR greater than 3.5, but is not a significant factor in influencing the time to reach stable dose in Korean patients with MHVR when treated with warfarin as compared to genotype AA.	3.0
655385392	982045891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045891	19297219	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	2.75
655385392	982045909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045909	19297219	Allele A is associated with a more rapid attainment of target INR and higher frequency of dose adjustments when treated with warfarin as compared to allele G.	2.5
655385392	982047450	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047450	21273734	Genotype AA is associated with decreased dose of warfarin in children with Heart Diseases as compared to genotypes AG + GG.	1.5
655385392	827567313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567313	15883587	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	827642014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827642014	17329985	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	827647045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827647045	16611750	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.25
655385392	827654491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827654491	17111199	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	827661232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827661232	16432637	Allele A is associated with decreased dose of warfarin as compared to allele G.	3.0
655385392	827845768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845768	22248286	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.75
655385392	655388076	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388076	16676068	Allele A is associated with decreased dose of warfarin.	2.5
655385392	637879816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879816	20203262	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.0
655385392	769277894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277894	15358623	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	1183697705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697705	23990957	Genotypes AA + AG is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype GG.	2.25
655385392	1183699109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699109	19177029	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.75
655385392	1183701330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701330	17989110	Allele A is associated with decreased dose of warfarin as compared to allele G.	0.0
655385392	1183704872	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704872	24019055	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385392	1184169091	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169091	24728385	Genotype AA is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.	2.5
655385392	1184472429	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472429	20128861	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	1184483630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483630	23159229	Genotypes AA + AG is associated with decreased maintenance dose of warfarin when treated with warfarin as compared to genotype GG.	2.75
655385392	1184510021	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510021	22549502	Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	1184510186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510186	22075505	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.25
655385392	1184511615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511615	25026456	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	982037652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037652	17391071	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.5
655385392	1451130683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451130683	31653973	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	1448109658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109658	27121899	Allele A is associated with dose of warfarin as compared to allele G.	0.0
655385392	1448267909	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267909	20585834	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.25
655385392	1448267942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267942	26996562	Genotypes AG + GG are associated with increased dose of warfarin in people with Stroke as compared to genotype AA.	2.0
655385392	1448267977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267977	21981797	Genotype AA is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.	2.0
655385392	1448268060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268060	22534826	Genotypes AG + GG are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.	2.25
655385392	1448275994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448275994	21326313	Genotype GG is associated with increased dose of warfarin as compared to genotype AA.	3.0
655385392	1448276279	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276279	25989350	Allele A are associated with dose of warfarin in people with Stroke.	0.0
655385392	1448431482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431482	26223945	Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.	2.5
655385392	1448601916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601916	27938396	Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.	2.5
655385392	1449005156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005156	29054760	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1449005203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005203	28262345	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1449260063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449260063	27617219	Allele A is associated with decreased dose of warfarin as compared to allele G.	1.75
655385392	1446765916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765916	26257249	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1447519665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519665	18466099	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.25
655385392	1447520081	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520081	26433837	Genotypes AG + GG are not associated with decreased dose of warfarin as compared to genotype AA.	-1.125
655385392	1447573633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447573633	19074728	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	827642001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827642001	17329985	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.0
1451141900	PA166228121	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228121		Annotation of CPIC Guideline for hydrocodone and CYP2D6	100
1451141900	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451141900	1451141860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141860	31969823	CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.	0.25
1451286320	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286320	1447987416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987416	22490566	Genotypes CC + CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
1451286320	1447945633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945633	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451286320	1450954700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954700	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.5
1451286320	1451147880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451147880	32378051	Allele C is associated with increased risk of Diarrhea due to capecitabine in women with Breast Neoplasms as compared to allele T.	2.0
1451286320	1448123245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123245	21498394	Genotypes CC + CT are not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-3.0
1451286320	1448124670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124670	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	-2.0
1451286320	1448124831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124831	24647007	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451286320	1448125094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125094	25677447	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms or gastroesophageal cancer as compared to genotype TT.	-1.5
1451286320	1448262704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262704	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286320	1448994783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994783	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451286320	1449162048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162048	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451286320	1449732013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732013	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451282240	PA166181885	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166181885		Annotation of CPIC Guideline for atomoxetine and CYP2D6	100
1451282240	PA166104989	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104989		Annotation of DPWG Guideline for atomoxetine and CYP2D6	100
1451282240	1183688875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688875	22803597	CYP2D6 poor metabolizers are not associated with clinically significant change in QT(c) when exposed to atomoxetine in healthy individuals.	-0.75
1451282240	1446896699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446896699	25919121	CYP2D6 *3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.	2.5
1451274045	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274045	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451274045	827825073	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827825073	16115930	Genotype AT is associated with decreased catalytic activity of DPYD in peripheral blood mononuclear cells.	0.0
1451274045	827892661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892661	17064846	Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	2.75
1451274045	1450964760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964760	31745289	Allele A is associated with decreased activity of DPYD as compared to allele T.	0.0
1451274045	1444700055	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700055	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.	0.0
1451274045	1447814319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814319	26804652	Genotype AT is associated with increased exposure to fluorouracil in women with Colonic Neoplasms.	0.25
1451274045	1448109745	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448109745	26265035	Genotype AT is associated with decreased activity of DPYD.	0.0
1451274045	1448109863	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448109863	26804652	Allele A is associated with decreased activity of DPYD.	0.0
1451274045	1448124032	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124032	23588312	Genotype AT is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype TT.	-0.0
1451274045	1448126052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448126052	26216193	Genotype AT is not associated with metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.	-1.0
1451274045	1448255178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255178	11988088	Genotype AT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.0
1451274045	1448267635	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267635	25410891	Allele A is not associated with activity of DPYD.	-0.0
1451274045	1448605290	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605290	28295243	Genotype AT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype TT.	0.0
1451287360	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287360	1449161585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161585	29239269	Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.0
1451287360	1447987449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987449	22490566	Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
1451287360	769169640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169640	19104657	Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.	2.75
1451287360	827810914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810914	21498394	Genotypes CC + CT are associated with increased severity of Diarrhea and hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	0.0
1451287360	1444698729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698729	25782327	Genotype CT is associated with increased severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	2.25
1451287360	1447945605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945605	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451287360	1448122697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122697	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451287360	1448123099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123099	20819423	Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	0.0
1451287360	1448124184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124184	23736036	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451287360	1448124647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124647	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-2.0
1451287360	1448124868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124868	24647007	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451287360	1448125103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125103	25677447	Genotypes CC + CT are not associated with risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms and gastroesophageal cancer as compared to genotype TT.	-1.5
1451287360	1448262663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262663	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287360	1448994748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994748	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451287360	1449161605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161605	29239269	Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.	-2.5
1451287360	1449162069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162069	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451287360	1449732006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732006	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451287360	1450371940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371940	30723313	Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	-2.0
1451286326	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286326	1447945626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945626	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286326	1450953025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953025	26603945	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele C.	-1.0
1451286326	1450954660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954660	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451286326	1448123237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123237	21498394	Genotypes CT + TT is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-3.0
1451286326	1448124239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124239	23736036	Genotype CT is associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.0
1451286326	1448124661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124661	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451286326	1448124838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124838	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451286326	1448262697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262697	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286326	1448568402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568402	27995989	Genotype CT is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype CC.	-1.5
1451286326	1448994776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994776	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451286326	1449161763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161763	28427087	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CT + TT.	-2.0
1451286326	1449162040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162040	29065426	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	-2.0
1451286326	1449732020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732020	30114658	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.5
1451290840	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451290840	1444703361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703361	25624441	Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.5
1451290840	1447682392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682392	26405151	Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1451290840	1447682626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682626	26033531	Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1451290840	1447682735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682735	26076924	Genotype CT is associated with decreased dose of azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	2.5
1451290840	1447682776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682776	26503813	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.75
1451290840	1447989193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989193	27095468	Genotypes CT + TT is associated with decreased dose of azathioprine or mercaptopurine.	0.25
1451290840	1447989974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989974	27193222	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.5
1451290840	1448260651	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260651	27577869	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.0
1451290840	1449575844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575844	29923122	Genotype TT is associated with decreased dose of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.	2.5
1451290840	1449749328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749328	28418010	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.75
1451290840	1449750266	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750266	29720126	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	0.0
1451290840	1447945037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945037	26878724	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .	1.625
1451290840	1448576430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576430	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451290840	1448624581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624581	28445187	NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.25
1451290840	1448624596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624596	28445187	NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451290840	1448635204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635204	28659275	NUDT15 *1/*2 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	0.25
1451290840	1449750346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750346	29967377	NUDT15 *1/*3 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 + *1/*5 + *1/*6 + *1/*2.	0.0
1451290840	1449750363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750363	29967377	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.	0.0
1451287240	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287240	1448994618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994618	28481884	Allele G is associated with decreased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele A.	2.0
1451287240	1450953284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953284	20819423	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele A.	-1.0
1451287240	1450954546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954546	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.5
1451287240	1450961080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450961080	21498394	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-3.0
1451287240	1448124639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124639	24590654	Allele G is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A.	-2.0
1451287240	1448124875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124875	24647007	Genotypes AG + GG are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-2.0
1451287240	1448125079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125079	25677447	Genotypes AG + GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1451287240	1448125087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125087	25677447	Genotypes AG + GG is associated with increased risk of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.	1.75
1451287240	1448262652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262652	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287240	1449162062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162062	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1451287240	1449731947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731947	30114658	Genotypes AA + AG is associated with decreased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.0
1451287240	1449732144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732144	29998006	Genotypes AA + AG is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms as compared to genotype GG.	-2.0
1451265780	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1451265780	PA166104964	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104964		Annotation of DPWG Guideline for clomipramine and CYP2D6	100
1451265780	1183683989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683989	2741190	CYP2D6 poor metabolizers are associated with side effects when treated with clomipramine.	0.125
1451265780	981476405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476405	18070221	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	3.5
1451265780	982030065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030065	16871470	CYP2D6 *4/*6 is associated with increased risk of Drug Toxicity when treated with clomipramine and quetiapine in people with Depressive Disorder, Major.	0.25
1451265780	1183616659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616659	15252821	CYP2D6 *1/*4 is associated with increased risk of side effects when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2.	0.25
1451265780	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451265780	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451274984	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274984	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274984	769176388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176388	20819423	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
1451274984	1450950682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950682	19104657	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1451274984	981352330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352330	17000685	Genotype CT is associated with Death when treated with capecitabine in women with Breast Neoplasms.	0.25
1451274984	981352355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352355	20507294	Genotype CT is associated with Death and Drug Toxicity when treated with capecitabine in women with Breast Neoplasms.	0.25
1451274984	982006233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006233	23603345	Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
1451274984	982010242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010242	23585145	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274984	827810882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810882	21498394	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	3.5
1451274984	827823452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823452	19530960	Genotype CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451274984	769166460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166460	17203168	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.25
1451274984	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451274984	1184000475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000475	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-3.5
1451274984	1184471962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471962	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1451274984	1450951380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951380	27454530	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC.	2.5
1451274984	1450951410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951410	27864592	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotype CC.	0.0
1451274984	1450951460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951460	28950804	Genotype TT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC.	0.25
1451274984	1450951504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951504	31382864	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Colonic Neoplasms.	0.25
1451274984	1450951600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951600	27738344	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.25
1451274984	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
1451274984	1450956264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450956264	23736036	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1451274984	1447959056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959056	24923815	Allele T is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
1451274984	1447988460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988460	19795123	Allele T is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274984	1448124202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124202	23736036	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451274984	1448124817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124817	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451274984	1448994797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994797	28481884	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.	2.5
1451274984	1449162076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162076	29065426	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	0.0
1451274984	1449731693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731693	30114658	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	4.0
1451274984	1449732176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732176	29998006	Genotype CT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
1451274984	1450371900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371900	30723313	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451274984	1450373052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373052	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1451666660	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451666660	1451228555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228555	29950617	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	2.5
1451666660	1448612852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612852	28322941	Genotype GT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	0.25
1451666660	1451352522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352522	25673568	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	0.125
1451666660	1451358668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358668	27557342	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	1.75
1451666660	655388369	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388369	16784736	Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes GT + TT.	1.5
1451666660	655388373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388373	19474787	Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.	2.0
1451666660	1183631249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631249	23930675	Genotype TT is associated with increased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype GG.	2.25
1451666660	1184169604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169604	23876492	Allele T is associated with increased plasma concentrations of rosuvastatin as compared to allele G.	1.5
1451666660	1444693893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693893	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.	0.0
1451666660	1451124102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124102	31857620	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	1.5
1451666660	1451141440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141440	32361904	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.	2.25
1451436133	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436133	1444699717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699717	15841390	Allele C is associated with Ototoxicity when treated with gentamicin in children as compared to allele T.	0.25
1451436133	1444699702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699702	15555598	Allele C is associated with Ototoxicity when treated with gentamicin as compared to allele T.	0.25
1451436133	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436133	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451285240	PA166176068	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176068		Annotation of CPIC Guideline for tamoxifen and CYP2D6	100
1451285240	PA166104966	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104966		Annotation of DPWG Guideline for tamoxifen and CYP2D6	100
1451285240	1183703991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703991	24329190	CYP2D6 poor metabolizer is associated with increased risk of Recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1 (assigned as normal metabolizer phenotype) .	0.0
1451285240	1444712493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712493	23100173	CYP2D6 normal metabolizers are not associated with event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	-0.75
1451285240	1444930785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930785	23842856	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1444932944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932944	25091503	CYP2D6 poor metabolizers are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.875
1451285240	1444932970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932970	25091503	CYP2D6 normal metabolizers are associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms.	1.125
1451285240	1444935131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935131	22395643	CYP2D6 poor metabolizers are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1444935762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935762	22395644	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1445402890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402890	22735900	CYP2D6 poor metabolizers are not associated with increased risk of Breast Neoplasms when treated with tamoxifen as compared to CYP2D6 normal metabolizers.	-0.875
1451285240	1445556295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556295	20454926	Genotype *1/*1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *3 + *4 + *5 + *10 + *41.	0.0
1451285240	1445556335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556335	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *4 + *10.	-0.5
1451285240	1445556346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556346	20454926	Genotype *1/*1 (assigned as normal metabolizers phenotype) are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *3 + *4 + *5 + *10 + *41.	-0.5
1451285240	1445556373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556373	20454926	CYP2D6 normal metabolizers are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype *4.	-0.375
1451285240	1445556396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556396	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556415	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556423	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556437	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556444	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556444	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.375
1451285240	1445556502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556502	23712329	Genotype *1/*1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival and overall survival when treated with tamoxifen in women with Breast Neoplasms.	0.875
1451285240	1445556517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556517	23712329	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.5
1451285240	1445556526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556526	23712329	CYP2D6 intermediate metabolizers are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	0.0
1451285240	1445556576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556576	23712329	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.5
1451285240	1445556583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556583	23712329	CYP2D6 poor metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556597	23712329	Genotype *10/*10 (assigned as poor metabolizers phenotype) are not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *1/*1 + *1/*10.	-0.4375
1451285240	1448260933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260933	26681084	CYP2D6 poor metabolizers are not associated with Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.125
1451285240	1448821366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821366	28730340	CYP2D6 poor metabolizer is not associated with likelihood of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.	-1.125
1451285240	1449717459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717459	30022682	CYP2D6 low activity is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 high activity.	1.375
1451285240	769146130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146130	16361630	Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	2.0
1451285240	769146179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146179	19809024	Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.	3.0
1451285240	769146129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146129	16361630	Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	2.0
1451285240	769146144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146144	17244352	Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	0.0
1451285240	769146138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146138	16361630	Allele T is not associated with decreased overall survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.	-1.5
1451285240	827707602	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707602	21880792	CYP2D6 *1 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707600	21880792	CYP2D6 *3 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707609	21880792	CYP2D6 *6 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707615	21880792	CYP2D6 *41 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707613	21880792	CYP2D6 *17 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707607	21880792	CYP2D6 *5 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827813293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813293	21830868	CYP2D6 *4 is not associated with response to antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.75
1451285240	827707604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707604	21880792	CYP2D6 *4 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707611	21880792	CYP2D6 *10 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	1183630771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630771	24060820	CYP2D6 *3/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630816	24060820	CYP2D6 *3/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630822	24060820	CYP2D6 *3/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630834	24060820	CYP2D6 *4/*11 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630840	24060820	CYP2D6 *4/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630846	24060820	CYP2D6 *4/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630852	24060820	CYP2D6 *4/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630858	24060820	CYP2D6 *4/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630894	24060820	CYP2D6 *5/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630900	24060820	CYP2D6 *6/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630906	24060820	CYP2D6 *6/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1444706217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706217	20309015	CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7 (assigned as poor metabolizers phenotype) are associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.	1.75
1451285240	1444708216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708216	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	3.5
1451285240	1444708249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708249	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	-2.0
1451285240	1444708269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708269	19809024	CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	3.0
1451285240	1444708297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708297	19809024	CYP2D6 *1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3 (assigned as heterozygous normal metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451285240	1444708449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708449	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.0
1451285240	1444708481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708481	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	2.5
1451285240	1444708528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708528	18024866	CYP2D6 *1/*4 + *1/*5 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444708545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708545	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.5
1451285240	1444708574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708574	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	2.0
1451285240	1444708609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708609	18024866	CYP2D6 *1/*4 + *1/*5 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444708626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708626	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	-1.5
1451285240	1444708801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708801	15632378	CYP2D6 *3 + *4 + *5 + *6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.75
1451285240	1444709086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709086	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451285240	1444709154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709154	17244352	CYP2D6 *4/*4 is associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	2.5
1451285240	1444709176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709176	17244352	CYP2D6 *4 is not associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-2.0
1451285240	1444709377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709377	20849243	CYP2D6 *4/*4 is not associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	-1.75
1451285240	1444709399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709399	20849243	CYP2D6 *4/*4 is associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	2.0
1451285240	1444709414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709414	16361630	CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	3.0
1451285240	1444709440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709440	16361630	CYP2D6 *4/*4 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	-1.5
1451285240	1444709457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709457	16361630	CYP2D6 *4/*4 is associated with decreased risk of Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	0.0
1451285240	1444709474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709474	20124171	CYP2D6 *1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444709600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709600	22180457	CYP2D6 *4 + *5 + *10 + *14 + *21 + *36 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444709657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709657	22623212	CYP2D6 *4/*4 + *4/*5 + *4/*10 are associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*4.	3.5
1451285240	1444709772	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709772	18294285	CYP2D6 *10/*10 is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	2.75
1451285240	1444709809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709809	19189210	CYP2D6 *4 + *3 + *5 + *10 + *41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1 + *2 + *35.	-1.25
1451285240	1444709919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709919	19189210	CYP2D6 *4/*4 + *4/*41 + *1/*5 + *2/*5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.	1.75
1451285240	1444710214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710214	24682508	CYP2D6 *3 + *4 + *5 + *6 + *10 + *41 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444710290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710290	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	2.75
1451285240	1444710323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710323	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are not associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	-1.5
1451285240	1444710359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710359	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	-1.5
1451285240	1444710610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710610	19596663	CYP2D6 *10/*10 is not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.5
1451285240	1444710646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710646	19596663	CYP2D6 *10/*10 is not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.5
1451285240	1444710956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710956	20574415	CYP2D6 *1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *1/*36 + *1/*41 + *5/*5 + *5/*10 + *5/*21 + *10/*10 + *10/*21 + *21/*41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN.	-1.5
1451285240	1444711469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711469	21437611	CYP2D6 *1/*10 + *1/*41 + *1/*5 + *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-2.0
1451285240	1444711494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711494	21437611	CYP2D6 *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41 + *1/*5.	-1.5
1451285240	1444711544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711544	21437611	CYP2D6 *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41 + *1/*5.	-1.5
1451285240	1444711617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711617	23167378	CYP2D6 *10/*5 + *10/*10 + *10/*41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*36 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *10/*35.	-0.25
1451285240	1444711651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711651	23167378	CYP2D6 *10/*5 + *10/*10 + *10/*41 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*36 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *10/*35.	2.5
1451285240	1444711687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711687	23167378	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	2.5
1451285240	1444712315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712315	16877740	CYP2D6 *4/*4 is associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.	2.5
1451285240	1444712361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712361	24125101	CYP2D6 *3/*4 + *4/*4 + *4/*6 + *6/*6 + *1/*4 + *1/*41 + *4/*41 + *1/*3 + *4/*10 + *3/*41 + *1/*6 + *1/*10 + *10/*10 + *10/*41 + *6/*41 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444712505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712505	25211580	CYP2D6 *1/*4 + *1/*10 + *4/*10 + *10/*10 + *4/*4 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444712582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712582	21823108	CYP2D6 *4/*4 + *3/*4 + *4/*10 + *10/*10 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*1xN.	-1.5
1451285240	1444712614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712614	19156902	CYP2D6 *10/*10 is not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-1.5
1451285240	1444712651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712651	23226070	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.	1.5
1451285240	1444712664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712664	23226070	CYP2D6 *1/*1 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.	2.0
1451285240	1444712685	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712685	23226070	CYP2D6 *10/*10 is not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.25
1451285240	1444712890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712890	17115111	CYP2D6 *4/*4 + *1/*4 are associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.0
1451285240	1444712932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712932	17115111	CYP2D6 *4/*4 + *1/*4 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444712957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712957	17115111	CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.5
1451285240	1444712986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712986	17115111	CYP2D6 *1/*4 is not associated with decreased event-free survival, overall survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444713029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713029	20515869	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.	3.25
1451285240	1444713116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713116	20515869	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 (assigned as normal metabolizers phenotype) .	2.75
1451285240	1444713311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713311	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizers phenotype) .	2.0
1451285240	1444713343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713343	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizers phenotype) .	2.25
1451285240	1444713382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713382	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizers phenotype) .	2.0
1451285240	1444713399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713399	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizers phenotype) .	2.25
1451285240	1444713499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713499	23776391	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	1.5
1451285240	1444930474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930474	23476897	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.	-1.0
1451285240	1444930567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930567	18407954	CYP2D6 *10/*10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.125
1451285240	1444930651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930651	23842856	CYP2D6 *4 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444930760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930760	23842856	CYP2D6 *41 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444930906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930906	21325141	CYP2D6 *4 is not associated with increased likelihood of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444932107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932107	25701109	CYP2D6 *10 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444932596	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932596	20809362	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizers phenotype) .	-2.0
1451285240	1444932651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932651	20809362	CYP2D6 *3 + *4 + *5 + *6 + *7 + *9 + *10 + *41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN + *1/*35 + *2/*2.	-2.0
1451285240	1444932674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932674	20809362	CYP2D6 *3 + *4 + *5 + *6 + *7 + *9 + *10 + *41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN + *1/*35 + *2/*2.	2.75
1451285240	1444932743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932743	20809362	CYP2D6 *4 + *5 + *10 + *41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	0.0
1451285240	1444933205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933205	23570465	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5 are associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1xN/*4 + *1/*1xN + *1/*1 + *1/*41 + *1/*10.	2.25
1451285240	1444933287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933287	23570465	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5 are not associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1xN/*4 + *1/*1xN + *1/*1 + *1/*41 + *1/*10.	-1.5
1451285240	1444933385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933385	21860550	CYP2D6 *5/*10 + *10/*10 + *1/*10 + *1/*5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.	-0.25
1451285240	1444933835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933835	23776391	CYP2D6 *10/*10 is not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-0.25
1451285240	1444933870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933870	23776391	CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizers phenotype) are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *5/*10 + *10/*14 (assigned as intermediate metabolizers phenotype) .	-1.0
1451285240	1444933926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933926	23213055	CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444933959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933959	23213055	CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444933987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933987	23213055	CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444934738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934738	15987423	CYP2D6 *1/*4 + *4/*4 are associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	2.5
1451285240	1444934783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934783	15987423	CYP2D6 *1/*1 is not associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	-1.5
1451285240	1444935174	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935174	22395643	CYP2D6 *4 is not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444935249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935249	22183189	CYP2D6 *10/*10 + *4/*10 + *5/*10 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.25
1451285240	1444935399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935399	19189212	CYP2D6 *4/*4 is associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.25
1451285240	1444935416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935416	19189212	CYP2D6 *1/*4 is not associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444935873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935873	20731819	CYP2D6 *4 + *5 + *9 + *10 + *41 are not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444936265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936265	15952058	CYP2D6 *4/*4 + *1/*4 are not associated with overall survival or progression-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1445400664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400664	24265036	CYP2D6 *3 + *4 + *6 + *14 + *41 are not associated with increased risk of Hot Flashes when treated with tamoxifen in women Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1445558113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558113	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.75
1451285240	1445558158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558158	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-1.0
1451285240	1445558282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558282	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-1.0
1451285240	1444930579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930579	18407954	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *1/*1.	3.0
1451287440	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287440	769176398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176398	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1451287440	1444698773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698773	25782327	Genotype AG is associated with increased severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1451287440	1447945640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945640	26099996	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.75
1451287440	1448122765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122765	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451287440	1448123338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123338	21498394	Genotype AG is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-1.5
1451287440	1448125175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125175	25677447	Genotype AG is associated with increased severity of Stomatitis when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.	1.75
1451287440	1448262714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262714	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287440	1448994790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994790	28481884	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele A.	-1.5
1451287440	1449162083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162083	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1451263877	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263877	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263877	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263877	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263877	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451282340	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1451282340	1445296755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296755	25258374	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.	0.5
1451282340	769245468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245468	21392617	Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.	0.5
1451282340	769245459	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245459	21392617	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.	-1.5
1451282340	769245456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245456	21392617	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282340	769245465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245465	21392617	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	1.75
1451282340	981844125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844125	22265638	Allele A is not associated with decreased platelet inhibition when treated with clopidogrel as compared to genotype GG.	-1.5
1451282340	1447986842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447986842	25730082	Genotypes AA + AG are associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	981344520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344520	22990067	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	-1.75
1451282340	982033044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033044	19463375	Genotype CC is associated with greater platelet inhibition 2 h after a 600-mg dose when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.	1.75
1451282340	982033119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033119	20492469	Genotypes CT + TT are associated with decreased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
1451282340	827815445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815445	22228204	Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
1451282340	827919816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919816	22462746	Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	2.25
1451282340	699638703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638703	20083681	Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	3.0
1451282340	1184469584	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469584	19496924	Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	3.0
1451282340	1184470013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470013	18781853	Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	-1.5
1451282340	1448258619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258619	25060201	Genotypes CT + TT are not associated with response to clopidogrel in people with Acute coronary syndrome.	-1.25
1451282340	981344388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344388	22990067	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981344408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344408	22990067	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	982033598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033598	18346178	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033614	18323861	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	2.0
1451282340	982034226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034226	19576320	Allele A is associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	2.75
1451282340	982034575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034575	21786436	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	2.5
1451282340	982034728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034728	18532997	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982035447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035447	21168310	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	1043765783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043765783	20650435	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	2.5
1451282340	1043818407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818407	20724801	Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.	3.0
1451282340	827919808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919808	22462746	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.25
1451282340	1448258608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258608	25060201	Genotype AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.25
1451282340	981344366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344366	22990067	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981344377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344377	22990067	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981801214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981801214	22427735	Allele A is associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	981802548	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802548	22427735	Allele A is associated with decreased platelet inhibition when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	981843471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843471	22624833	Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	3.5
1451282340	981844053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844053	18004210	Genotypes AA + AG are associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.0
1451282340	981844094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844094	18004210	Genotypes AA + AG are associated with increased residual platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.5
1451282340	982029072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029072	19463375	Allele A is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	1.75
1451282340	982032787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032787	17900275	Allele A is associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to allele G.	1.75
1451282340	982033103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033103	20492469	Genotypes AA + AG are associated with increased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	982033160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033160	18577829	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	1.5
1451282340	982033431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033431	16772608	Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033484	18323861	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	2.0
1451282340	982033525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033525	18346178	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033630	18394438	Allele A is associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282340	982033674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033674	18482659	Genotypes AA + AG are associated with increased risk of high-on clopidogrel platelet reactivity when treated with clopidogrel in patients undergoing elective coronary stent placement as compared to genotype GG.	3.0
1451282340	982034249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034249	19576320	Allele A is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	-1.75
1451282340	982034526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034526	21786436	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	2.5
1451282340	982034621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034621	21426546	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.5
1451282340	982034718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034718	18532997	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982035424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035424	21168310	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	982037635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037635	21831410	Allele A is associated with high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	2.5
1451282340	1029227540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1029227540	19531897	Genotypes AA + AG are associated with increased platelet reactivity when treated with clopidogrel in PCI-scheduled patients as compared to genotype GG.	1.5
1451282340	1043760981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043760981	19624462	Genotypes AA + AG are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel as compared to genotype GG.	2.5
1451282340	1043762214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043762214	20510210	Genotypes AA + AG are associated with increased risk of insufficient antiplatelet response to clopidogrel when treated with clopidogrel in patients undergoing elective coronary stent implantation as compared to genotype GG.	2.0
1451282340	1043765400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043765400	20650435	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	2.5
1451282340	827784087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784087	21881565	Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.	3.0
1451282340	827784103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784103	21881565	Allele A is associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele G.	0.0
1451282340	827787114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787114	22088980	Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	2.75
1451282340	827815433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815433	22228204	Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	827823391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823391	21628721	Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.	3.0
1451282340	827919768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919768	22462746	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.25
1451282340	1183702397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702397	24353446	Genotypes AA + AG is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	1184470005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470005	18781853	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	1184470036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470036	19926050	Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	2.0
1451282340	1184472508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472508	22285300	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.25
1451282340	1444702829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702829	25860557	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	1448258595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258595	25060201	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282340	1449192147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192147	28806186	Genotype AG is associated with increased platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype AA.	2.5
1451282340	1450129827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450129827	30487649	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	0.0
1451282340	981478604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478604	23150151	CYP2C19 *2 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	3.0
1451282340	981478609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478609	23150151	CYP2C19 *3 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	3.0
1451282340	827814107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814107	21806387	CYP2C19 *17 is associated with decreased likelihood of platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	0.0
1451282340	981802868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802868	23470885	CYP2C19 *2 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	2.0
1451282340	981802889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802889	23470885	CYP2C19 *3 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	2.0
1451282340	982023647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023647	23692149	CYP2C19 *2 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	982023653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023653	23692149	CYP2C19 *3 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	982042094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042094	23809542	CYP2C19 *2 is associated with increased post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	3.5
1451282340	982042102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042102	23809542	CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	-3.0
1451282340	982047473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047473	22955794	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	2.0
1451282340	982047486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047486	22955794	CYP2C19 *17 is not associated with increased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	-1.5
1451282340	1043818349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818349	21345843	CYP2C19 *2 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.5
1451282340	1043818357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818357	21345843	CYP2C19 *3 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.5
1451282340	1043818375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818375	21511217	CYP2C19 *2 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.25
1451282340	1043818382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818382	21511217	CYP2C19 *3 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.25
1451282340	1183491857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491857	23428009	CYP2C19 *1/*1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2 + *2/*2.	2.25
1451282340	1183631797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631797	24088578	CYP2C19 *2 is associated with increased On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.0
1451282340	1183631808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631808	24088578	CYP2C19 *3 is associated with increased on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.0
1451282340	1183681446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681446	24019397	CYP2C19 *1/*1 + *1/*17 + *2/*17 + *3/*17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.75
1451282340	1183681642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681642	24019752	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.	1.75
1451282340	1183689255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689255	23001453	CYP2C19 *2 + *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	3.0
1451282340	1183697283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697283	24214141	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1451282340	1183697317	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697317	24214141	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1451282340	1183702381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702381	24353446	CYP2C19 *1/*2 + *2/*2 is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.0
1451282340	1183702492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702492	24336898	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of high platelet reactivity when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	3.0
1451282340	1183703514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703514	22974728	CYP2C19 *2 + *3 is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.25
1451282340	1183704618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704618	23517020	CYP2C19 *1/*2 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282340	1183704627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704627	23517020	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282340	1183704635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704635	23517020	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*2.	2.5
1451282340	1183705597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705597	24535487	CYP2C19 *2 + *3 are associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	2.5
1451282340	1183848900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848900	24576527	CYP2C19 *1/*17 + *1/*2 + *17/*17 + *2/*17 are not associated with platelet aggregation activity as measured by the VerifyNow P2Y12 test when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.0
1451282340	1184168830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168830	23726091	CYP2C19 *1/*2 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282340	1184168844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168844	23726091	CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	0.0
1451282340	1184168856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168856	23726091	CYP2C19 *1/*3 + *3/*3 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-2.75
1451282340	1184168878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168878	23726091	CYP2C19 *1/*17 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-1.75
1451282340	1184348910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348910	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.5
1451282340	1184348932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348932	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.75
1451282340	1184348998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348998	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.	1.0
1451282340	1184349010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349010	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*17 + *17/*17.	0.125
1451282340	1184349199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349199	24418943	CYP2C19 *1/*2 is associated with increased platelet aggregation with ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	1.25
1451282340	1184349853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349853	23895809	CYP2C19 *2 is associated with increased platelet reactivity by P2Y12 reaction units when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.	2.25
1451282340	1184469799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469799	21075428	CYP2C19 *1/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *1/*3.	-1.25
1451282340	1184469816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469816	21075428	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	3.0
1451282340	1184469836	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469836	21075428	CYP2C19 *2/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *2/*3.	-0.25
1451282340	1184469934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469934	19429918	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	1.5
1451282340	1184470291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470291	22045970	CYP2C19 *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.75
1451282340	1184472114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472114	22123356	CYP2C19 *1/*17 + *17/*17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282340	1184472347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472347	22390861	CYP2C19 *2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	3.5
1451282340	1184472379	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472379	22390861	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	-2.0
1451282340	1184473178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473178	23993903	CYP2C19 *2/*2 is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	2.0
1451282340	1184473190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473190	23993903	CYP2C19 *2/*2 + *1/*2 is associated with increased ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	2.5
1451282340	1184987641	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987641	24508947	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1184987661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987661	24508947	CYP2C19 *3 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1444607076	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607076	25542807	CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282340	1444667855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667855	24440142	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451282340	1444667887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667887	24440142	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451282340	1444701698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701698	25832119	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1444701710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701710	25828136	CYP2C19 *2 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-0.25
1451282340	1444701722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701722	25828136	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1451282340	1444702906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702906	25850030	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.25
1451282340	1444704608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704608	24402637	CYP2C19 *1/*2 + *2/*2 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.75
1451282340	1444704692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704692	24856643	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.0
1451282340	1444706389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706389	25891840	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	3.0
1451282340	1444706434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706434	25897911	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.5
1451282340	1444706449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706449	25897911	CYP2C19 *2 + *3 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-1.75
1451282340	1444936339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936339	25712182	CYP2C19 *2/*2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*2.	3.25
1451282340	1444936352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936352	25712182	CYP2C19 *17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	-1.75
1451282340	1445296396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296396	25115434	CYP2C19 *17/*17 + *1/*17 are associated with increased platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1451282340	1445296466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296466	25175362	CYP2C19 *1/*1 is associated with decreased platelet reactivity when treated with clopidogrel in people with as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	3.0
1451282340	1446899066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899066	26265231	CYP2C19 *2 + *4 are associated with decreased response to clopidogrel as compared to CYP2C19 *1 + *17.	3.0
1451282340	1448112663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112663	26526111	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	2.5
1451282340	1448115828	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448115828	26526111	CYP2C19 *17 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	-1.5
1451282340	1448119221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119221	27380588	CYP2C19 *2 + *3 are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.	3.5
1451282340	1448603367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603367	28255319	CYP2C19 *2 is associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448603378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603378	28255319	CYP2C19 *17 is associated with decreased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448631999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631999	28329746	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2.	2.75
1451282340	1448633723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633723	28135763	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448633744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633744	28135763	CYP2C19 *1/*17 is associated with increased platelet aggregation inhibition when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448633755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633755	28135763	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	-1.75
1451282340	1448633804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633804	28135763	CYP2C19 *17 is not associated with response to clopidogrel as compared to CYP2C19 *1/*1.	-1.75
1451282340	1448634286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634286	28604225	CYP2C19 *1/*1 is associated with decreased platelet aggregation when treated with aspirin and clopidogrel in people with Acute coronary syndrome and Myocardial Infarction as compared to CYP2C19 *1/*2 + *2/*2.	2.75
1451282340	1448634534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634534	28589365	CYP2C19 *1 + *17 are associated with decreased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *2.	3.0
1451282340	1449187738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187738	29397568	CYP2C19 *3 is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	3.0
1451282340	1449187754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187754	29397568	CYP2C19 *2 is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282340	1449296254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296254	29653637	CYP2C19 *2 is associated with decreased response to clopidogrel.	3.0
1451282340	1449712939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449712939	30020015	CYP2C19 *2 is associated with increased platelet aggregation when treated with aspirin and clopidogrel as compared to CYP2C19 *1 + *17.	2.0
1451282340	1450253685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450253685	30061570	CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.5
1451282340	1450370841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450370841	29536505	CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .	2.5
1451282340	1450664741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450664741	21689142	CYP2C19 *2/*2 + *2/*3 are associated with increased high on-treatment platelet reactivity when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	0.0
1451282340	1450664799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450664799	21806387	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	2.5
1451274140	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274140	982009671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009671	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype TT.	1.75
1451274140	1444699959	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444699959	24648345	Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.	0.0
1451274140	1447990735	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447990735	24107927	Genotype CT is associated with decreased activity of DPYD as compared to genotype TT.	0.0
1451274140	1448097582	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448097582	16361556	Allele C is associated with decreased activity of DPYD.	0.0
1451666740	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451666740	1450823480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823480	30989645	Allele G is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele A.	2.0
1451666740	982037414	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037414	12891229	Allele T is not associated with response to fluvastatin in healthy individuals as compared to allele C.	-0.125
1451666740	982037405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037405	12891229	Genotype CC is not associated with response to fluvastatin in healthy individuals as compared to genotype AA.	-0.125
1451666740	982037396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037396	12891229	Genotypes CT + TT are not associated with metabolism of fluvastatin in healthy individuals as compared to genotype CC.	-0.125
1451666740	982037386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037386	12891229	Genotype CC is associated with decreased metabolism of fluvastatin in healthy individuals as compared to genotype AA.	1.5
1451666740	1450823485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823485	30989645	CYP2C9 *3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451666740	1451666680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666680	22941809	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451666740	1451666701	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666701	19663817	CYP2C9 *1/*3 is associated with decreased metabolism of fluvastatin as compared to CYP2C9 *1/*1.	0.0
1451666740	1451666721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666721	32373204	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451666740	1450823501	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823501	30989645	CYP2C9 *2 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1444699308	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444699308	1444699562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699562	25515069	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	1.5
1444699308	1444699568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699568	19682603	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	0.25
1444699308	1448256024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256024	27397648	Allele T is associated with risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	0.25
1444699308	1444699253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699253	14681830	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele C.	0.0
1444699308	1444699296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699296	17698299	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1444699308	1444699302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699302	20100600	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials in children as compared to allele C.	This annotation is not used for clinical annotation scoring. Subjects previously reported in PMID 17698299
1444699308	1444699290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699290	17698030	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1444699308	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451285360	PA166104998	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104998		Annotation of CPIC Guideline for nortriptyline and CYP2D6	100
1451285360	PA166104961	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104961		Annotation of DPWG Guideline for nortriptyline and CYP2D6	100
1451285360	1183683958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683958	6111662	CYP2D6 poor metabolizers are associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major.	0.125
1451285360	1444702163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702163	25761838	CYP2D6 poor metabolizers are not associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	-0.875
1451285360	1183615499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615499	15483356	CYP2D6 *5/*10 is associated with increased Constipation, Dizziness and dry mouth when treated with nortriptyline.	0.25
1451285360	1183615525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615525	22389859	CYP2D6 *10/*10 is associated with violent psychosis when treated with nortriptyline.	0.125
1451285360	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451285360	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451155020	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451155020	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451155020	1183617989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617989	8988065	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.	1.5
1451155020	1183684640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684640	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.75
1451155020	1183684653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684653	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of nausea when treated with tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.125
1451155020	1183684657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684657	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.	0.75
1451155020	1183684661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684661	18204346	CYP2D6 normal metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.	0.75
1451155020	1446896368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896368	20488759	CYP2D6 ultrarapid metabolizer genotype is associated with increased metabolism of tramadol.	1.0
1451155020	1449154915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154915	27082504	CYP2D6 deficiency is associated with decreased exposure to o-desmethyl-tramadol in infants with Pain.	0.0
1451155020	1449162774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162774	24709712	CYP2D6 poor metabolizer genotype is not associated with exposure to o-desmethyl-tramadol or tramadol as compared to CYP2D6 normal metabolizer genotype.	-0.0625
1451155020	1449752869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752869	29555325	CYP2D6 ultrarapid metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 normal metabolizer.	0.875
1451155020	1449752878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752878	29555325	CYP2D6 poor metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain and Osteoarthritis as compared to CYP2D6 normal metabolizer.	0.875
1451155020	1451134163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134163	31744222	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of tramadol in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1451155020	1451134168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134168	31744222	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1451155020	1451153020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153020	9476037	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.875
1451155020	1451155560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155560	15906019	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.	0.0625
1451155020	1451155820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155820	17175164	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.5
1451155020	1451207900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207900	24968714	CYP2D6 poor metabolizer is associated with increased exposure to tramadol as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.0625
1451155020	1451230620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230620	30051214	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	0.875
1451155020	1451230640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230640	30051214	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of n-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	0.875
1451155020	1183617999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617999	12893130	CYP2D6 *4 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618008	12893130	CYP2D6 *3 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618016	12893130	CYP2D6 *6 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618024	16368820	CYP2D6 *4/*4 is associated with decreased tramadol metabolism and response when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1451155020	1183678578	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678578	17470523	CYP2D6 *10 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.	0.0
1451155020	1183678588	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678588	17470523	CYP2D6 *17 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.	0.0
1451155020	1183680395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680395	14624403	CYP2D6 *4/*4 is associated with decreased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1451155020	1451154280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451154280	12191703	CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.	1.0
1451155020	1451155780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155780	16763825	CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1451156620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156620	17667796	CYP2D6 *1/*1xN is associated with decreased concentrations of tramadol in healthy individuals as compared to CYP2D6 *1/*2 + *2/*4.	0.125
1451155020	1451157780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157780	18317231	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.	1.75
1451155020	1451157820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157820	18317231	CYP2D6 *1/*1xN is associated with increased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.	1.75
1451155020	1451157920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157920	18520597	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .	1.25
1451155020	1451207940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207940	25560051	CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41 (assigned as normal metabolizer phenotype) .	0.125
1451155020	1451208380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208380	26926096	CYP2D6 *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.	0.0
1451155020	1451229440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229440	29196917	CYP2D6 *10/*10 is associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1 + *2.	1.5
1451155020	1451229484	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229484	29524157	CYP2D6 *5/*5 + *10/*10 are associated with decreased concentrations of n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1 + *2.	0.125
1451155020	1451229680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229680	29992026	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with decreased exposure to n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*9 + *1/*35 + *1/*41 + *2/*5 + *2/*35 + *2/*41 + *4/*35 + *4/*41 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	0.125
1451155020	1451552540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552540	32538291	CYP2D6 *1/*4 + *1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer genotype phenotype) .	1.5
1451155020	1451565700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451565700	33131142	CYP2D6 *1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.	1.75
1451155020	1183618125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618125	20456744	CYP2D6 *10/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1183618134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618134	20456744	CYP2D6 *2/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1183618142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618142	20456744	CYP2D6 *2/*2 is not associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1451282840	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1451282840	PA166104977	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104977		Annotation of DPWG Guideline for citalopram and CYP2C19	100
1451282840	1183701647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701647	8835706	CYP2C19 poor metabolizers is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	-0.625
1451282840	1184748582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748582	25122046	CYP2C19 poor metabolizers is associated with increased risk of electrocardiogram qt prolonged when treated with citalopram as compared to CYP2C19 normal metabolizers.	0.0
1451282840	1449717838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717838	30135031	CYP2C19 poor metabolizer phenotype is not associated with risk of adverse events due to citalopram or escitalopram in people with as compared to CYP2C19 normal metabolizer phenotype.	-0.5
1451282840	1451715793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451715793	33608663	Genotype AG is associated with increased likelihood of adverse events due to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.	2.5
1451282840	1183619342	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619342	21192344	CYP2C19 *4 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	0.0
1451282840	1183619350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619350	21192344	CYP2C19 *2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.5
1451282840	1450415299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450415299	30983508	CYP2C19 *1/*2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 *1/*1.	-1.5
1451282840	1183619955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619955	18382661	CYP2C19 *2 + *3 +*17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	-2.0
1444699743	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444699743	1444699671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699671	11313749	Allele C is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele T.	0.25
1444699743	1444699735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699735	25515069	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele T.	1.5
1444699743	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451274165	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274165	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274165	1183681878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681878	23736036	Genotype CG is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.	-1.75
1451274165	1184471970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471970	24167597	Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1451274165	1444698794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698794	25782327	Genotype CG is not associated with severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	-1.25
1451274165	1447954949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954949	24923815	Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	3.75
1451274165	1449161752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161752	28427087	Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.	-2.0
1451274165	1449162097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162097	29065426	Genotype CG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype GG.	-2.0
1451276160	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451276160	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451276160	1447959040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959040	24923815	Allele C is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Article designed about c.11295923C>G as additional risk variant and not to detect association with toxicity and c.1679T>G In the conclusion the authors state: "....c.11295923C>G DPYD variant as a predictive marker of earlyonset FP toxicity in a realworld clinical setting. We estimate that fewer than 50 patients need to be screened prior to therapy for this variant and for c.1905+1G>A, c.1679T>G and c.2846A>T in order to prevent one case of severe FP toxicity."
1451276160	1447945597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945597	26099996	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population Only two patients carried the varian and both had toxicities.
1451276160	1447991202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991202	19530960	Genotype AC is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population. Only 1 heterozygote variant carrier, which experienced grade 0-2 toxicity
1451276160	1450372235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372235	30858516	Genotypes AC + CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. c.1679T>G was present in 2 of the cases group, but were absent in the controls group. 2 patients developed Grade >=3 toxicity. Non-significance likely due to sample size.
1451276160	1448124824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124824	24647007	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Low number of subjects carried the variant, 1 out of 142 cases and 0 out of 330 control in Arm A and 1 out of 192 cases and 1 out of 340 controls in Arm B. Article mentioned also "Most patients with severe myelosuppression carried a rare DPYD allele: *2A, 2846T>A, *13 or A551T", with *13 being rs55886062.
1451276160	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1451276160	1448123368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123368	21498394	Genotype AC is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-1.5
1451276160	1448124253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124253	23736036	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451276160	1449161870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161870	28427087	Genotype AA is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AC + CC.	-2.0
1451276160	1450373067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373067	30485432	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	0.25
1451231100	PA166211021	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166211021		Annotation of DPWG Guideline for siponimod and CYP2C9	100
1451231100	PA166182738	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166182738		Annotation of FDA Label for siponimod and CYP2C9	100
1451231100	1451230861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230861	30088221	CYP2C9 *2/*3 + *3/*3 are associated with increased concentrations of siponimod in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1451231100	1451230840	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451230840	29273968	CYP2C9 *3/*3 + *2/*2 are associated with decreased metabolism of siponimod as compared to CYP2C9 *1/*1.	0.0
1183616718	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1183616718	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1183616718	1451152807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152807	9357098	CYP2D6 ultrarapid metabolizer phenotype is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0
1183616718	1451152848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152848	9357098	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0
1183616718	1451153620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153620	10850391	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0625
1183616718	1451157860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157860	18334103	CYP2D6 ultrarapid metabolizer genotype is associated with increased exposure to morphine in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.5
1183616718	1451206040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206040	24747667	CYP2D6 poor metabolizers are associated with decreased metabolism of codeine.	0.875
1183616718	1451568920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451568920	33404848	CYP2D6 poor metabolizer phenotype is associated with decreased exposure to morphine in infants as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	1.25
1183616718	827641940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641940	19940985	Genotype TT is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to genotypes CC + CT.	0.125
1183616718	827566510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566510	16819548	CYP2D6 *1/*2xN (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566496	16819548	CYP2D6 *1xN/*10 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566502	16819548	CYP2D6 *1xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566506	16819548	CYP2D6 *2xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566514	16819548	CYP2D6 *1xN/*1 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	982047720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047720	16920476	CYP2D6 *2/*2xN is associated with increased metabolism of codeine.	0.125
1183616718	982047744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047744	19692698	CYP2D6 *1xN is associated with increased metabolism of codeine.	0.125
1183616718	1183623185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623185	8823235	CYP2D6 *36 is associated with decreased codeine metabolism and morphine and glucuronides formation when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183616718	1183632349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632349	24077935	CYP2D6 *1/*10 + *10/*10 is associated with decreased plasma levels of morphine, M3G and M6G levels but not those of codeine when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183616718	1183632366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632366	19940985	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.	1.5
1183616718	1183678427	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678427	9415713	CYP2D6 *17 is associated with decreased activity of CYP2D6 when assayed with bufuralol or codeine as compared to CYP2D6 *1.	0.0
1183616718	1183678599	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678599	17470523	CYP2D6 *10 is associated with decreased clearance of codeine as compared to CYP2D6 *1.	0.0
1183616718	1183678609	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678609	17470523	CYP2D6 *17 is associated with decreased clearance of codeine as compared to CYP2D6 *1.	0.0
1183616718	1183680593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680593	19395173	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680606	19395173	CYP2D6 *3/*4 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680612	19395173	CYP2D6 *4/*6 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680618	19395173	CYP2D6 *4/*41 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680624	19395173	CYP2D6 *1/*1 + *1xN/*1xN is associated with increased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680992	9129563	CYP2D6 *1/*1 + *1/*4 is associated with increased plasma level of morphine when treated with codeine in healthy individuals as compared to CYP2D6 *3/*4 + *4/*4 + *5/*5.	1.0
1183616718	1183684566	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684566	12438554	CYP2D6 *10 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1183684576	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684576	12438554	CYP2D6 *2 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1183684584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684584	12438554	CYP2D6 *17 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1184756913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756913	11823760	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.	2.0
1183616718	1184756952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756952	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1183616718	1447963867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963867	19357842	CYP2D6 *17 is associated with decreased metabolism of codeine in people with Anemia, Sickle Cell.	1.25
1183616718	1451156680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156680	17872605	CYP2D6 *2/*2xN is associated with increased metabolism of codeine in women.	0.125
1451264020	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264020	1184510886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510886	9199552	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to allele C.	0.0
1451264020	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451264020	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451264020	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451264020	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451264020	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451282440	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1451282440	PA166104956	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104956		Annotation of DPWG Guideline for clopidogrel and CYP2C19	100
1451282440	1183699694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699694	24262617	CYP2C19 normal metabolizers are associated with decreased risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 poor metabolizers and intermediate metabolizers.	0.75
1451282440	1449140365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449140365	29102571	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.	1.25
1451282440	1451116983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451116983	31316169	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with percutaneous coronary intervention.	1.75
1451282440	1450112843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450112843	30487649	Genotypes AA + AG are not associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-1.5
1451282440	981843458	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843458	23364775	Allele T is associated with decreased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	2.5
1451282440	981843680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843680	22190063	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.	-2.0
1451282440	1043818226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818226	23922007	Genotype CT is not associated with bleeding events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	1043818236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818236	23922007	Genotype CT is not associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	1043818242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818242	23922007	Genotype CT is not associated with increased risk of cardiovascular events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	769146312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146312	20979470	Allele T is associated with decreased cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome.	2.5
1451282440	1184472133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472133	22028352	Genotypes CT + TT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype CC.	2.25
1451282440	1449310952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310952	29540324	Allele T is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele C.	2.5
1451282440	981352416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352416	19106083	Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA.	3.5
1451282440	982028948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028948	19106084	Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	3.0
1451282440	982032538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032538	20801498	Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	2.5
1451282440	981344417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344417	22990067	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282440	981352394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352394	19106083	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	982028939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028939	19106084	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	982032530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032530	20801498	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	982035455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035455	21168310	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	1.5
1451282440	981239613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239613	22940005	Genotype AA is associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotypes AG + GG.	3.5
1451282440	981344397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344397	22990067	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282440	981794408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794408	21972404	Allele A is associated with increased risk of major cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.25
1451282440	981802939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802939	23364775	Genotype AA is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282440	981802954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802954	23364775	Genotype AA is associated with increased risk of composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282440	981843499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843499	21918510	Genotype AA is associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	981843514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843514	21918510	Genotype AA is associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	981843601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843601	22624833	Genotype AA is associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.25
1451282440	981843612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843612	22624833	Genotype AG is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-2.0
1451282440	981843646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843646	22190063	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.	3.0
1451282440	982028928	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028928	19106084	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	982033160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033160	18577829	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	1.5
1451282440	982035437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035437	21168310	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	1.5
1451282440	1027543294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1027543294	19108880	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	3.25
1451282440	1027950849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1027950849	19108880	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	3.25
1451282440	1028218721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1028218721	19193675	Genotypes AA + AG are associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype GG.	3.5
1451282440	1043763118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043763118	20845077	Genotypes AA + AG are associated with increased risk of cardiovascular events when treated with clopidogrel as compared to genotype GG.	1.75
1451282440	827814610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814610	21700758	Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.	2.5
1451282440	769258868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769258868	21527445	Genotype AA is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282440	655388276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388276	19106083	Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	3.0
1451282440	769146008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146008	19106084	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	769146034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146034	19706858	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.	2.5
1451282440	769146043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146043	20801498	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	769146308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146308	20979470	Allele A is not associated with cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	-2.0
1451282440	1184472125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472125	22028352	Genotypes AA + AG is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	3.25
1451282440	1449310942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310942	29540324	Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	1449732819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732819	30188374	Genotypes AA + AG are associated with increased major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.5
1451282440	981352424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352424	19106083	CYP2C19 *5 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.5
1451282440	981478613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478613	23150151	CYP2C19 *2 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	0.0
1451282440	981478617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478617	23150151	CYP2C19 *3 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	0.0
1451282440	981483636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483636	22723959	CYP2C19 *2 is associated with increased risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	2.25
1451282440	981483641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483641	22723959	CYP2C19 *3 is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	-1.25
1451282440	981500454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500454	22464343	CYP2C19 *2 is associated with increased risk of major adverse cardiovascular events and stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	2.0
1451282440	981755468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755468	23429358	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282440	981755473	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755473	23429358	CYP2C19 *1/*3 + *2/*3 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282440	982023666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023666	23692149	CYP2C19 *2 is associated with increased risk of stent thrombosis (ST) after 1 year when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	982023672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023672	23692149	CYP2C19 *3 is associated with increased risk of stent thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	1043858934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858934	19106083	CYP2C19 *4 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.5
1451282440	1043880481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880481	20801498	CYP2C19 *6 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880487	20801498	CYP2C19 *8 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880576	20801498	CYP2C19 *5 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880590	19106084	CYP2C19 *5 is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681283	24019397	CYP2C19 *2/*2 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681306	24019397	CYP2C19 *2/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681314	24019397	CYP2C19 *1/*2 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-2.0
1451282440	1183681338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681338	24019397	CYP2C19 *1/*17 + *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	-2.0
1451282440	1183681384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681384	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	3.5
1451282440	1183681419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681419	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	-2.0
1451282440	1183681542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681542	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	3.0
1451282440	1183705616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705616	24535487	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	2.5
1451282440	1184348948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348948	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.75
1451282440	1184348964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348964	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282440	1184349625	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349625	24080325	CYP2C19 *2 + *3 are associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282440	1184349639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349639	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282440	1184349649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349649	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.25
1451282440	1184349659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349659	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349669	24080325	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349679	24080325	CYP2C19 *2 + *3 are associated with increased risk of ischaemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349692	24080325	CYP2C19 *2 + *3 are not associated with increased risk of Mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.0
1451282440	1184349702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349702	24762860	CYP2C19 *2 is associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.5
1451282440	1184349711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349711	24762860	CYP2C19 *2 is not associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-1.75
1451282440	1184349747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349747	24762860	CYP2C19 *2 is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	0.0
1451282440	1184349821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349821	24762860	CYP2C19 *9 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-2.5
1451282440	1184467283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467283	23402725	CYP2C19 *2/*2 + *1/*2 is associated with increased likelihood of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.25
1451282440	1184987695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987695	24508947	CYP2C19 *3 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	1184987748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987748	24996381	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	0.5
1451282440	1444701909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701909	25828136	CYP2C19 *2 is associated with increased risk of when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1451282440	1444702878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702878	25851472	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1444704450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704450	25877345	CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.25
1451282440	1444704497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704497	25877345	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282440	1444704529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704529	25877345	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are not associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	-0.5
1451282440	1444704559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704559	24402637	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.25
1451282440	1444706464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706464	25897911	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.0
1451282440	1444706496	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706496	25897911	CYP2C19 *2 + *3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282440	1446899082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899082	26265231	CYP2C19 *2 + *4 are not associated with risk of Death, Ischemic Attack, Transient, Stroke or Thrombosis when treated with clopidogrel as compared to CYP2C19 *1 + *17.	-1.0
1451282440	1446899112	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899112	26265231	CYP2C19 *2 + *4 are associated with increased risk of Myocardial Infarction when treated with clopidogrel as compared to CYP2C19 *1 + *17.	2.0
1451282440	1446899985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899985	26019129	CYP2C19 *2 is associated with increased likelihood of Stroke when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	0.0
1451282440	1447678787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678787	26757134	CYP2C19 *1/*2 + *2/*3 + *1/*3 + *2/*17 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.5
1451282440	1447949788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949788	26961113	CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	2.75
1451282440	1448101486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101486	26071277	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.	2.5
1451282440	1448257000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257000	27348249	CYP2C19 *2 + *3 are not associated with likelihood of Hemorrhage when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	-2.0
1451282440	1448602737	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602737	27368038	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	3.0
1451282440	1448603394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603394	28255319	CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282440	1448617237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617237	27806998	CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.5
1451282440	1448617264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617264	27806998	CYP2C19 *2 + *3 + *8 are associated with increased risk of composite endpoints (stroke, myocardial infarction, or vascular death) when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.5
1451282440	1448617742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617742	27653892	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1448631945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631945	28377187	CYP2C19 *2 + *3 are not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	-2.0
1451282440	1448631958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631958	28329746	CYP2C19 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1449187703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187703	29397568	CYP2C19 *3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.5
1451282440	1449187720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187720	29397568	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282440	1449751959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449751959	30191759	CYP2C19 *3/*17 is associated with Thrombosis when treated with aspirin and clopidogrel.	0.25
1451282440	1450370889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450370889	29536505	CYP2C19 *1/*1 (assigned as normal metabolizer phenotype phenotype) is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*2 + *2/*2 + *2/*17 + *17/*17 + *1/*17.	-1.5
1451282440	1448624845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624845	27981573	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2.	-1.75
1451282440	1444667802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667802	24440142	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1451282440	1444667831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667831	24440142	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1451286040	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286040	1449732030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732030	30114658	Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	This annotation is not used for clinical annotation scoring. From the discussion section: "no associations with common variants remained statistically significant after correction"
1451286040	1447987436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987436	22490566	Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.	-1.75
1451286040	1450954760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954760	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.5
1451286040	827810898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810898	21498394	Genotypes CT + TT is associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.0
1451286040	1449162055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162055	29065426	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
1451286040	1447945619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945619	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286040	1448124677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124677	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451286040	1448124810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124810	24647007	Genotypes CT + TT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451286040	1448262721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262721	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286040	1448723954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448723954	28745575	Genotypes CC + CT is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	2.75
1451286040	1448994804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994804	28481884	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.	-1.5
1451286040	1450371918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371918	30723313	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286040	1450372243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372243	30858516	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
1451265560	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1451265560	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1451265560	1183684386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684386	2293406	CYP2D6 poor metabolizers are associated with decreased dose of imipramine in people with Diabetic Neuropathies as compared to CYP2D6 normal metabolizer phenotype.	0.125
1451265560	1183617426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617426	18070221	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	2.5
1451265560	1446902201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902201	17667959	CYP2D6 *1/*1xN + *1/*2xN (assigned as ultra-metabolizer phenotype phenotype) are associated with increased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.5
1451265560	1446902225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902225	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	3.0
1451264060	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264060	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264060	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451237940	PA166104940	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104940		Annotation of DPWG Guideline for phenprocoumon and VKORC1	100
1451237940	827864542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864542	20833980	Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.	1.75
1451237940	1444707634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707634	24224579	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.5
1451237940	1444707652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707652	23423913	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.	2.5
1451237940	1444707757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707757	23299853	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.5
1451237940	1444707853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707853	18629445	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	0.0
1451237940	982046650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046650	21110013	Genotype CC is associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	2.25
1451237940	1043818234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818234	20376629	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT.	1.5
1451237940	1043858478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858478	21057703	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.	1.75
1451237940	1448255689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255689	26984978	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.25
1451237940	1448259259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259259	21636598	Allele T is associated with dose of acenocoumarol or phenprocoumon.	0.0
1451275220	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451275220	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451275220	982009679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009679	23588312	Genotype AC is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype AA.	1.75
1451275220	1450949780	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450949780	11895907	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1450950400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950400	11988088	Genotype AC is associated with increased severity of Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype AA.	0.0
1451275220	1450953540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953540	16361556	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1450965000	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450965000	31745289	Allele C is associated with decreased activity of DPYD as compared to allele A.	0.0
1451275220	1450952540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952540	10803677	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1447987724	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987724	23328581	Genotype CC is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype AA.	0.0
1451275220	1448267612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267612	25410891	Allele C is not associated with activity of DPYD.	-0.0
1451275220	1448605300	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605300	28295243	Genotype AC is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype AA.	0.0
1445400206	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400206	1444697865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697865	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1444698012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698012	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1445297038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297038	20681998	Allele A is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele G.	0.25
1445400206	1445297392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297392	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400206	1447634061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634061	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1447672469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672469	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447673950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673950	10484775	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to methoxyflurane as compared to allele G.	0.0
1445400206	1447674319	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674319	10051009	Allele A is associated with increased risk of Malignant Hyperthermia and multi-core congenital myopathy as compared to allele G.	0.0
1445400206	1447674385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674385	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447675923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675923	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447946199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946199	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447948719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948719	12709367	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447952549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952549	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447952717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952717	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1445400206	1447960670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960670	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1447961289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961289	19191333	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447987594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987594	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400206	1449160148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160148	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1445400156	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400156	1184510652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510652	24361844	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.0
1445400156	1449160880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160880	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160905	15210166	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160912	12123492	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160919	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160936	25256590	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447676001	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447676001	1447672796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672796	8220423	Allele G is associated with increased risk of Myopathy, Central Core as compared to allele C.	0.0
655385024	1451340084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340084	31869433	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	1.0
655385024	1451589745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589745	31114289	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.25
655385024	982038164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038164	20203262	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	2.0
655385024	982044349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044349	16611750	Allele G is associated with increased dose of warfarin as compared to allele A.	2.25
655385024	827567321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567321	15883587	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385024	1183701268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701268	18574025	Allele A is associated with dose of warfarin.	2.5
655385024	1183704894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704894	24019055	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385024	1184472436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472436	20128861	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385024	1450980680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980680	18322281	Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.	2.75
655385024	1450980780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980780	18322281	Genotypes AA + AG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype GG.	3.75
655385024	1448106998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106998	18030307	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.25
655385024	1448276172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276172	21326313	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385024	1447519671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519671	18466099	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.25
655385024	1447519944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519944	19752777	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.75
655385024	613977249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613977249	16270629	Allele A is associated with decreased dose of warfarin.	2.5
1451263966	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263966	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263966	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263966	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263966	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263966	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451274200	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274200	1450960041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960041	9865912	Genotype AC is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451274200	1448124993	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124993	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.	0.0
655384733	1451340144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340144	31869433	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	1.0
655384733	1451589762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589762	31114289	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.25
655384733	981483987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483987	20653676	Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.	2.5
655384733	981500585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500585	21127708	Allele T is associated with increased dose of warfarin in people with Myocardial Infarction as compared to allele C.	0.0
655384733	982034243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034243	16270629	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655384733	827567329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567329	15883587	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
655384733	655388073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388073	16676068	Allele T is associated with increased dose of warfarin.	2.5
655384733	1183697222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697222	22349464	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655384733	1183697701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697701	23990957	Genotypes CT + TT is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to genotype CC.	2.25
655384733	1183704904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704904	24019055	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	3.0
655384733	1184472447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472447	20128861	Allele T is associated with increased dose of warfarin as compared to allele C.	2.5
655384733	1184483453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483453	23208322	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
655384733	1184756163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756163	25126975	Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	3.5
655384733	1185002294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002294	21635147	Allele T is associated with increased dose of warfarin as compared to allele C.	2.0
655384733	1444694676	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694676	25594941	Genotype CC is not associated with dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	-1.5
655384733	1444694686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694686	25594941	Genotype CC is associated with decreased concentrations of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	2.5
655384733	1450979280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450979280	25084205	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655384733	1448276167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276167	21326313	Genotype TT is associated with increased dose of warfarin as compared to genotype CC.	3.0
655384733	1447519684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519684	18466099	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.75
655384733	769277903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277903	15358623	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655384733	827649690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827649690	16611750	Allele T is associated with increased dose of warfarin as compared to allele C.	1.75
655384733	769277912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277912	17049586	Genotype CT is associated with increased dose of warfarin as compared to genotype CC.	2.25
1451263986	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263986	1184510886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510886	9199552	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to allele C.	0.0
1451263986	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263986	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263986	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263986	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263986	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451263980	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263980	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263980	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263980	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263980	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451263973	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263973	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263973	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263973	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263973	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263973	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1184648909	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1184648909	PA166104952	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104952		Annotation of DPWG Guideline for mercaptopurine and TPMT	100
1184648909	1184174063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174063	20136357	TPMT poor metabolizer phenotype is associated with increased risk of myelotoxicity when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1184648909	1184174068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174068	20136357	TPMT intermediate metabolizer phenotype is associated with increased risk of mild leukopenia when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1184648909	1184233739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233739	20308917	TPMT intermediate metabolizer phenotype is associated with decreased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT poor metabolizer phenotype.	1.0
1184648909	1184348822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348822	1960624	TPMT poor metabolizer phenotype is associated with increased severity of hematological toxic effects when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1184648909	1184407184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407184	16543290	TPMT intermediate metabolizers is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184427832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184427832	8257179	TPMT poor metabolizer phenotype is associated with increased severity of myelosuppression when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1184648909	1444704973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704973	25347948	TPMT intermediate metabolizer phenotype is not associated with increased severity of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-0.875
1184648909	1184407197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407197	16543290	TPMT intermediate metabolizers is not associated with increased likelihood of specific adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.	-0.625
1184648909	981239095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239095	22846425	Allele C is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	3.0
1184648909	1451106020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451106020	32265697	Allele C is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	2.5
1184648909	1449749281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749281	28418010	Genotype CT is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.25
1184648909	978639710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639710	22838948	TPMT *12 is associated with increased severity of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1.	2.25
1184648909	1184134111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134111	16202677	TPMT *1/*2 + *1/*3A is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1184648909	1184134311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134311	10376773	TPMT *1/*3A is associated with hepatic toxicity when treated with azathioprine, mercaptopurine or purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184134359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134359	17164697	TPMT *1/*2 + *1/*3A + *3A/*3B is associated with increased risk of leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1184648909	1184169661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169661	17617792	TPMT *1/*3A is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169687	17617792	TPMT *1/*3C is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169693	17617792	TPMT *3A/*3C is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169875	18987660	TPMT *1/*3A is associated with increased likelihood of Drug Toxicity, Infection and Stomatitis when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.75
1184648909	1184233729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233729	20308917	TPMT *1/*3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.75
1184648909	1184278692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184278692	11337943	TPMT *1/*3C is associated with increased risk of severe leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	1.5
1184648909	1184348445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348445	12142782	TPMT *1/*3A is associated with myelotoxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184348606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348606	10354134	TPMT *3A/*3A is associated with severe hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184349368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349368	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of overall ADRs when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184349431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349431	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184349446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349446	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is not associated with increased likelihood of hepatotoxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.0
1184648909	1184349470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349470	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is not associated with increased likelihood of pancreatitis when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.0
1184648909	1184467021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467021	9510461	TPMT *3A/*3C is associated with severe pancytopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184467028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467028	9510461	TPMT *3A/*3A is associated with severe pancytopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184518693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184518693	21319286	TPMT *1/*3A + *1/*3C + *3A/*3A are associated with increased likelihood of tolerance of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	1.5
1184648909	1184642842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184642842	7862671	TPMT *2 is associated with increased risk of Drug Toxicity when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1448256046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256046	27452984	TPMT *1/*3A is associated with increased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.25
1184648909	1448261284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261284	27604507	TPMT *1/*3C is not associated with risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to TPMT *1/*1.	-1.75
1184648909	1448268166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268166	18662289	TPMT *3A + *3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1184648909	1448576485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448576485	28146264	TPMT *1/*2 + *1/*3A are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1184648909	1449161615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161615	29210335	TPMT *6 is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.5
1184648909	1449161632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161632	29210335	TPMT *3C is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-2.5
1184648909	1355779542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1355779542	25441457	TPMT *1/*3A is associated with Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1184648909	1358207197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1358207197	25441457	TPMT *1/*3C is associated with Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1184648909	1351431664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1351431664	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 are associated with increased risk of Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1184648909	1184133979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184133979	20175817	TPMT *2 + *3A + *3B + *3C is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.25
1184648909	1184233422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233422	18188716	TPMT *1/*2 + *1/*3A + *1/*3C is associated with increased likelihood of hematological toxicity when treated with mercaptopurine or purine analogues in people with Leukemia as compared to TPMT *1/*1.	0.25
1451286020	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451286020	1449732030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732030	30114658	Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	This annotation is not used for clinical annotation scoring. From the discussion section: "no associations with common variants remained statistically significant after correction"
1451286020	1447987436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987436	22490566	Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.	-1.75
1451286020	1450952660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952660	11156223	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to genotype CC.	0.25
1451286020	1450953980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953980	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-2.0
1451286020	1450954760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954760	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.5
1451286020	981394398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981394398	19473056	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286020	1449162055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162055	29065426	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
1451286020	1447945384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945384	26846104	Genotype CC is not associated with Drug Toxicity when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	-1.5
1451286020	1447945619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945619	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286020	1447949996	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949996	26794347	Allele T is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms or Colorectal Neoplasms as compared to allele C.	3.5
1451286020	1448262721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262721	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286020	1448997530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997530	28614820	Genotype TT is associated with Drug Toxicity when treated with fluorouracil.	0.25
1451286020	1450371918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371918	30723313	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286020	1450372243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372243	30858516	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
1451214480	PA166124619	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166124619		Annotation of CPIC Guideline for tacrolimus and CYP3A5	100
1451214480	PA166104983	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104983		Annotation of DPWG Guideline for tacrolimus and CYP3A5	100
1451214480	1448994558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994558	28704257	CYP3A5 poor metabolizers are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 intermediate metabolizers.	1.125
1451214480	981858976	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858976	23073468	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	981858994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858994	23073468	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	982047178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047178	23175667	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	-1.0
1451214480	982047183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047183	23175667	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.25
1451214480	827698515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698515	21206424	Genotypes CT + TT are associated with decreased trough concentrations when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	827698684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698684	20818834	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.25
1451214480	827812467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812467	21635144	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	827813909	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813909	21806386	Allele C is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele T.	2.5
1451214480	769172716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172716	15521904	Allele C is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation.	-0.75
1451214480	769174170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769174170	19865079	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1183533891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533891	23459029	Genotype TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183533896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533896	23459029	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183533912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533912	22706623	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.	1.5
1451214480	1183684051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684051	21903774	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183690054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690054	23073208	Genotypes CT + TT is associated with increased metabolism of tacrolimus in healthy individuals as compared to genotype CC.	1.0
1451214480	1183697938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697938	21094796	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.25
1451214480	1183698005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698005	23149441	Genotype CC is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.0
1451214480	1183698721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698721	23557867	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.0
1451214480	1183700136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700136	24024898	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184470313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470313	24658827	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184514498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514498	22889968	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184514504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514504	22469198	Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.5
1451214480	1184514507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514507	23633119	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184514513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514513	21480817	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.75
1451214480	1184514516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514516	21072155	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1184514519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514519	21436775	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.25
1451214480	1184514528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514528	23278282	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514534	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514534	21094797	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514537	21677300	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514540	15502717	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184514543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514543	16906020	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514546	17192769	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514555	20415563	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1184514561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514561	15729180	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514567	17635182	Genotype CC is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.25
1451214480	1184514570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514570	17032130	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1184514573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514573	18334918	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	3.0
1451214480	1184514579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514579	18589174	Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514582	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514582	19067682	Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184514585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514585	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514588	21273673	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.	1.5
1451214480	1184514591	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514591	16146556	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184514594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514594	16249748	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514665	21839244	Allele T is not associated with metabolism of tacrolimus in people with heart transplantation as compared to allele C.	-0.125
1451214480	1184514668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514668	24231473	Genotypes CT + TT is not associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	-0.25
1451214480	1184514696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514696	16424824	Genotype CT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.	1.0
1451214480	1184514835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514835	15919447	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515001	21671989	Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.	0.0
1451214480	1184515004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515004	21102498	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with HSCT as compared to genotype CC.	1.0
1451214480	1184515016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515016	23580812	Genotype CC is associated with decreased metabolism of tacrolimus in Kidney Transplantation.	0.125
1451214480	1184515019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515019	17430486	Genotypes CT + TT are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515022	18334918	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515026	19067682	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184515029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515029	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515035	16146556	Genotype CC is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184515163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515163	24024898	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1184515181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515181	17192769	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184515224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515224	24118301	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.0
1451214480	1184515270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515270	16753004	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515288	21366650	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1184515373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515373	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515446	20415563	Genotype CC is associated with increased PBMC concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.25
1451214480	1184515460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515460	20393454	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515480	16906020	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184515781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515781	21544031	Genotype CC is not associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	-2.0
1451214480	1184998169	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998169	21698374	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184998356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998356	21922127	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184998389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998389	22369694	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184998516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998516	23364483	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1185023279	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023279	25201288	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1185023332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023332	25271728	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1296599155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599155	25303300	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1444666410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666410	25487141	Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1444693964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693964	22786571	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	0.75
1451214480	1444694094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694094	24739669	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	1.75
1451214480	1444694110	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694110	24739669	Genotypes CT + TT is not associated with concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	-0.75
1451214480	1444694176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694176	24435759	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1444694209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694209	25279405	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1444694255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694255	25565672	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with hemopoietic stem cell transplant as compared to genotype CC.	2.0
1451214480	1444694284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694284	25594874	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1448597114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448597114	27977332	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
1451214480	1448603528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603528	28246425	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.	1.25
1451214480	1449575706	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575706	29804290	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	0.125
1451214480	1449747826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747826	29454235	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.75
1451214480	1448112425	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112425	27314545	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	1.75
1451214480	1448106854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106854	17495880	Allele C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1451415515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415515	32843687	Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1451714340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451714340	33512723	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1183693321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693321	22660440	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1183699973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699973	23305195	CYP3A5 *1/*1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1183699984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699984	23305195	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1183954989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183954989	18429967	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1183959875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959875	20383212	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of tacrolimus in children with hemopoietic stem cell transplant as compared to CYP3A5 *3/*3.	-0.25
1451214480	1184085726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184085726	24126681	CYP3A5 *3/*3 is associated with increased tacrolimus plasma trough levels and severely diminished tacrolimus clearance when treated with tacrolimus as compared to CYP3A5 *1/*1.	0.125
1451214480	1184470264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470264	24625991	CYP3A5 *3/*3 is associated with increased likelihood of achieving target concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1184470680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470680	24875272	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.25
1451214480	1184470726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470726	24656015	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1184470790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470790	24655974	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
1451214480	1184470893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470893	24528196	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
1451214480	1184470932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470932	24522145	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1184470999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470999	24465960	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
1451214480	1184471077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471077	24465960	CYP3A5 *3/*3 is not associated with likelihood of achieving target concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-1.0
1451214480	1184471246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471246	24444408	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	2.5
1451214480	1184471300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471300	24444408	CYP3A5 *3/*3 is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	2.5
1451214480	1184471417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471417	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1451214480	1184514654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514654	23990505	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1184515038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515038	19545678	CYP3A5 *1/*3 + *3/*3 is associated with increased blood concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.25
1451214480	1184515044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515044	21930396	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentrations of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1184515084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515084	21528942	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.125
1451214480	1184515125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515125	22210422	CYP3A5 *1/*1 + *1/*3 is not associated with blood concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1451214480	1184515192	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515192	22339449	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with lung transplantation as compared to CYP3A5 *3/*3.	0.0
1451214480	1184515210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515210	24238261	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1184515311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515311	21528942	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.125
1451214480	1185023177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023177	24383873	CYP3A5 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.5
1451214480	1444706282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706282	25894154	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1444934203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934203	25846845	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.75
1451214480	1445164647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164647	26177012	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1445584925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584925	26228923	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447520652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520652	26227094	CYP3A5 *1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447520795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520795	26543771	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447673635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447673635	26114223	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1447674165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674165	26635230	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1447674267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674267	26622455	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447674595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674595	26325438	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447674691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674691	26615671	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447946634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946634	26770526	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1447947435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947435	26915847	CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1447947447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947447	26915847	CYP3A5 *1/*1 is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	-0.375
1451214480	1447949204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949204	25673014	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1448267244	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267244	26667830	CYP3A5 *3 + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.	0.0
1451214480	1448285615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285615	26990259	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1448285727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285727	27110018	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1448525595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448525595	27885697	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1448530624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530624	28030534	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
1451214480	1448569672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569672	28094348	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1448602336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602336	28050888	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	0.0
1451214480	1448640944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640944	26924289	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1448819453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819453	28540692	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1448820606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820606	28736028	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1449004146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449004146	29043387	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	2.75
1451214480	1449165818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165818	28945481	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.25
1451214480	1449170380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170380	27138785	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
1451214480	1449170428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170428	29162334	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	1.0
1451214480	1449171352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171352	27966227	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1449183240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449183240	29441922	CYP3A5 *1 is not associated with metabolism of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	-0.75
1451214480	1449748012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748012	29547545	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.5
1451214480	1449748260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748260	29603629	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1449748829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748829	29691732	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	2.25
1451214480	1449748903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748903	29731062	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1449749340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749340	29733390	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1449749618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749618	29878980	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1449750499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750499	30251062	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1450372838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372838	30260084	CYP3A5 *1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	0.75
1451214480	1450372870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372870	29229354	CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1450377052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450377052	30730287	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3 + *1/*1.	1.0
1451214480	1450415351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415351	30983501	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.25
1451214480	1451118200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118200	31513279	CYP3A5 *3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	2.25
1451214480	1183699846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699846	23588314	CYP3A5 *6 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183699837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699837	23588314	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183699855	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699855	23588314	CYP3A5 *7 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1184515509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515509	23588314	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183945249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183945249	16501005	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in human liver microsomes as compared to CYP3A5 *3/*3.	This annotation is not used for clinical annotation scoring.
1451214480	1184515204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515204	24089074	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
1451332611	PA166105002	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105002		Annotation of CPIC Guideline for desipramine and CYP2D6	100
1451332611	1183684281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684281	9049581	CYP2D6 poor metabolizer are associated with increased risk of Hypotension, Orthostatic and sedation when treated with desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.125
1451332611	1183684295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684295	8422746	CYP2D6 poor metabolizers are associated with cardiotoxicity when treated with desipramine in people with.	0.125
1451332611	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1447673787	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673787	1447522105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522105	19191329	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1447673787	1447672329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672329	18306019	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447672379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672379	11928716	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447673084	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673084	16917943	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447675440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675440	16732084	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451288200	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1451288200	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1451288200	1183682358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682358	22492761	CYP2D6 ultra-metabolizer phenotype is associated with increased risk of Death or Severe Respiratory Depression when treated with codeine in children with adenotonsillectomies for obstructive sleep apnea syndrome.	0.125
1451288200	1183684089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684089	22398969	CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain.	0.0
1451288200	1183617941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617941	12920424	CYP2D6 *1/*2xN is associated with increased risk of Drug Toxicity when treated with codeine, hydrocodone or oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.0
1451288200	1183618114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618114	18713907	CYP2D6 *1xN is associated with Respiratory Insufficiency when treated with codeine as compared to CYP2D6 *1/*1.	0.25
1451288200	1183623194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623194	15625333	CYP2D6 *1/*1xN is associated with Life-threatening opioid intoxication when treated with codeine as compared to CYP2D6 *1/*1.	0.25
1451288200	1183632396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632396	21743374	CYP2D6 *1/*2xN + *2/*2xN are associated with increased opioid related adverse events ( immediate pain relief from codeine but stopped taking it due to dizziness and constipation) when treated with codeine in women as compared to CYP2D6 *1/*1.	0.25
1451288200	1183680580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680580	9357099	CYP2D6 *1xN is associated with severity of abdominal pain when treated with codeine.	0.25
1451288200	1183682365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682365	22492761	CYP2D6 *1/*2xN is associated with risk of Death when treated with codeine in children with adenotonsillectomy for obstructive sleep apnea syndrome.	0.25
1451288200	1183623203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623203	18719619	CYP2D6 *2/*2xN is associated with increased risk of cns depression or Death when treated with codeine in infants as compared to CYP2D6 *1/*1xN.	2.25
1451288220	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1451288220	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1451288220	1450376074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376074	30784356	CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.25
1451288220	1451351660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351660	31141989	CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 poor metabolizers and intermediate metabolizers.	0.0
1451288220	1451404282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451404282	33750887	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to codeine in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	0.0
1451288220	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451288220	982046905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046905	17517247	CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046919	17517247	CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046931	17517247	CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046937	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046937	17517247	CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	1183617920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617920	16631290	CYP2D6 *4/*6 is associated with intolerance to codeine ( significant side effects as well as no pain relief) when treated with codeine.	0.25
1451288220	1183632376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632376	21743374	CYP2D6 *4/*4 + *4/*5 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 *1/*1.	0.25
1451264140	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264140	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264140	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1446905703	981481593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481593	21274861	Allele C is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	2.5
1446905703	1444707735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707735	20547162	Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	3.25
1446905703	1446905501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446905501	26441325	Genotype AA is associated with increased risk of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AC + CC.	2.5
1446905703	1447682522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682522	26670100	Allele A is not associated with increased risk of Anemia when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with as compared to allele C.	-1.75
1446905703	1448255902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255902	20173735	Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with as compared to allele A.	0.0
1446905703	1448532157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532157	26438033	Genotype AA is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AC + CC.	1.5
1451259580	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1451259580	PA166104982	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104982		Annotation of DPWG Guideline for amitriptyline and CYP2D6	100
1451259580	1448612606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448612606	28350251	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is associated with decreased likelihood of Constipation, dry mouth, Fatigue, Urinary Retention and Vision Disorders when treated with amitriptyline in people with Diabetic Neuropathies as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	0.125
1451259580	981476405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476405	18070221	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	3.5
1451259580	1183615533	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615533	21614669	CYP2D6 *4/*4 is associated with toxicity when exposed to amitriptyline.	0.25
1451259580	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451259580	1183617442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617442	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	2.0
1451259580	1183619031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619031	17008819	CYP2D6 *4/*4 is associated with side effects when treated with amitriptyline.	0.25
1451259580	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451264081	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264081	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264081	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1447675871	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447675871	1446900666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900666	25658027	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447675871	1447673172	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673172	16163667	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447675871	1447987304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987304	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447676077	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447676077	1445297310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297310	24433488	Allele C is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	0.0
1447676077	1447961097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961097	14641996	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1444842106	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1444842106	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
1444842106	1183702544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702544	12698304	CYP2C9 *1/*3 is associated with increased AUC, higher half-life and lower flurbiprofen clearance when treated with flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1444842106	1183702553	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702553	12698304	CYP2C9 *1/*2 is associated with increased AUC and longer longer flurbiprofen elimination half-life when treated with flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1444842106	1444828093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828093	25712887	CYP2C9 *1/*3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1444842106	1444828107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828107	25712887	CYP2C9 *1/*1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*3.	1.5
981345350	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
981345350	1451228580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228580	29950617	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.0
981345350	1451358200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358200	31981411	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.	1.5
981345350	1451358660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358660	27557342	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	1.75
981345350	827827497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827497	17473846	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.	1.5
981345350	1183631263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631263	23930675	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	2.25
981345350	1184169599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169599	23876492	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.	2.0
981345350	1444693880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693880	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.	0.0
981345350	1451124180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124180	31857620	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.125
981345350	1451141460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141460	32361904	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.	2.25
981345350	1447989994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989994	25673568	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	0.125
981345350	1449733005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449733005	16198652	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	1.5
981345350	1451226461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226461	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
981345350	982043808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043808	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
981345350	982043792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043792	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
981345350	982043801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043801	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1451678240	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451678240	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451678240	1451228540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451228540	29950617	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.	3.0
1451678240	1451356526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451356526	20347093	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.25
1451678240	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451678240	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678240	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451678240	1448821127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821127	28812116	Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.	3.25
1451678240	1183689623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689623	23708174	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.	-2.0
1448102439	981477593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477593	19749757	Allele G is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	2.0
1448102439	1444705070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705070	22328925	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AG + GG.	3.0
1448102439	1444705502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705502	21346780	Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	3.5
1448102439	1444843596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843596	23281610	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AG.	3.0
1451678600	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678600	982048103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048103	17289397	CYP2C9 *3 is not associated with likelihood of myopathy when treated with fluvastatin, rosuvastatin or simvastatin as compared to CYP2C9 *1.	-0.25
1451678600	1451678500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451678500	24024895	CYP2C9 *2 + *3 are associated with increased likelihood of adverse events when treated with fluvastatin in people with Kidney Transplantation as compared to CYP2C9 *1/*1.	2.25
1451678600	982048096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048096	17289397	CYP2C9 *2 is not associated with likelihood of myopathy when treated with fluvastatin, rosuvastatin or simvastatin as compared to CYP2C9 *1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1451677736	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1451677736	1451151642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151642	32453264	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.	-1.5
1451677736	1451163185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163185	32128760	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.	3.0
1451677736	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451677736	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1451677736	1451390498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390498	26376374	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-0.875
1451677736	1451390500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390500	30569848	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.5
1451677736	1451390640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390640	27296832	Genotypes CC + CT are not associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to genotype TT.	-1.75
1451677736	1451465304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465304	34114646	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-2.0
1451677736	1451479880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479880	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.375
1451677736	1451480162	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480162	33150478	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-1.0
1451677736	1451352267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451352267	25992810	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.	-2.0
1451677736	827810986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810986	21928084	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	-1.5
1451677736	769164520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164520	21243006	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.	-0.25
1451677736	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451677736	1183699594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699594	24263182	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.	3.25
1451677736	1447689782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447689782	26086347	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.	2.5
1451677736	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451677736	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1451677736	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451677736	1451905600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905600	35034348	SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.	2.5
1451678620	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678620	1450823491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823491	30989645	Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C.	This annotation is not used for clinical annotation scoring. this is in LD with rs4149056 which is already included in scoring.
1451678620	827827170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827170	17015053	Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.	-0.125
1451678620	1450823509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823509	30989645	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.	2.0
1451678620	1451226441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226441	30528195	SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	-0.125
1451678620	1451451102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451102	18408565	SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	-0.125
1447989784	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989784	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1447989784	827823468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823468	19530960	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	2.0
1447989784	1448119085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119085	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
1447989784	1448120697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448120697	19473056	Genotype CT is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	-1.5
1447989784	1448122949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122949	20803296	Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele C.	2.0
1447989784	1448124454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124454	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1447989784	1448255378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255378	26603945	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1447989784	1448262687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262687	24923815	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1447989784	1450373074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373074	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1451264087	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264087	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264087	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
981345293	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
981345293	1451226263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226263	30549267	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.	1.0
981345293	1451451120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451120	26744986	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.	1.75
981345293	982042588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042588	15226675	Genotype CT is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype TT.	1.5
981345293	982043146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043146	16722833	Genotype CT is not associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.125
981345293	982043158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043158	16722833	Genotype CT is associated with increased metabolism of pravastatin in children with Transplantation as compared to genotype TT.	-1.0
981345293	827826991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826991	15116054	Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.	1.0
981345293	827827131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827131	16678544	Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.	1.0
981345293	827827157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827157	17015053	Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.	1.5
981345293	827827440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827440	17622941	Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.	1.5
981345293	769170865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170865	12811365	Allele C is associated with decreased metabolism of pravastatin in healthy individuals as compared to allele T.	0.125
981345293	827827514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827514	19776292	SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.	1.75
981345293	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
981345293	1451451060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451060	17047488	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
981345293	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
981345293	982043980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043980	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA on rs4149056.
981345293	982043959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043959	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
981345293	982043998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043998	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
981345293	982044004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044004	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1183700410	PA166127637	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127637		Annotation of CPIC Guideline for fluvoxamine and CYP2D6	100
1183700410	1183703205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703205	9174682	CYP2D6 poor metabolizer is associated with increased areas under the serum concentration-time curve when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703476	11791895	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703487	8823236	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703504	9517369	CYP2D6 poor metabolizer is not associated with differences in the area under the serum concentration-timecurv when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	-0.0625
1183700410	1183700294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700294	20547595	CYP2D6 *10/*10 + *5/*10 are associated with increased fluvoxamine plasma concentrations when treated with fluvoxamine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183700410	1183700359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700359	18978520	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *5/*10 are not associated with differences in in the fluvoxamine plasma level at 100, 150, and 200 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.	-0.125
1183700410	1183703160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703160	12883230	CYP2D6 *1/*1 is not associated with differences in steady-state plasma concentrations of fluvoxamine and its demethylated metabolite fluvoxamino acid when treated with fluvoxamine in people with Depression as compared to CYP2D6 *10/*10 + *5/*10.	-0.125
1183700410	1183703194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703194	12610741	CYP2D6 *1/*1 is not associated with differences in plasma fluvoxamine concentration when treated with fluvoxamine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*10 + *10/*10.	-0.125
1183700410	1183703493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703493	10668847	CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased AUC, Cmax and half-life time of fluvoxamine when treated with fluvoxamine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	0.125
1183700410	1184137435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137435	18978520	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *5/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.	1.0
1183700410	1449577638	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577638	20118554	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are associated with increased steady-state concentration of fluvoxamine as compared to CYP2D6 *1/*1.	0.125
1183700410	1449577681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577681	20118554	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are not associated with increased concentrations of fluvoxamine as compared to CYP2D6 *1/*1.	-0.125
1451264128	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264128	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264128	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451264120	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264120	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264120	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
655384011	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
655384011	PA166182844	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182844		Annotation of DPWG Guideline for simvastatin and SLCO1B1	100
655384011	1451231960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451231960	29242847	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.	2.25
655384011	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
655384011	655386692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386692	18650507	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.	3.5
655384011	981420028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420028	18650507	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.	0.0
655384011	769164512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164512	21243006	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.	1.75
655384011	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
655384011	1183699615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699615	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	0.0
655384011	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
655384011	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
655384011	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451681540	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1451681540	1446896983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896983	26164721	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.	2.5
1451681540	1451249860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451249860	17108811	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.	1.5
1451681540	1184754854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754854	24598718	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.	0.0
1451681540	1447983120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983120	25446771	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	0.5
1451681540	1451352480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352480	26774055	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	1.5
1451681540	1451352500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352500	25673568	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.	0.125
1451681540	1446907580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907580	26367500	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	2.0
1451681540	1448612369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612369	28350522	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.	1.0
1451681540	1449556752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449556752	29469964	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.	1.5
1449191373	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191373	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191373	1449191093	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191093	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1183619154	1183618754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618754	22926595	CYP2D6 *3/*4 + *4/*6 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.	1.0
1183619154	1183618807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618807	19429471	CYP2D6 *4/*4 + *4/*6 is associated with increased dose/weight adjusted AUC for mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.75
1183619154	1183618967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618967	17329996	CYP2D6 *4/*4 is associated with decreased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183619154	1183618996	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618996	17329996	CYP2D6 *1/*1xN is associated with increased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619012	17329996	CYP2D6 *4/*4 is not associated with differences in desmethyl-mirtazapine parameters when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183619051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619051	15538128	CYP2D6 *4/*4 is associated with decreased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619060	15538128	CYP2D6 *1/*1xN is associated with increased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619088	15538128	CYP2D6 *1/*1xN is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183619103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619103	15538128	CYP2D6 *4/*4 is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183618857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618857	19071885	CYP2D6 *4 + *5 are associated with increased serum concentrations of S(+)-mirtazapine, mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine when treated with mirtazapine in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.25
1451677518	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451677518	1451465284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465284	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.	3.5
1043880818	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1043880818	PA166182843	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182843		Annotation of DPWG Guideline for atorvastatin and SLCO1B1	100
1043880818	1451151642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151642	32453264	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.	-1.5
1043880818	1451163185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163185	32128760	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.	3.0
1043880818	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1043880818	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1043880818	1451390498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390498	26376374	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-0.875
1043880818	1451390500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390500	30569848	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.5
1043880818	1451465304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465304	34114646	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-2.0
1043880818	1451479880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479880	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.375
1043880818	1451480162	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480162	33150478	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-1.0
1043880818	827810986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810986	21928084	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	-1.5
1043880818	769164520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164520	21243006	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.	-0.25
1043880818	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1043880818	1183699594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699594	24263182	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.	3.25
1043880818	1447689782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447689782	26086347	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.	2.5
1043880818	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1043880818	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1043880818	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
827923032	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
827923032	1184988306	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988306	20952418	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
827923032	1184988061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988061	20338069	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.75
827923032	1184233697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233697	24145522	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections.	0.0
827923032	1446905193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905193	25611810	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	1447680376	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680376	26774523	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.5
827923032	1447680746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680746	26779253	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	1448104256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104256	27299708	Genotype GG is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	1.5
827923032	1448107499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107499	26196596	Genotype GG is associated with increased dose of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	0.0
827923032	981478640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478640	22471906	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	981480729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981480729	22927450	Genotype TT is associated with increased exposure of efavirenz in women with HIV Infections as compared to genotypes GG + GT.	2.5
827923032	982046514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046514	23080225	Allele T is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele G.	2.5
827923032	827692937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827692937	20860463	Genotype TT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	827695744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695744	15864119	Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	827807674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807674	18281305	Allele T is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele G.	2.5
827923032	827811199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811199	20723261	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	827922951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922951	15622315	Allele T is associated with increased plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy when treated with efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	769162981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162981	20860463	Genotypes GT + TT are associated with increased PBMC-associated drug concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	769163543	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163543	16267764	Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.	2.75
827923032	769163473	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163473	19371316	Genotype TT is associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	769163086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163086	19779319	Genotype TT is associated with increased plasma concentration (p<0.001) of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	769162974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162974	15864119	Genotype TT is associated with increased intracellular PBMC exposure of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1183491412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491412	23254426	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1183491417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491417	23254426	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	2.0
827923032	1183491421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491421	23254426	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1183634127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634127	23970651	Genotype GT is associated with increased plasma level of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1183634159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634159	24080498	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.25
827923032	1184233832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233832	24551111	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.5
827923032	1184349348	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349348	20625352	Genotypes GT + TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184471312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471312	19659438	Genotype TT (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG (assigned as normal metabolizer phenotype) .	1.5
827923032	1184471369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471369	19659438	Allele T (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele G (assigned as normal metabolizer phenotype) .	1.5
827923032	1184472014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472014	24551111	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	3.0
827923032	1184473116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473116	24316028	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1184473123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473123	24316028	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.25
827923032	1184473161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473161	24316028	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele G.	1.75
827923032	1184473237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473237	23399569	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184473241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473241	23399569	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GT.	1.25
827923032	1184473245	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473245	23399569	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184473309	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473309	23172109	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1184473321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473321	23172109	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	2.0
827923032	1184511673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511673	20441246	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.	0.25
827923032	1184512470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512470	22057858	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	0.0
827923032	1184987905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987905	24956253	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.	0.0
827923032	1185234900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234900	25303294	Genotypes GT + TT is associated with concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1451122240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451122240	32209837	Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.	2.0
827923032	1451127146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451127146	31628422	Genotypes GT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype GG.	1.0
827923032	1451131980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451131980	32106141	Genotype TT is associated with decreased metabolism of efavirenz in women with HIV Infections as compared to genotype GG.	0.125
827923032	1444698851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698851	25669165	Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.	2.5
827923032	1448265859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448265859	27655857	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	1.0
827923032	1448633511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633511	28145050	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448636173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636173	28692529	Genotypes GT + TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923032	1448663995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448663995	28816644	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1448684688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448684688	28187506	Genotypes GT + TT are associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	1.0
827923032	1448821568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821568	28718515	Genotypes GT + TT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.5
827923032	1448993476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993476	24521642	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.75
827923032	1448993691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993691	25974723	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448993700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993700	19218571	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	1448994222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994222	22950382	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448994415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994415	28886044	Genotype TT is associated with increased concentrations of efavirenz in children with HIV Infections.	1.5
827923032	1448995933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995933	18728241	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.5
827923032	1448995941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995941	17918089	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.25
827923032	1448997108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997108	26831894	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	0.125
827923032	1448997129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997129	26107645	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997148	25889207	Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448997209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997209	25882300	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448997218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997218	25831219	Genotypes GT + TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997225	25501988	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	0.125
827923032	1448997232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997232	24831655	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1448997239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997239	24299220	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1448997257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997257	22481606	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1448997449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997449	20841522	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.0
827923032	1448997462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997462	20720517	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	1448997483	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997483	19704172	Genotypes GT + TT are associated with increased concentrations of efavirenz as compared to genotype GG.	1.5
827923032	1448997489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997489	19531981	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.25
827923032	1448997496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997496	19433561	Genotypes GT + TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	0.125
827923032	1448997672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997672	19124658	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.5
827923032	1448997679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997679	18784455	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.0
827923032	1448997691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997691	18057928	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	0.0
827923032	1448997712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997712	17968817	Genotype GT is associated with increased concentrations of efavirenz in women HIV Infections as compared to genotype GG.	0.0
827923032	1448997743	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997743	17047492	Genotypes GT + TT are associated with increased exposure to efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997777	16495778	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.25
827923032	1448997797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997797	16392089	Genotype TT is associated with increased exposure to efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.0
827923032	1448998426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998426	15825040	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923032	1448998441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998441	15668854	Genotype TT is associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	0.125
827923032	1448998466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998466	16857630	Genotype GT is associated with increased concentrations of efavirenz in men with HIV Infections as compared to genotype GG.	0.125
827923032	1448998482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998482	18839779	Genotypes GT + TT are associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	0.125
827923032	1448998489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998489	19474465	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1449156764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449156764	23763943	Genotype GT is associated with increased concentrations of efavirenz as compared to genotype GG.	0.125
827923032	1449275102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449275102	29624706	Genotype TT is associated with increased concentrations of efavirenz in people with Hepatitis B and HIV Infections as compared to genotypes GG + GT.	0.0625
827923042	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
827923042	827695756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695756	15864119	Genotype TT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.75
827923042	827695768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695768	15864119	Genotype TT is associated with increased likelihood of Fatigue when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.	3.0
827923042	827811208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811208	20723261	Genotype TT is not associated with increased likelihood of Drug Toxicity when treated with efavirenz, lamivudine and stavudine in people with HIV Infections as compared to genotypes GG + GT.	-1.25
827923042	827922504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922504	21715435	Genotype TT is associated with early (< 3 months) termination of efavirenz therapy when treated with efavirenz as compared to genotypes GG + GT.	3.25
827923042	827922962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922962	15622315	Allele T is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele G.	2.0
827923042	1183614660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614660	23859571	Allele T is associated with risk of central nervous system adverse side effects when treated with efavirenz in people with HIV Infections as compared to allele G.	2.5
827923042	1183634134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634134	23970651	Genotype GT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923042	1183634227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634227	24080498	Genotypes GT + TT are not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.75
827923042	1184473278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473278	24517233	Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in men with HIV Infections.	2.5
827923042	1184987941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987941	24956253	Allele T is associated with increased likelihood of Disorders of Excessive Somnolence when treated with efavirenz in people with HIV Infections.	2.0
827923042	1448265875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265875	27655857	Allele T is not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele G.	-0.25
827923042	1448633500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633500	28145050	Genotypes GT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923042	1448636188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636188	28692529	Genotype TT is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-2.0
827923042	1448993680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993680	25974723	Genotype TT is not associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.5
827923042	1448993713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993713	19218571	Genotype TT is not associated with increased risk of Central Nervous System Diseases when treated with efavirenz or nevirapine in people with HIV Infections.	-1.5
827923042	1448994229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994229	22950382	Genotypes GT + TT are not associated with increased risk of Depression when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.25
827923042	1448997115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997115	26831894	Genotypes GT + TT are associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in children with HIV Infections as compared to genotype GG.	0.25
827923042	1448997441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997441	21633320	Genotype TT is associated with increased likelihood of Epilepsy, Absence when treated with efavirenz in children with HIV Infections as compared to genotype GG.	0.25
827923042	1448997475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997475	20441246	Genotype TT is associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	0.25
827923042	1448997704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997704	17968817	Genotype GT is associated with increased likelihood of Psychotic Disorders when treated with efavirenz in women HIV Infections as compared to genotype GG.	0.25
827923042	1448998433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998433	15668854	Genotype TT is associated with increased likelihood of Psychotic Disorders when treated with efavirenz in women with HIV Infections as compared to genotype GG.	0.25
827923042	1448998455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998455	16857630	Genotype GT is associated with Central Nervous System Diseases when treated with efavirenz in men with HIV Infections as compared to genotype GG.	0.25
827923042	1449156598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156598	28492729	Genotypes GT + TT are not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.0
827923042	1449156613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156613	25889207	Allele T is not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele G.	-1.5
827923042	1449156651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156651	20720517	Genotypes GT + TT are associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923042	1449156692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156692	17356468	Genotypes GT + TT are not associated with Drug Toxicity when treated with efavirenz in children with HIV Infections as compared to genotype GG.	-1.25
827923042	1449156706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156706	18503405	Genotype GT is associated with Sleep Disorders when treated with efavirenz as compared to genotype GG.	0.25
827923042	1449156714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156714	18655316	Allele T is associated with Status Epilepticus when treated with efavirenz as compared to allele G.	0.25
827923042	1449156757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156757	23763943	Genotype GT is associated with increased risk of Toxic liver disease when treated with efavirenz as compared to genotype GG.	0.25
827923042	1184168515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168515	23734829	CYP2B6 *1 is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV as compared to CYP2B6 *6.	-1.5
1451678626	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678626	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678626	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
981201535	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201535	1449161585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161585	29239269	Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	-3.0
981201535	1447987449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987449	22490566	Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
981201535	981398678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981398678	19473056	Genotypes CC + CT are associated with decreased likelihood of Neutropenia when treated with fluorouracil in women with Neoplasms as compared to genotype TT.	-2.25
981201535	769169640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169640	19104657	Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.	2.75
981201535	827892931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892931	14635116	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	0.0
981201535	1447945605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945605	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201535	1447991474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991474	11156223	Allele C is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.25
981201535	1448119062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119062	18299612	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
981201535	1448122697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122697	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
981201535	1448123099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123099	20819423	Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	0.0
981201535	1448124184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124184	23736036	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201535	1448124647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124647	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-2.0
981201535	1448126260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126260	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele T.	-2.0
981201535	1448262663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262663	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201535	1449161605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161605	29239269	Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.	-2.5
981201535	1449162069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162069	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981201535	1449732006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732006	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
981201535	1450371940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371940	30723313	Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	-2.0
1183616940	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1183616940	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1183616940	1183682179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682179	3769385	CYP2D6 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183616940	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183616940	1183684371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684371	7965806	CYP2D6 poor metabolizers is associated with increased mean area under the plasma concentration-time curve (AUC) of desipramine when treated with imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183616940	1183684376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684376	3533565	CYP2D6 poor metabolizers is associated with increased imipramine and desipramine plasma concentrations when treated with imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1183616940	1184470658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470658	2741190	CYP2D6 poor metabolizers are associated with increased plasma concentration of imipramine and desipramine when treated with imipramine.	0.0625
1183616940	1446905104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905104	3356084	CYP2D6 poor metabolizers are not associated with metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	-0.0625
1183616940	1183684359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684359	7965806	CYP2D6 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183616940	1183684336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684336	7640151	CYP2D6 *3/*4 + *4/*4 + *5/*5 are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	0.0
1183616940	1446900845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900845	9014200	CYP2D6 *3/*5 + *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*5 + *1/*3 + *1/*4.	0.0
1183616940	1446902165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902165	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	2.5
981201946	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201946	1447945626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945626	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
981201946	827892923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892923	14635116	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
981201946	1450953025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953025	26603945	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele C.	-1.0
981201946	1450954000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954000	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
981201946	1450954540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954540	19473056	Genotype CT is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	-1.5
981201946	1450954660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954660	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
981201946	1450959905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450959905	15591715	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
981201946	1448124239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124239	23736036	Genotype CT is associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.0
981201946	1448126269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126269	26794347	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele C.	-1.75
981201946	1448262697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262697	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201946	1449161763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161763	28427087	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CT + TT.	-2.0
981201946	1449162040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162040	29065426	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	-2.0
981201946	1449732020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732020	30114658	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.5
1183618725	PA166104998	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104998		Annotation of CPIC Guideline for nortriptyline and CYP2D6	100
1183618725	PA166104961	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104961		Annotation of DPWG Guideline for nortriptyline and CYP2D6	100
1183618725	1183698887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698887	24257813	CYP2D6 poor metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1446900047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900047	4082245	CYP2D6 ultrarapid metabolizer phenotype is associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major.	0.0625
1183618725	1446901165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901165	6111662	CYP2D6 poor metabolizers are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major.	0.0625
1183618725	1447519878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519878	24257813	CYP2D6 intermediate metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1447519884	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519884	24257813	CYP2D6 ultrarapid metabolizer phenotype are associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1183618214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618214	9585799	CYP2D6 *4 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618225	9585799	CYP2D6 *3 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618233	9585799	CYP2D6 *5 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618241	9585799	CYP2D6 *1/*2xN is associated with increased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618249	9585799	CYP2D6 *4/*4 is associated with decreased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183618725	1183618362	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618362	11682257	CYP2D6 *4 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618379	11682257	CYP2D6 *3 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618387	11682257	CYP2D6 *5/*10 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618467	10770451	CYP2D6 *10 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183618725	1183618505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618505	10770451	CYP2D6 *5 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183618725	1183624207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624207	8867869	CYP2D6 *1/*4 + *1/*5 is not associated with differences in nortriptyline concentrations when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	-0.125
1183618725	1183624218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624218	8867869	CYP2D6 *1/*4 + *1/*5 is associated with decreased concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183624247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624247	11673748	CYP2D6 *1/*1xN is associated with very low nortriptyline after 7 days of treatment when treated with nortriptyline.	0.125
1183618725	1183678562	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678562	17470523	CYP2D6 *10 is associated with decreased clearance of nortriptyline as compared to CYP2D6 *1.	0.0
1183618725	1183678570	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678570	17470523	CYP2D6 *17 is associated with decreased clearance of nortriptyline as compared to CYP2D6 *1.	0.0
1183618725	1184468489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468489	9797795	CYP2D6 *1/*10 is not associated with metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183618725	1184468498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468498	9797795	CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1183618725	1184468532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468532	16778723	CYP2D6 *1/*10 is not associated with metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1183618725	1184468543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468543	16778723	CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.	0.125
1183618725	1184468865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468865	15483356	CYP2D6 *5/*10 is associated with increased plasma concentrations when treated with nortriptyline.	0.125
1183618725	1446901389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901389	8093319	CYP2D6 *2/*1xN is associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major.	0.125
1183618725	1446902725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902725	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	1.0
1183618725	1446903079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903079	20531370	CYP2D6 *3 + *4 + *5 + *6 are associated with increased concentrations of nortriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.0
1183618725	1446904319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904319	8093319	CYP2D6 *2/*1xN is associated with increased dose of nortriptyline in people with Depressive Disorder, Major.	0.125
1183618725	1446904458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904458	11682257	CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.	1.5
1183618725	1446904494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904494	9585799	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.	2.0
1183618725	1446899759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899759	12814461	CYP2D6 *1/*10 is not associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1447989732	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989732	1449575578	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575578	29769267	Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.	0.0
1447989732	1448125041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125041	24648345	Allele A is not associated with activity of DPYD when assayed with fluorouracil as compared to allele C.	-0.0
1447989732	1449575614	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575614	29769267	Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.	0.0
1447964187	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1447964187	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1447964187	1447964156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964156	25698453	Allele A is associated with response to ivacaftor in Cystic Fibrosis as compared to allele G.	0.25
1447964187	1447984881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984881	26324139	Genotype AG is associated with response to ivacaftor in women with Cystic Fibrosis.	0.25
1447964187	1447984897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984897	26070913	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	1.75
1447964187	1447986312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447986312	26070913	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	1.75
1447964187	1449191039	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191039	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447964187	1449192603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192603	28419121	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183621726	PA166104969	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104969		Annotation of DPWG Guideline for flecainide and CYP2D6	100
1183621726	1448099915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099915	26195225	CYP2D6 normal metabolizer genotype is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	1.0
1183621726	1183621641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621641	22718623	CYP2D6 *10 is not associated with pharmacokinetics of flecainide in healthy Chinese subjects when exposed to flecainide in healthy individuals as compared to CYP2D6 *1.	-0.125
1183621726	1183621590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621590	22941032	CYP2D6 *4 + *5 + *10 + *21 + *36 are associated with increased age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias when treated with flecainide as compared to CYP2D6 *1.	2.0
1183621726	1183621673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621673	16944116	CYP2D6 *5/*36 + *10/*10 + *10/*36 + *21/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.	1.25
1451435945	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451435945	1444699296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699296	17698299	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1451435945	1449732321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732321	29876232	Allele T is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele C.	0.25
1451435945	1444699283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699283	17434445	Allele T is associated with Ototoxicity when treated with gentamicin as compared to allele C.	0.25
1451435945	1444699290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699290	17698030	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1451435945	1444699271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699271	20416460	Allele T is not associated with Ototoxicity when treated with gentamicin as compared to allele C.	-0.25
1451435945	1444699259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699259	16380089	Allele T is associated with Ototoxicity when treated with gentamicin, micronomicin or streptomycin as compared to allele C.	0.25
1451435945	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451435945	1451440104	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451440104	25474306	Allele T is associated with decreased activity of MT-RNR1 when exposed to gentamicin.	0.0
1451954560	1451947080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947080	35484400	Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	3.0
981201981	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201981	769169883	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169883	17848752	Genotype AG is associated with increased likelihood of Nausea and Vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	1.75
981201981	1451287140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451287140	17848752	Genotype AG is not associated with increased likelihood of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.25
981201981	1447676563	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676563	24434920	Allele G is associated with increased risk of hand-foot syndrome, Photophobia and Unspecified conjunctivitis when treated with fluorouracil in women with Rectal Neoplasms.	0.25
981201981	1447945354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945354	26846104	Genotypes AG + GG is associated with increased Infection, nephrotoxicity and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	2.0
981201981	981390734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981390734	19473056	Genotypes AG + GG are associated with decreased likelihood of overall gastrointestinal toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	2.0
981201981	827892796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892796	17121937	Genotypes AG + GG are not associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.75
981201981	827892947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892947	14635116	Genotype AG is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.5
981201981	1450951020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951020	23481061	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Head and Neck Neoplasms as compared to allele A.	-0.25
981201981	1450951420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951420	27752409	Genotype AG is associated with increased risk of Cardiomyopathies when treated with fluorouracil in people with Rectal Neoplasms.	0.25
981201981	1450952670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952670	11156223	Allele G is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms.	0.25
981201981	1450953284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953284	20819423	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele A.	-1.0
981201981	1450954100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954100	18299612	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
981201981	1450954546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954546	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.5
981201981	1448126278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126278	26794347	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele A.	-2.0
981201981	1448262652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262652	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201981	1449162062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162062	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
981201981	1449731947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731947	30114658	Genotypes AA + AG is associated with decreased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.0
981201981	1449732144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732144	29998006	Genotypes AA + AG is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms as compared to genotype GG.	-2.0
981203618	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981203618	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
981203618	982006241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006241	23603345	Allele A is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
981203618	827824687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824687	17700593	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	2.25
981203618	827892780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892780	17121937	Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
981203618	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
981203618	1184471966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471966	24167597	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	3.25
981203618	1444607104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607104	25381393	Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	4.0
981203618	1449731731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731731	30114658	Genotype AT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	4.0
981203618	1447945538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945538	26099996	Genotype AT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.0
981203618	1447950006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447950006	26794347	Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele T.	4.0
981203618	1447959064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959064	24923815	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
981203618	1447988411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988411	19795123	Allele A is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
981203618	1447991448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991448	11156223	Allele A is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.25
981203618	1447991648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991648	19104657	Allele A is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.0
981203618	1448118919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448118919	18299612	Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil.	3.0
981203618	1448123106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123106	20819423	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	-1.25
981203618	1448123303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123303	21498394	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	3.0
981203618	1448124229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124229	23736036	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
981203618	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
981203618	1449161738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161738	28427087	Genotype TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AA + AT.	-2.0
981203618	1449162090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162090	29065426	Genotype AT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981203618	1449716974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716974	27122156	Genotype AT is associated with risk of Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
981203618	1450372255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372255	30858516	Genotypes AA + AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.25
981203618	1450373060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373060	30485432	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	0.25
1451436121	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436121	1447964718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964718	18830133	Allele T is associated with increased risk of Ototoxicity when treated with tobramycin in people with Cystic Fibrosis as compared to allele C.	0.25
981238341	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
981238341	PA166182842	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182842		Annotation of DPWG Guideline for warfarin and CYP2C9	100
981238341	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
981238341	1449164047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164047	29298995	CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers.	1.5
981238341	1451221905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451221905	32559398	Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.	2.5
981238341	982033292	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033292	10073515	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982033561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033561	10961881	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
981238341	982036689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036689	18542936	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	982036901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036901	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982037879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037879	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	982038144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982038144	11966680	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	827602050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827602050	18305455	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
981238341	827641894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641894	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	827657784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827657784	17111199	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
981238341	827814765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814765	21148049	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.	-1.5
981238341	827823816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823816	21110192	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	608431758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431758	19794411	Allele T is associated with decreased dose of warfarin.	2.75
981238341	655387565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387565	19228618	Allele T is associated with decreased dose of warfarin.	0.0
981238341	827864546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864546	21228733	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1183699325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699325	17387222	Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C.	2.25
981238341	1183701883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701883	8004131	Allele T is associated with decreased metabolism of warfarin as compared to allele C.	0.125
981238341	1448109670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109670	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
981238341	1448112390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112390	26010205	Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.	2.5
981238341	1449192282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192282	28049362	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.	3.25
981238341	1449262882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449262882	29568565	Allele T is associated with dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	0.5
981238341	1449269199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269199	28973620	Allele T is associated with dose of warfarin as compared to allele C.	0.0
981238341	981785769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785769	23376925	Allele A is associated with decreased S-warfarin clearance when treated with warfarin as compared to allele G.	1.5
981238341	981785989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785989	23376925	Allele A is associated with decreased median weekly warfarin dose requirements when treated with warfarin as compared to allele G.	2.0
981238341	827787814	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787814	21635147	Allele A is associated with warfarin variability when treated with warfarin as compared to allele G.	2.0
981238341	608431781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431781	20072124	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.0
981238341	827864548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864548	21228733	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
981238341	608431785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431785	20072124	Allele del is associated with decreased dose of warfarin.	2.5
981238341	1448109688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109688	27121899	Allele A is associated with dose of warfarin as compared to allele del.	0.0
981238341	1449005482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005482	28685643	Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A.	0.25
981238341	982036973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036973	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982043421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043421	15970795	Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.	2.0
981238341	608431789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431789	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1448109696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109696	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
981238341	982032955	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032955	18535201	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982033206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033206	9630825	Genotype AC is associated with decreased in vivo metabolism of (S)-warfarin but not (R)-warfarin when treated with warfarin as compared to genotype AA.	1.75
981238341	982033269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033269	10073515	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982033533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033533	10961881	Allele C is associated with decreased dose of warfarin as compared to allele A.	3.0
981238341	982035694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035694	18030307	Genotype AC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.	2.5
981238341	982036698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036698	18542936	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	982036874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036874	19387626	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982037860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037860	20072124	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	827602228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827602228	18305455	Allele C is associated with decreased dose of warfarin as compared to allele A.	3.0
981238341	827641903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641903	19300499	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	827658659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827658659	17111199	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	827661941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827661941	16432637	Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.	3.0
981238341	827814740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814740	21148049	Allele C is associated with decreased dose of warfarin as compared to allele A.	1.5
981238341	827823825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823825	21110192	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	827845798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845798	22248286	Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.	2.75
981238341	655388494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388494	11127854	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	608431732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431732	19794411	Allele C is associated with decreased dose of warfarin.	2.75
981238341	655387562	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387562	19228618	Allele C is associated with decreased dose of warfarin.	0.0
981238341	769182559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182559	21383771	Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC.	2.5
981238341	827864562	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864562	21228733	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	1183699129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699129	19177029	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.75
981238341	1183699320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699320	17387222	Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A.	2.25
981238341	1183700614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700614	10509530	Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.	2.5
981238341	1184169096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169096	24728385	Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC.	3.0
981238341	1184482810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482810	23941071	Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC.	2.75
981238341	1184511620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511620	25026456	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1184756158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756158	25126975	Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	3.5
981238341	1444694693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694693	25594941	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	2.5
981238341	1446765922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765922	26257249	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1447519932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519932	19752777	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.75
981238341	1448109677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109677	27121899	Allele A is associated with dose of warfarin as compared to allele C.	0.0
981238341	1448112396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112396	26010205	Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.	2.5
981238341	1448431507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431507	26223945	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	2.5
981238341	1448615546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615546	28429387	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	3.0
981238341	1448624168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624168	28550460	Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.	2.5
981238341	1449005162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005162	29054760	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1449005213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005213	28262345	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1449190935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190935	29432897	Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A.	2.75
981238341	1449192290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192290	28049362	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	3.25
981238341	1449258301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449258301	27617219	Allele C is associated with decreased dose of warfarin as compared to allele A.	1.75
981238341	1449269204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269204	28973620	Allele C is associated with dose of warfarin as compared to allele A.	0.0
981238341	982034970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034970	21228733	Genotype CT is associated with decreased dose of warfarin as compared to genotype TT.	2.5
981238341	982036710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036710	18542936	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
981238341	982036958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036958	19387626	Allele C is associated with decreased dose of warfarin as compared to allele T.	0.0
981238341	982036951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036951	19387626	Allele G is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982036966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036966	19387626	Allele G is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	608431793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431793	20072124	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	827864554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864554	21228733	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1448109681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109681	27121899	Allele C is associated with dose of warfarin as compared to allele G.	0.0
981238341	1449005488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005488	28685643	Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C.	0.25
981238341	827919407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919407	22378156	CYP2C9 *8 is associated with decreased in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein when treated with warfarin as compared to CYP2C9 *1/*1.	1.0
981238341	827783868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783868	21174619	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827925130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925130	22528326	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1.	2.5
981238341	978614428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614428	22676192	CYP2C9 *2 is associated with dose of warfarin.	0.0
981238341	978614420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614420	22676192	CYP2C9 *8 is associated with dose of warfarin.	0.0
981238341	978614436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614436	22676192	CYP2C9 *3 is associated with dose of warfarin.	0.0
981238341	981344709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344709	12496751	CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	1.25
981238341	981344716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344716	12496751	CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	1.25
981238341	981345061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981345061	12496751	CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	0.75
981238341	981345093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981345093	12496751	CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	0.75
981238341	981483998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483998	20653676	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1.	2.5
981238341	827783863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783863	21174619	CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827783312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783312	22040439	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	0.25
981238341	827807419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807419	18322281	CYP2C9 *1/*1 is associated with increased dose of warfarin.	2.75
981238341	827783860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783860	21174619	CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827863693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863693	21692828	CYP2C9 *3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	0.0
981238341	827863698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863698	21692828	CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	0.0
981238341	827919392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919392	22378156	CYP2C9 *8 is associated with decreased unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	827919897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919897	22594507	CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.	3.0
981238341	827919924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919924	22594507	CYP2C9 *3 is associated with decreased dose of warfarin.	3.0
981238341	827919905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919905	22594507	CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin.	-2.0
981238341	827919910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919910	22594507	CYP2C9 *2 is associated with decreased dose of warfarin.	3.0
981238341	981505317	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505317	21185752	CYP2C9 *2 is associated with lower warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	981505330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505330	21185752	CYP2C9 *3 is associated with decreased warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	981754835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754835	23061746	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3.	2.5
981238341	981858924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858924	23183958	CYP2C9 *1/*2 + *1/*3 is not associated with dose of warfarin in children as compared to CYP2C9 *1/*1.	-0.25
981238341	982037353	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037353	19745563	CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982037661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037661	17391071	CYP2C9 *1/*3 + *1/*4 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982040707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982040707	19135231	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043050	17510308	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043064	17510308	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043409	15590403	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982043415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043415	15590403	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982043530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043530	17049586	CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	982043569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043569	16493479	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043575	16493479	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043654	17456829	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	3.0
981238341	982043785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043785	12621390	CYP2C9 *1/*3 is associated with decreased unbound oral clearance for S-warfarin when treated with warfarin as compared to CYP2C9 *1/*1.	1.25
981238341	982043863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043863	14656880	CYP2C9 *3 is associated with decreased warfarin dose (40% lower) when treated with warfarin as compared to CYP2C9 *1.	0.25
981238341	982043913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043913	15883587	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	982043919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043919	15883587	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	982043928	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043928	15947090	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982043935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043935	15947090	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982044336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044336	16611750	CYP2C9 *3 is associated with decreased warfarin dose after adjustment for VKORC1*1173 when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982044343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044343	16611750	CYP2C9 *2 is not associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	-1.25
981238341	982044381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044381	16890578	CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982044620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044620	18756910	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982044655	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044655	18836275	CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	982045728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045728	19077919	CYP2C9 *1/*3 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982045852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045852	19297219	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982045885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045885	19297219	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982046133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046133	19874474	CYP2C9 *2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982046140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046140	19874474	CYP2C9 *3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982047396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047396	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*3.	2.5
981238341	982047403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047403	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*2.	0.0
981238341	982047409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047409	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*2.	2.5
981238341	982047415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047415	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*3.	2.5
981238341	982047968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047968	22130800	CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1.	0.0
981238341	1183697100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697100	22349464	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.25
981238341	1183697679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697679	23990957	CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	2.75
981238341	1183699114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699114	19177029	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1183699285	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699285	17387222	CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	2.25
981238341	1183699310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699310	17387222	CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	2.25
981238341	1183700066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700066	19031075	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700096	19031075	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700106	19031075	CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700115	19031075	CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700123	19031075	CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700166	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700587	10509530	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in men as compared to CYP2C9 *1/*1.	2.5
981238341	1183700648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700648	15001971	CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700669	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700669	15001971	CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700730	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700730	20375999	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.0
981238341	1183700748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700748	20375999	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.0
981238341	1183700775	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700775	17851566	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700824	17851566	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700910	19663669	CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.0
981238341	1183701108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701108	18574025	CYP2C9 *2 is associated with decreased dose of warfarin.	2.5
981238341	1183701116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701116	18574025	CYP2C9 *3 is associated with decreased dose of warfarin.	2.5
981238341	1183701135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701135	18574025	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin.	0.0
981238341	1183701311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701311	17989110	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.0
981238341	1183701320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701320	17989110	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.0
981238341	1183701419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701419	19802360	CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.25
981238341	1183701501	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701501	20421126	CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1.	2.5
981238341	1183701514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701514	20421126	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.	2.5
981238341	1183701549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701549	16160068	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	0.25
981238341	1183701565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701565	16160068	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	0.25
981238341	1183701573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701573	15094935	CYP2C9 *1/*3 is associated with decreased dose of warfarin.	0.25
981238341	1183701586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701586	15094935	CYP2C9 *6/*6 is associated with decreased dose of warfarin.	0.25
981238341	1184471902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471902	22892446	CYP2C9 *1/*3 is associated with decreased Unbound oral clearance for S-warfarin when treated with warfarin in children as compared to CYP2C9 *1/*1.	0.125
981238341	1184472455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472455	20128861	CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin.	1.5
981238341	1184472857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472857	24474498	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	1.75
981238341	1184472866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472866	24474498	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	0.0
981238341	1184473587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473587	25001883	CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1.	2.25
981238341	1184482762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482762	23949431	CYP2C9 *3/*3 + *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184483457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483457	23208322	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1184483798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483798	23104259	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184509852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509852	22854539	CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.0
981238341	1184510026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510026	22549502	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1184510108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510108	22274142	CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1184510172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510172	22075505	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.25
981238341	1184510232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510232	21782804	CYP2C9 *3/*13 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.25
981238341	1184510263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510263	21590310	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1184510278	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510278	21590310	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.	2.5
981238341	1184510322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510322	21320153	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184511561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511561	25042728	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.0
981238341	1184511945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511945	24029542	CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as poor metabolizers and intermediate metabolizers phenotype) .	1.5
981238341	1184654356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654356	24330000	CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654374	24330000	CYP2C9 *2/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	0.0
981238341	1184654383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654383	24330000	CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654392	24330000	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654401	24330000	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184748897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748897	25084205	CYP2C9 *3 is associated with decreased dose of warfarin.	2.0
981238341	1185235722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235722	24601977	CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	2.25
981238341	1444695840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695840	25712185	CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	1445296737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296737	26024874	CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1447519652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519652	18466099	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1447682605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682605	26745506	CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.75
981238341	1448267984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267984	21981797	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.	2.5
981238341	1448268043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268043	22534826	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	2.75
981238341	1448269030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448269030	21326313	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3.	3.0
981238341	1448573256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573256	28135054	CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183689399	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689399	22990331	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.0
981238341	1451120160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451120160	31395958	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1451130680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451130680	31653973	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1451516060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451516060	20833980	CYP2C9 *2 + *3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.	-1.25
981238341	982045974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045974	19582440	CYP2C9 *1/*3 + *3/*3 are associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1451436138	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436138	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436138	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
981419257	PA166104997	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104997		Annotation of CPIC Guideline for abacavir and HLA-B	100
981419257	PA166104991	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104991		Annotation of DPWG Guideline for abacavir and HLA-B	100
981419257	PA166104833	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104833		Annotation of FDA Label for abacavir and HLA-B	100
981419257	981349371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349371	18256392	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.0
981419257	981349377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349377	15247625	HLA-B *57:01:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.75
981419257	981475111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475111	11888582	HLA-B *57:01:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV.	3.5
981419257	981476261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476261	22197535	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.25
981419257	1444705964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705964	25877443	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	1.0
981419257	1444707690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707690	25934581	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.0
981419257	1444876870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444876870	15024131	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.0
981419257	1444877117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444877117	18184080	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.25
981419257	1444877145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444877145	19195327	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.75
981419257	1448255629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255629	27403179	HLA-B *57:01:01 is associated with Drug Hypersensitivity when treated with abacavir in people with HIV.	2.0
981419257	1448260768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260768	27530904	HLA-B *57:01:01 is associated with risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	0.25
1447989739	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989739	1450960027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450960027	9865912	Genotype AC is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Breast Neoplasms as compared to genotype CC.	0.25
1447989739	1447945441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945441	26846104	Genotype CC is not associated with Drug Toxicity when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.	-1.5
981419260	PA166105003	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105003		Annotation of CPIC Guideline for allopurinol and HLA-B	100
981419260	827919454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919454	21545408	HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0.0
981419260	981345627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345627	21393610	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
981419260	981345632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345632	21301380	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
981419260	981345637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345637	19696695	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.75
981419260	981345642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345642	19018717	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	981345647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345647	18192896	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	3.0
981419260	981345654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345654	15743917	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	981419988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419988	22909208	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	3.5
981419260	981420004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420004	22909208	HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	2.75
981419260	1183682459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682459	23669020	HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682532	23600531	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682546	23280169	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.	0.25
981419260	1183682555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682555	22348415	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1183682626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682626	21906289	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	2.0
981419260	1183685075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685075	17587850	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.	0.25
981419260	1183685103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685103	22017528	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	3.5
981419260	1183685113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685113	19483528	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.	0.25
981419260	1183685121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685121	22901319	HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.	0.25
981419260	1184467886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467886	21912425	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1184470833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470833	24858023	HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	-1.75
981419260	1184748340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748340	25115449	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1184755884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755884	19002350	HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.	-0.25
981419260	1184756798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756798	21393610	HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.625
981419260	1184987721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987721	25257159	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.75
981419260	1184998111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998111	25327504	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.	1.5
981419260	1445362018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445362018	26104483	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1447672343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672343	26632391	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	1447676605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676605	26655481	HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	1.0
981419260	1447949095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949095	26937673	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.	0.25
981419260	1448255668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255668	26996548	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.75
981419260	1448256105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256105	27486401	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1448530471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530471	25899558	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol.	0.25
981419260	1448997619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997619	28857441	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	4.0
981419260	1449170079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170079	29392141	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.	3.75
981419260	1450342159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342159	30383575	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic when treated with allopurinol.	0.25
981419260	1451211440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211440	32433341	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.25
981419260	1446902249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902249	25566896	HLA-B *58:01 is associated with Drug Hypersensitivity and Exanthema when treated with allopurinol.	0.25
981419260	1448429006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448429006	27835909	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.0
981419260	1183685128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685128	21790926	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.	0.25
981419260	1448624570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624570	28509689	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	3.0
1451434880	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434880	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434880	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434880	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434880	1451437476	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437476	12127547	Allele G is associated with increased affinity to MT-RNR1 of kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434880	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434880	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434880	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434880	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1449191413	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191413	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191413	1449191128	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191128	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191424	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191424	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191424	1449191044	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191044	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191430	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191430	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191430	1449191123	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191123	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191643	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191643	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191643	1449191133	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191133	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191649	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191649	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191649	1449191103	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191103	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191664	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191664	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191664	1449191073	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191073	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1451244740	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1451244740	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451244740	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451244740	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451244740	1451341160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451341160	19833260	SLCO1B1 *5 is not associated with increased risk of Drug Toxicity when treated with pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.	-1.5
1451678460	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1451678460	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678460	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451678460	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451678460	1451341160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451341160	19833260	SLCO1B1 *5 is not associated with increased risk of Drug Toxicity when treated with pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.	-1.5
1450806874	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1450806874	PA166104987	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104987		Annotation of DPWG Guideline for lansoprazole and CYP2C19	100
1450806874	1450806823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806823	9164419	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1450806874	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1450806874	982047056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047056	22076562	CYP2C19 *17/*17 is associated with increased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.25
1450806874	982047065	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047065	22076562	CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.75
1450806874	982047769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047769	23623526	CYP2C19 *2 + *3 + *8 + *9 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of lansoprazole in children with Asthma as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.25
1450806874	1183618547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618547	11929404	CYP2C19 *1/*1 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	1.5
1450806874	1183618564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618564	11929404	CYP2C19 *1/*2 + *1/*3 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	1.0
1450806874	1183618805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618805	12386647	CYP2C19 *1/*1 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.	1.75
1450806874	1183618830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618830	12386647	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.	1.25
1450806874	1183623395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623395	18241283	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.125
1450806874	1183629838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629838	22076562	CYP2C19 *1/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.25
1450806874	1183629846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629846	22076562	CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*2.	1.25
1450806874	1450806845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806845	9272410	CYP2C19 *2/*2 + *2/*3 are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1450806874	1450809629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809629	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1451434930	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434930	1447964710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964710	18830133	Allele G is associated with increased risk of Ototoxicity when treated with tobramycin in people with Cystic Fibrosis as compared to allele A.	0.25
1451434930	1451433420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451433420	24703164	Allele G is not associated with Ototoxicity when treated with tobramycin in children with Cystic Fibrosis as compared to allele A.	-0.25
1451434930	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434930	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434930	1451437476	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437476	12127547	Allele G is associated with increased affinity to MT-RNR1 of kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434930	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451678112	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451678112	1448601968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601968	27967318	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.	2.0
1451678112	1444713578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713578	26020121	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1451678210	PA166262261	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262261		Annotation of CPIC Guideline for pitavastatin and SLCO1B1	100
1451678210	1451674520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674520	23556337	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.	1.0
1451678210	1451674400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674400	17460607	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.	1.5
1451678188	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451678188	1448601968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601968	27967318	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.	2.0
1451678188	1444713578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713578	26020121	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1450814813	PA166262261	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262261		Annotation of CPIC Guideline for pitavastatin and SLCO1B1	100
1450814813	1451674520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674520	23556337	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.	1.0
1450814813	1450814783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814783	23007012	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.	2.0
1450814813	1451226403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226403	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1450814813	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1450814813	1451674400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674400	17460607	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.	1.5
1449191734	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191734	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191734	1449191049	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191049	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1451465324	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451465324	1451465284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465284	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.	3.5
981420042	PA166104789	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104789		Annotation of FDA Label for gefitinib and EGFR	100
981420042	1446908230	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908230	26490356	Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	1.75
981420042	1446908159	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908159	26490356	Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
981420042	981417211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417211	20022809	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.0
981420042	981417228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417228	20573926	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417247	20573926	Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.0
981420042	981417256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417256	20573926	Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417279	21900837	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417296	19692680	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.25
981420042	981417305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417305	19692680	Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.	3.0
981420042	981419226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419226	22760226	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419236	22760226	Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419322	20038723	Allele G is associated with increased response rates when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	0.0
981420042	981419331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419331	20038723	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.	3.0
981420042	981419441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419441	16204011	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.25
981420042	981419460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419460	17047654	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.0
981420042	981419469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419469	17047654	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	1.5
981420042	981419477	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419477	17473659	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419589	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419589	17106442	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419598	17106442	Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	1.5
981420042	981419607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419607	16956694	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419616	16956694	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419624	16956694	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419634	15897572	Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.	2.25
981420042	981419643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419643	15897572	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.	2.25
981420042	981419653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419653	16203769	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419668	17317677	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
981420042	981419710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419710	17387341	Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419719	17387341	Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419727	17192902	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419736	17192902	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419746	16865253	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419755	16865253	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	1.5
981420042	981419803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419803	16115929	Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419813	17285735	Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475192	17429313	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475201	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475201	17429313	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475368	22215752	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
981420042	981477340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477340	22370314	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.25
981420042	981477349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477349	22370314	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.75
981420042	981477357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477357	22370314	Allele G is not associated with Overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-1.25
981420042	981477365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477365	22370314	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.0
981420042	981477373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477373	22370314	Allele G is not associated with progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-0.25
981420042	981477381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477381	22370314	Allele G is not associated with overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-0.25
981420042	827926134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827926134	15118073	Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	0.0
1451434900	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434900	1444696947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696947	9039999	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.0
1451434900	1444697015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697015	9391883	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697127	12920080	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697353	19818876	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin in children with as compared to allele A.	0.0
1451434900	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434900	1444697120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697120	12031626	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697145	14755216	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697179	16168391	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele A.	0.25
1451434900	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697212	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697212	16631122	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697250	17637808	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697293	19376484	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444696916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696916	7689389	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434900	1444697037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697037	9779807	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697046	9831149	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697075	9950117	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1446897414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897414	11174059	Allele G is associated with Ototoxicity when treated with isepamicin or streptomycin as compared to allele A.	0.25
1451434900	1451436280	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436280	8687424	Allele G is associated with decreased activity of MT-RNR1 when exposed to streptomycin in HeLa cells.	0.0
1451434900	1451436622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436622	11870684	Allele G is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451434900	1451437464	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437464	12054632	Allele G is not associated with activity of MT-RNR1 when exposed to streptomycin in cybrids.	-0.0
1451434900	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434900	1451437675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437675	16935512	Allele G is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451434900	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1451434900	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434900	1451437874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437874	19835846	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1451434900	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434900	1451440086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440086	23256547	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1451434900	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1447681932	PA166104995	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104995		Annotation of DPWG Guideline for metoprolol and CYP2D6	100
1447681932	1183685331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685331	23665868	CYP2D6 poor metabolizer is associated with increased peak plasma metoprolol concentration (CMax/dose), increased area under the concentration-time curve (AUC/dose), increased elimination half-life, and decreased apparent oral clearance (CL/F) when treated with metoprolol as compared to CYP2D6 ultra-metabolizer phenotype.	0.5625
1447681932	1447676621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676621	26461463	CYP2D6 normal metabolizers are associated with increased clearance of metoprolol in women with Pregnancy as compared to CYP2D6 intermediate metabolizers.	0.5
1447681932	1450944125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944125	10223777	Allele A is not associated with increased concentrations of metoprolol in healthy individuals as compared to allele G.	-0.125
1447681932	769181593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769181593	19037197	Allele T is associated with increased plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. when treated with metoprolol as compared to allele C.	2.25
1447681932	751923645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751923645	19037197	Genotype del/del is associated with increased plasma concentrations of metoprolol when treated with metoprolol.	1.25
1447681932	1450944140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944140	10223777	Allele A is associated with increased concentrations of metoprolol in healthy individuals as compared to allele G.	1.0
1447681932	1043858995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858995	15467211	CYP2D6 *10 is associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	0.5
1447681932	1043859002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859002	15467211	CYP2D6 *2 is not associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	-0.125
1447681932	1043859140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859140	15592325	CYP2D6 *2 is not associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	-2.0
1447681932	1043859395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859395	18834373	CYP2D6 *10 is associated with decreased metabolism of metoprolol in healthy individuals as compared to CYP2D6 *1.	1.0
1447681932	1184000492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000492	24193112	CYP2D6 *1/*4 + *4/*4 are associated with increased plasma metoprolol concentrations when treated with metoprolol as compared to CYP2D6 *1/*1.	2.5
1447681932	1184756327	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756327	10471072	CYP2D6 *4/*20 (assigned as poor metabolizers phenotype) is associated with decreased enzyme activity of CYP2D6 when assayed with metoprolol.	0.0
1447681932	1184756685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756685	15726636	CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of metoprolol in healthy individuals.	0.125
1447681932	1184756692	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756692	15726636	CYP2D6 *31 is associated with decreased enzyme activity of CYP2D6 when assayed with debrisoquine, dextromethorphan or metoprolol in yeast cells.	0.0
1447681932	1184756902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756902	11823760	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1447681932	1184756913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756913	11823760	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.	2.0
1447681932	1184756941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756941	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1447681932	1184986272	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184986272	11692084	CYP2D6 *35 is not associated with increased enzyme activity of CYP2D6 when assayed with debrisoquine, dextromethorphan or metoprolol in yeast cells as compared to CYP2D6 *1.	-0.0
1447681932	1043859051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859051	15592325	CYP2D6 *4 + *3 + *5 + *6 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	2.0
1447681932	1043859096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859096	15592325	CYP2D6 *9 + *29 + *45 + *46 + *17 + *10 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	2.0
981755803	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
981755803	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
981755803	981755665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755665	21083385	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	981755678	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755678	22047557	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	982009991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982009991	23590265	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	2.25
981755803	1043737620	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1043737620	23757361	Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.	0.0
981755803	1043737636	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1043737636	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
981755803	1183629335	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629335	24066763	Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.	0.25
981755803	1448267532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448267532	27745802	Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	1.5
981755803	1448423752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423752	27773592	Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	0.875
981755803	1449191908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191908	25682022	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	1449192031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192031	28651844	Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.	3.0
981755803	1449192055	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192055	28711222	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.25
981755803	1449192093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192093	25311995	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.0
981755803	1449192439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192439	28611235	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	1.5
981755803	1449192481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192481	26135562	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	1449192494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192494	25171465	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
981755803	1449192576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192576	25755212	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	1449192615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192615	26568242	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1449192709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192709	25473543	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	1449192721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192721	25145599	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1450043422	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450043422	23628510	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	3.0
981755803	1184512440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512440	25049054	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	1.5
981755803	981755746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755746	22942289	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	981755699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755699	19846789	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	981755787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755787	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	1043737597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737597	23757359	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	982006840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006840	23313410	Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.	0.25
981755803	1446903789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903789	24461666	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1448099051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099051	27158673	Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	2.0
1449191682	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191682	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191682	1449191108	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191108	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191682	1449192081	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192081	29279204	Allele T is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
982030369	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
982030369	1451408520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408520	28686080	Allele A is associated with dose of warfarin as compared to allele G.	0.0
982030369	982030316	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030316	23755828	Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.	0.0
982030369	982030322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030322	23755828	Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.	0.0
982030369	1185235783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235783	25461246	Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.	2.75
982030369	1445296716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296716	26024874	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.5
982030369	1447952633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952633	26877068	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.0
1183630065	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183630065	PA166104957	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104957		Annotation of DPWG Guideline for omeprazole and CYP2C19	100
1183630065	1450370714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370714	1505152	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0
1183630065	1450370721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370721	7648764	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450806689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806689	8675169	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.25
1183630065	1450806923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806923	9284848	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450806946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806946	9357389	CYP2C19 poor metabolizers are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	1450807902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807902	10626755	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	1450807931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807931	10671908	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	655387718	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387718	16413245	Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.	2.5
1183630065	655387742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387742	18294333	Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.	1.5
1183630065	1183619889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619889	15447734	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1183619918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619918	15447734	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1183623395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623395	18241283	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.125
1183630065	1183623411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623411	18241283	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	-0.125
1183630065	1183624136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624136	8747407	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183630065	1184471092	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184471092	24945780	CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with omeprazole in E. coli DH5alpha as compared to CYP2C19 *1.	0.0
1183630065	1184564759	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184564759	19661214	CYP2C19 *26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1184565887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184565887	19661214	CYP2C19 *26 is associated with decreased metabolism of mephenytoin and omeprazole as compared to CYP2C19 *1.	2.0
1183630065	1184566038	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184566038	19661214	CYP2C19 *26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1444696659	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696659	19661214	CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1444696670	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696670	19661214	CYP2C19 *10 is associated with decreased clearance of omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1447963286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963286	8747407	CYP2C19 *1/*2 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183630065	1447992028	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447992028	26153442	CYP2C19 *3 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1448263323	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448263323	27578295	CYP2C19 *24 is associated with decreased clearance of mephenytoin and omeprazole in E.coli as compared to CYP2C19 *1.	0.0
1183630065	1449166259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166259	29377228	CYP2C19 *2 is associated with decreased clearance of omeprazole in infants with Gastroesophageal Reflux as compared to CYP2C19 *1 + *17.	1.75
1183630065	1450806712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806712	8681489	CYP2C19 *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *1/*1.	1.0
1183630065	1450806762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806762	8823231	CYP2C19 *1/*1 is not associated with metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.75
1183630065	1450806785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806785	9014204	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1183630065	1450807298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807298	9797796	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.0
1183630065	1450807307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807307	9797796	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 (assigned as normal metabolizers phenotype) .	2.0
1183630065	1450807373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807373	9829356	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with acid-related disorders as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2.	2.0
1183630065	1450807702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807702	10206083	CYP2C19 *2/*3 + *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	0.125
1183630065	1450807854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807854	10511062	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.	2.0
1183630065	1450808537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808537	11046127	CYP2C19 *2/*2 are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.0
1183630065	1450809604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809604	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1447680365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680365	26244421	CYP2C19 *9 is associated with decreased metabolism of omeprazole in healthy individuals.	0.0
1183620575	PA166104962	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104962		Annotation of DPWG Guideline for propafenone and CYP2D6	100
1183620575	1450417472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450417472	14653957	CYP2D6 *10/*10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.	1.0
1183620575	1451294540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451294540	33203295	CYP2D6 *1/*5 + *2/*36 + *5/*10 + *5/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	1.5
1183620575	1451330400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451330400	12421483	CYP2D6 *10/*10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	1.0
982014094	PA166161954	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161954		Annotation of CPIC Guideline for ondansetron and CYP2D6	100
982014094	981954714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954714	12065557	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.	3.25
982014094	982006758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006758	15731591	CYP2D6 *1xN + *2xN are associated with decreased response to ondansetron in women as compared to CYP2D6 *1.	2.0
982014094	982006805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006805	15731591	CYP2D6 *1xN + *2xN are not associated with response to ondansetron in women as compared to CYP2D6 *5.	-1.5
982014094	981954745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954745	21840870	CYP2D6 *2/*2 + *2/*10 are not associated with response to ondansetron in people with Neoplasms.	-1.5
1183689217	PA166161537	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161537		Annotation of CPIC Guideline for voriconazole and CYP2C19	100
1183689217	PA166104990	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104990		Annotation of DPWG Guideline for voriconazole and CYP2C19	100
1183689217	1183685147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685147	15179414	CYP2C19 poor metabolizer genotype is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 normal metabolizer genotype.	0.0625
1183689217	1444714094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444714094	25558073	Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizers phenotype) .	0.0625
1183689217	1444714180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444714180	25239277	Genotypes *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.75
1183689217	1444827885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827885	25558073	Genotypes *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.0625
1183689217	1444827890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444827890	25558073	Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of Drug Toxicity when exposed to voriconazole as compared to CYP2C19 normal metabolizer.	0.125
1183689217	1444827896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827896	25239277	Genotypes *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.75
1183689217	1448123512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123512	27388292	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.	0.6875
1183689217	1449146934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146934	28923870	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.	1.125
1183689217	1449146940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146940	28923870	CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.	0.625
1183689217	1449732409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732409	29393850	Genotypes *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses.	0.75
1183689217	1449732418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732418	29393850	Genotypes *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) are not associated with metabolism of voriconazole in people with Mycoses.	-0.0625
1183689217	981565071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981565071	23215888	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in men with Granulomatous Disease, Chronic.	0.125
1183689217	982048012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048012	23588332	CYP2C19 *2 + *3 are associated with increased trough concentration of voriconazole in children as compared to CYP2C19 *1 + *17.	1.5
1183689217	1183685442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685442	19033450	CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2.	1.5
1183689217	1183848503	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848503	20669013	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1183689217	1183848916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848916	18982321	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183689217	1183848923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848923	18982321	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1183849008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849008	18982321	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .	2.0
1183689217	1183849398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849398	19299322	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183689217	1183849453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849453	21192313	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.	2.0
1183689217	1183944019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944019	24554646	CYP2C19 *1/*1 + *1/*17 are associated with increased metabolism of voriconazole.	0.0
1183689217	1183944026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944026	24554646	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of voriconazole.	0.0
1183689217	1184468739	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468739	21383338	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748470	25084200	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748497	25084200	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is not associated with dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	-0.25
1183689217	1184748512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748512	25084200	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748535	25084200	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184753704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753704	25155930	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of voriconazole in men with Hepatitis C, Lymphoma and Shock, Septic.	0.125
1183689217	1444713552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713552	26024717	CYP2C19 *2/*2 + *1/*2 + *1/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.75
1183689217	1444827924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827924	16890574	CYP2C19 *2/*2 is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183689217	1444827950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827950	24475354	CYP2C19 *2/*2 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3.	-1.0
1183689217	1444827966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827966	24475354	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) is associated with increased trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1444827994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827994	24403552	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.75
1183689217	1444828143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828143	22122271	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer genotype phenotype) is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828153	23400848	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.	0.125
1183689217	1444828163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828163	25120580	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828173	25986028	CYP2C19 *17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828207	21615537	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.	0.125
1183689217	1444841988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444841988	24475354	CYP2C19 *1/*1 + *1/*17 is associated with decreased trough concentration of voriconazole in people with Hematologic Diseases as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3.	2.0
1183689217	1444842336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842336	19033450	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.5
1183689217	1444842443	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842443	20002085	CYP2C19 *1/*1 (assigned as poor metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.0
1183689217	1444842618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842618	21507170	CYP2C19 *1/*2 is associated with increased concentrations of voriconazole.	0.125
1183689217	1445297704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297704	25999694	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	0.0
1183689217	1445556721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556721	26239729	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole as compared to CYP2C19 *1/*1.	0.125
1183689217	1445556737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556737	26239729	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to CYP2C19 *1/*1.	1.0
1183689217	1445584831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584831	25451051	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in children as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	0.125
1183689217	1446897275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897275	25239277	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) .	1.5
1183689217	1447672688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447672688	26239045	CYP2C19 *1/*2 + *1/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183689217	1447672698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447672698	26239045	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183689217	1447680755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680755	26775563	CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447680776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680776	26775563	CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447681020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681020	26775563	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447681039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681039	26775563	CYP2C19 *1/*2 + *2/*2 is not associated with dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	-0.125
1183689217	1447681077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681077	26775563	CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	1.5
1183689217	1447681119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681119	26775563	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447944033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944033	26861072	CYP2C19 *1/*1 is not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2.	-1.0
1183689217	1447944137	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944137	26861072	CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*3 + *2/*3.	1.5
1183689217	1447944149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944149	26861072	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1447944162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944162	26861072	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	-1.0
1183689217	1447962788	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447962788	27056297	CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in infants with Severe Combined Immunodeficiency.	0.125
1183689217	1448112553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112553	16003289	CYP2C19 *1/*1 is associated with increased clearance of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.0
1183689217	1448123702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123702	19933691	CYP2C19 *1/*2 is not associated with clearance of voriconazole in people with hematopoietic stem cell transplantation as compared to CYP2C19 *1/*1.	-0.125
1183689217	1448123818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123818	21831685	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3 are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	-0.125
1183689217	1448525969	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448525969	27937048	CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	1.75
1183689217	1448604929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604929	28306618	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.	2.25
1183689217	1448604948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604948	28306618	CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.	2.25
1183689217	1448616451	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616451	27432796	CYP2C19 *1 + *17 are associated with decreased exposure to voriconazole in healthy individuals as compared to CYP2C19 *2 + *3.	0.125
1183689217	1448616465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616465	27432796	CYP2C19 *2 + *3 are associated with increased exposure to voriconazole in healthy individuals as compared to CYP2C19 *1 + *17.	0.125
1183689217	1448820856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820856	28604474	CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*17.	1.75
1183689217	1449146891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146891	29026840	CYP2C19 *1/*2 is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*17.	1.5
1183689217	1449161276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161276	29285995	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses.	0.125
1183689217	1449275114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449275114	29607533	CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.	2.25
1183689217	1449732457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732457	28834922	CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.25
1183689217	1450372517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372517	30653146	CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1450372533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372533	30653146	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.	2.5
982037423	PA166104968	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104968		Annotation of DPWG Guideline for venlafaxine and CYP2D6	100
982037423	1451252940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451252940	12544511	CYP2D6 poor metabolizer phenotype is associated with decreased clearance of venlafaxine as compared to CYP2D6 normal metabolizer phenotype.	0.75
982037423	769143878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143878	16958828	Allele T is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele C.	1.5
982037423	750192626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/750192626	16958828	Allele del is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele A.	1.5
982037423	982015108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015108	16642541	Genotypes CT + TT are associated with increased venlafaxine concentration per unit dose when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.	1.5
982037423	982029364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029364	20174590	CYP2D6 *1/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
982037423	982029371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029371	20174590	CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.5
982037423	982029490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029490	10774634	CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
982037423	982029511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982029511	18214456	CYP2D6 *4/*4 is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
982037423	982029591	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029591	10877013	CYP2D6 *10/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
982037423	982029604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029604	10877013	CYP2D6 *1/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
982037423	982029627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029627	10233212	CYP2D6 *10/*10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
982037423	982029646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029646	10233212	CYP2D6 *5/*10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
982037423	1447950037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447950037	25510856	CYP2D6 *10/*10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.5
982037423	982029525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982029525	18214456	CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
982037423	1183617359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617359	16044105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 *1/*1.	1.25
982037423	1450815182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815182	23332809	CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine.	0.125
982037423	1183681035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681035	23357843	CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine in a person with depression.	0.125
1451253260	PA166104968	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104968		Annotation of DPWG Guideline for venlafaxine and CYP2D6	100
1451253260	1184169551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169551	23545896	CYP2D6 normal metabolizers is associated with increased risk of side effects when treated with venlafaxine in people with Obsessive-Compulsive Disorder.	0.0
1451253260	1043858956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858956	23799451	Genotype AG is associated with agitation and dysphoria when treated with venlafaxine in patient with depression.	0.25
1451253260	982029474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029474	16642541	Genotypes CT + TT are not associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.	-0.25
1451253260	982015063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015063	19822698	CYP2D6 *4/*4 is associated with tachycardia and agitation when treated with venlafaxine.	0.25
1451253260	982029483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029483	10780263	CYP2D6 *4/*4 is associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major.	0.25
1451253260	1183619024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619024	17008819	CYP2D6 *4/*4 is associated with side effects when treated with venlafaxine.	0.25
1451253260	1184169374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169374	23545896	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	-1.5
1451253260	1450934262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934262	31799914	CYP2D6 *1/*4 is associated with increased cardiotoxicity, Edema, Nausea and Vomiting when treated with venlafaxine in men with Alcohol-Related Disorders.	0.25
1451253260	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451253260	982015073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015073	16958828	CYP2D6 *5/*4 + *6/*6 + *6/*4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
982047500	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
982047500	PA166104984	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104984		Annotation of DPWG Guideline for phenytoin and CYP2C9	100
982047500	PA166104860	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104860		Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B	100
982047500	769248925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248925	21068649	Allele T is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to genotype CC.	2.0
982047500	769250028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250028	16815679	Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.	1.5
982047500	769250082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250082	10901705	Allele T is not associated with decreased metabolism of phenytoin.	-0.5
982047500	769249039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249039	16220110	Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG.	2.0
982047500	769249041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249041	16220110	Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.	2.0
982047500	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
982047500	769249040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249040	16220110	Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC.	2.0
982047500	769250083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250083	10901705	Allele C is associated with decreased metabolism of phenytoin.	0.0
982047500	769248929	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248929	21068649	Allele C is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to allele A.	2.0
982047500	769250031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250031	16815679	Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA.	0.125
982047500	769249016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249016	16220110	Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC.	2.0
982047500	981858971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858971	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*2.	2.0
982047500	981859014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859014	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *2/*2.	1.5
982047500	981859021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859021	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*3.	2.0
982047500	982046592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046592	21532277	CYP2C9 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	1.5
982047500	982046599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046599	21532277	CYP2C9 *1/*1 is associated with increased the intrinsic metabolic activity (V(max)/K(m)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	1.5
982047500	982046605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046605	9860067	CYP2C9 *1/*3 is associated with decreased the mean maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	0.0
982047500	982046623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046623	9333104	CYP2C9 *1/*1 is associated with increased the maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*3.	1.0
982047500	982046630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046630	11668218	CYP2C9 *1/*3 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	0.125
982047500	982046637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046637	11668218	CYP2C9 *1/*2 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	0.125
982047500	1448612922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612922	28302415	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	3.25
982047500	1448994156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994156	14659971	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	1.5
982047500	1449565307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565307	25597548	CYP2C9 *3 is associated with increased concentrations of phenytoin.	0.25
982047500	1449565369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565369	25998968	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in children.	0.25
982047500	1449565430	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565430	27163851	CYP2C9 *2 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565442	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565442	27163851	CYP2C9 *3 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565453	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565453	27163851	CYP2C9 *8 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565462	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565462	27163851	CYP2C9 *11 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565471	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565471	27163851	CYP2C9 *13 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565484	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565484	27163851	CYP2C9 *14 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565493	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565493	27163851	CYP2C9 *16 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565531	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565531	27163851	CYP2C9 *29 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565540	27163851	CYP2C9 *31 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565549	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565549	27163851	CYP2C9 *33 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565576	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565576	27163851	CYP2C9 *37 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565594	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565594	27163851	CYP2C9 *39 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565621	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565621	27163851	CYP2C9 *42 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565630	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565630	27163851	CYP2C9 *43 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565648	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565648	27163851	CYP2C9 *45 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565695	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565695	27163851	CYP2C9 *50 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565715	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565715	27163851	CYP2C9 *52 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565742	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565742	27163851	CYP2C9 *55 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565832	27179628	CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	1.75
982047500	1449565846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565846	27179628	CYP2C9 *1/*2 is not associated with concentrations of phenytoin in children with as compared to CYP2C9 *1/*1.	-0.75
982047500	1450969200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969200	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	2.5
982047500	1450969140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969140	31461080	CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	2.5
982047500	1450969293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969293	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1.	2.25
982047500	981859049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859049	15385837	CYP2C9 *1/*3 is associated with increased steady state concentration per dosage when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	1.5
982047500	1445388514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445388514	26122019	CYP2C9 *1/*1 + *1/*2 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	-0.75
1183631061	PA166104988	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104988		Annotation of DPWG Guideline for haloperidol and CYP2D6	100
1183631061	1448993570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993570	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.125
1183631061	1447682070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682070	26514968	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.0625
1183631061	1183622774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622774	14499311	CYP2D6 *10/*10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 *1/*1 + *1/*10.	-1.0
1183631061	1183623437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623437	12784098	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183623462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623462	12784098	CYP2D6 *2 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183623471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623471	12784098	CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	0.0
1183631061	1183624234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624234	11560558	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.5
1183631061	1183629618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629618	10942177	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183629749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629749	10096261	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183629922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629922	11595402	CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183630106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630106	11595402	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183630925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630925	12746736	CYP2D6 *4/*4 is associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4.	1.0
1183631061	1447677736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677736	12960748	CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183631061	1447677749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677749	12960748	CYP2D6 *10/*10 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*10.	0.0
1183631061	1449189048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449189048	29472872	CYP2D6 *1xN is associated with extrapyramidal symptoms, hepatic cytolysis and Weight gain when exposed to haloperidol, levomepromazine and risperidone in children with Schizophrenia as compared to CYP2D6 *1.	0.0
1183631061	1183629904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629904	9352580	CYP2D6 *5 + *10 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183631061	1183630934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630934	12746736	CYP2D6 *1/*10 + *17/*17 are not associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1183631061	1183622259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622259	17667795	CYP2D6 *3 + *4 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.5
1183631061	1183623024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623024	12919180	CYP2D6 *2 + *10 are not associated with increased metabolism of haloperidol as compared to CYP2D6 *1.	-1.0
1183619068	PA166104937	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104937		Annotation of DPWG Guideline for aripiprazole and CYP2D6	100
1183619068	1183906189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183906189	24232129	CYP2D6 intermediate metabolizers is not associated with serum concentration of dehydroaripiprazole when treated with aripiprazole as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6.	-1.0
1183619068	1447682087	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682087	26514968	CYP2D6 poor metabolizer is associated with decreased metabolism of aripiprazole in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer.	0.5
1183619068	1448993561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993561	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of aripiprazole in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.0
1183619068	1451251861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451251861	24232129	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .	1.375
1183619068	1183618939	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618939	17965519	CYP2D6 *2 is not associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.	-0.375
1183619068	1183697499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697499	21739267	CYP2D6 *1/*1 + *1/*10 + *1/*21 + *1/*5 (assigned as normal metabolizer phenotype) are not associated with decreased metabolism of aripiprazole in healthy individuals also being given fluvoxamine as compared to CYP2D6 *10/*10 + *5/*10 (assigned as intermediate metabolizer phenotype) .	-0.125
1183619068	1183618626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618626	17828532	CYP2D6 *4 + *5 + *6 is associated with decreased metabolism of aripiprazole as compared to CYP2D6 *1.	1.25
1183619068	1183618864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618864	17965519	CYP2D6 *5 + *10 + *41 is associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.	1.5
1183619068	1183697486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697486	21739267	CYP2D6 *1/*1 + *1/*10 (assigned as normal metabolizer phenotype) are associated with decreased metabolism of aripiprazole in healthy individuals also being given paroxetine as compared to CYP2D6 *10/*10 + *10/*21 (assigned as intermediate metabolizer phenotype) .	This annotation is not used for clinical annotation scoring. Paroxetine is a strong CYP2D6 inhibitor
1183619068	1451548640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451548640	30604050	CYP2D6 *3 + *4 + *4xN + *5 + *6 + *10 + *41 are associated with increased concentrations of aripiprazole as compared to CYP2D6 *1 + *1xN.	1.75
1449191690	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191690	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191690	1449191113	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191113	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1451439812	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451439812	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451435940	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451435940	1444699253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699253	14681830	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele C.	0.0
1451435940	1444699277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699277	17085680	Allele T is associated with Ototoxicity when treated with streptomycin as compared to allele C.	0.25
1451435940	1449732321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732321	29876232	Allele T is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele C.	0.25
1451435940	1444699259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699259	16380089	Allele T is associated with Ototoxicity when treated with gentamicin, micronomicin or streptomycin as compared to allele C.	0.25
1451435940	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1447953029	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447953029	1447673606	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673606	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1447953029	1447674751	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674751	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1447953029	1446900671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900671	25658027	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447953029	1447948695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948695	16244001	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype CC.	0.0
1447953029	1447952837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952837	9138151	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447953029	1447960961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960961	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447953029	1447987348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987348	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1451436140	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436140	1444699662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699662	11079536	Allele C is associated with Ototoxicity when treated with streptomycin as compared to allele T.	0.25
1451436140	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436140	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1449191708	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191708	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191708	1449190985	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449190985	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1043859155	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1043859155	PA166104964	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104964		Annotation of DPWG Guideline for clomipramine and CYP2D6	100
1043859155	1183683963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683963	1451721	CYP2D6 poor metabolizer is associated with decreased metabolism of clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1043859155	1183683968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683968	3582462	CYP2D6 poor metabolizer is associated with increased plasma concentrations of clomipramine and desmethylclomipramine when treated with clomipramine.	0.0625
1043859155	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1043859155	1184470662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470662	2741190	CYP2D6 poor metabolizers are associated with increased plasma concentrations of clomipramine and desmethylclomipramine when treated with clomipramine.	0.0625
1043859155	982030030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030030	11763000	CYP2D6 *10/*10 is not associated with difference in the metabolic ratio of desmethyl clomipramine (DC)/hydroxy desmethyl clomipramine (HDC) when treated with clomipramine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-0.75
1043859155	1183616635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616635	8181196	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616668	10460069	CYP2D6 *4/*4 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1183616898	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616898	8181196	CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616907	8181196	CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616915	10460069	CYP2D6 *3/*4 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1183616923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616923	10460069	CYP2D6 *4/*5 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1446901329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901329	8093319	CYP2D6 *2/*1xN is associated with decreased concentrations of clomipramine in people with Agoraphobia.	0.125
1043859155	1446901449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901449	16871470	CYP2D6 *4/*6 is associated with increased concentrations of clomipramine in people with Depressive Disorder, Major.	0.125
1043859155	1446901471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901471	9562213	CYP2D6 *1/*1xN is associated with decreased concentrations of clomipramine in people with Depression.	0.125
1043859155	1446903175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903175	20531370	CYP2D6 *3 + *4 + *5 + *6 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.0
1043859155	1450368707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450368707	29894392	CYP2D6 *4/*5 is associated with decreased metabolism of clomipramine.	0.0
1043859155	1448631815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631815	28470111	CYP2D6 *4/*41 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.	0.0
1449191722	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191722	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191722	1449191029	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191029	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1451434860	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434860	1444697353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697353	19818876	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin in children with as compared to allele A.	0.0
1451434860	1444697282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697282	18820594	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434860	1449732298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732298	29805548	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.0
1451434860	1444697639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697639	25155176	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin in infants as compared to allele A.	3.0
1451434860	1444697089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697089	11857751	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697250	17637808	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697293	19376484	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697449	20416460	Allele G is associated with Ototoxicity when treated with gentamicin in infants as compared to allele A.	0.25
1451434860	1444697463	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697463	21495045	Allele G is not associated with Ototoxicity when treated with gentamicin in infants as compared to allele A.	-0.25
1451434860	1444697495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697495	22475488	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434860	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434860	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434860	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434860	1451437709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437709	17723226	Allele G is associated with increased risk of Ototoxicity due to gentamicin.	0.25
1451434860	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1451434860	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434860	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434860	1451440094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440094	24252789	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin.	0.25
1451434860	1451440143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440143	26497601	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin.	0.25
1451434860	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1449191740	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191740	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191740	1449191083	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191083	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1043859430	PA166105000	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105000		Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6	100
1043859430	PA166104994	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104994		Annotation of DPWG Guideline for doxepin and CYP2D6	100
1043859430	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1043859430	1446900301	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446900301	11037801	CYP2D6 poor metabolizers are associated with decreased metabolism of doxepin in human liver microsomes as compared to CYP2D6 normal metabolizers.	0.0
1043859430	982030079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030079	12360109	CYP2D6 *4/*4 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1043859430	982030087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030087	12360109	CYP2D6 *4/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1043859430	982030093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030093	12360109	CYP2D6 *3/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1043859430	982030125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030125	16007002	CYP2D6 *1/*1xN is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1043859430	1183617426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617426	18070221	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	2.5
1043859430	1183622800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622800	16007002	CYP2D6 *2xN/*1 is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183622848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622848	16007002	CYP2D6 *35/*1xN is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183622858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622858	16007002	CYP2D6 *2xN/*35 is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1446905682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905682	17721180	CYP2D6 *3/*4 is associated with decreased metabolism of doxepin.	0.125
1043859430	1446905879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905879	12360109	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1043859430	1446905772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905772	16007002	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.	2.0
1183616699	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1183616699	PA166184528	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184528		Annotation of DPWG Guideline for clomipramine and CYP2C19	100
1183616699	1446906755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446906755	8181196	CYP2C19 poor metabolizers are associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183616699	1183616535	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616535	11763000	CYP2C19 *2 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.75
1183616699	1183616544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616544	11763000	CYP2C19 *3 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.25
1183616699	1446903139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903139	20531370	CYP2C19 *2/*2 is associated with decreased metabolism of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183616699	1446903149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903149	20531370	CYP2C19 *17 + *2 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183616699	1448631821	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631821	28470111	CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.	0.0
1449191752	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191752	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191752	1449191098	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191098	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191758	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191758	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191758	1449191005	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191005	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191770	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191770	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191770	1449191012	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191012	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447676595	PA166265341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265341		Annotation of DPWG Guideline for lamotrigine and HLA-B	100
1447676595	981859078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859078	20235791	HLA-B *15:02:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in Epilepsy.	-1.25
1447676595	1183680871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680871	23692434	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	-0.25
1447676595	1183680901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680901	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	1.25
1447676595	1184466675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466675	21071176	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine.	-0.25
1447676595	1184466819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466819	21306565	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine in people with Epilepsy.	-1.5
1447676595	1184988720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988720	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	1.25
1447676595	1446902388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902388	25647819	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine or valproic acid in people with Epilepsy.	-0.25
1447676595	1447676580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676580	25428396	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	1.5
1447676595	1449169849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169849	29238301	HLA-B *15:02:01 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	3.25
1447676595	1451780623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451780623	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.	3.75
1449191746	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191746	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191746	1449191063	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191063	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449188570	655388486	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388486	11692083	Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.	0.0
1449188570	982031251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031251	23651023	CYP2C9 *2 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449188570	982031260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031260	23651023	CYP2C9 *3 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449188570	1184996740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184996740	18781852	CYP2C9 *1/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.0
1449188570	1184996754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184996754	18781852	CYP2C9 *1/*2 + *2/*2 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.0
1449188570	1444705857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705857	24956252	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444705909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705909	24919870	CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444706561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706561	22252093	CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444706597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706597	22252093	CYP2C9 *1/*2 + *2/*2 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444707009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707009	19225451	CYP2C9 *2/*2 + *2/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.5
1449188570	1444707293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707293	15128048	CYP2C9 *1/*2 + *2/*2 + *2/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.5
1449188570	1444707332	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707332	15116052	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444707358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707358	15116052	CYP2C9 *1/*2 + *2/*2 are not associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
1449188570	1444707371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707371	14614357	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.25
1449188570	1444707455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707455	12634980	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	0.0
1449188570	1444707467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707467	12414349	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.75
1449188570	1444707520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707520	11692083	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.25
1449188570	1444708161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708161	24911077	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	2.75
1449188570	1447678839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678839	16815313	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1449188485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188485	29479633	CYP2C9 *3 is associated with increased likelihood of Blood Coagulation Disorders when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.	1.5
827848365	1184746658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746658	25007187	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	769170671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170671	18458567	Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	751696635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751696635	12915598	Allele A is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
827848365	769171025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171025	16870553	Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-2.0
827848365	1184510298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510298	23488607	Genotypes AA + AG is associated with increased risk of hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	2.75
827848365	1451464465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451464465	19031955	Genotype AA is associated with increased risk of Neurotoxicity Syndromes and Toxic liver disease when treated with methotrexate in children with Osteosarcoma.	0.25
827848365	1451465191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465191	21534867	Genotypes AA + AG are associated with increased risk of Thrombocytopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.5
827848365	1447979303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979303	25110820	Genotypes AA + AG are associated with increased risk of Leukopenia or Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	3.25
827848365	637879736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879736	17488658	Genotype AA is associated with increased risk of Thrombocytopenia or Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.	2.75
827848365	827829042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829042	22143415	Genotype AA is associated with increased risk of toxicity when treated with methotrexate as compared to genotype GG.	0.5
827848365	769146371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146371	16501586	Genotype AA is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype GG.	This annotation is not used for clinical annotation scoring. Overlap of authors and likely overlap of cohort with PMID 11418485
827848365	637879745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879745	17512587	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	This annotation is not used for clinical annotation scoring. Overlap of authors and patient cohort with PMID 12453860
827848365	655387891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387891	19648163	Genotype AA is associated with increased risk of gastrointestinal toxicity, Leukopenia and Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	This annotation is not used for clinical annotation scoring. Author overlap with PMID 17488658
827848365	1451504586	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504586	22074251	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
827848365	1451511426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451511426	25177243	Genotypes AA + AG are associated with increased risk of Leukopenia or Thrombocytopenia due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	2.5
827848365	1451552860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451552860	32612964	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
827848365	1451553448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553448	32695297	Genotype AA is associated with increased risk of hematotoxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.75
827848365	1451634220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634220	34346513	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.25
827848365	1451635256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451635256	33841551	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.25
827848365	1446898640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898640	21644011	Genotypes AA + AG is associated with increased Drug Toxicity when treated with methotrexate in children with as compared to genotype GG.	2.5
827848365	1447675071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675071	25778468	Genotype GG is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.	-2.25
827848365	1451547041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451547041	27104192	Allele A is not associated with risk of mucositis, nephrotoxicity or Toxic liver disease due to methotrexate in children with Osteosarcoma as compared to allele C.	-0.25
827848365	1451547222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451547222	27781293	Genotype AG is associated with increased risk of hematotoxicity due to methotrexate in people with primary central nervous system lymphoma as compared to genotype GG.	3.0
827848365	1451548500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548500	29911750	Genotype AG is associated with increased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	1451548770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548770	30684021	Genotypes AG + GG are associated with increased severity of Leukopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	-2.25
827848365	981475997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475997	23089671	Genotype AA is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	-0.5
827848365	637879769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879769	12453860	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotypes AG + GG.	1.75
827848365	637879722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879722	17488658	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.	3.25
827848365	637879773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879773	11418485	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	2.0
827848365	1184169119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169119	23648444	Genotypes AA + AG is associated with increased risk of Toxic liver disease when treated with methotrexate in children with Neoplasms as compared to genotype GG.	1.75
827848365	1184169137	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169137	23648444	Allele A is not associated with risk of Toxic liver disease when treated with methotrexate in people with Neoplasms as compared to allele G.	-1.0
827848365	1184510310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510310	23488607	Genotypes AA + AG is not associated with risk of non-hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	-1.25
827848365	1184514065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514065	24241962	Allele G is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele A.	-0.75
827848365	1448124321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124321	27399166	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.	-1.25
827848365	1448997017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997017	28696419	Genotype GG is associated with decreased risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes AA + AG.	1.5
1449309937	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449309937	1449310291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449310291	11389482	Allele GAG is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to allele del.	0.25
1449309937	1449275168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275168	27857962	Allele del is associated with increased risk of Malignant Hyperthermia when treated with isoflurane or sevoflurane in children as compared to allele GAG.	0.25
1449269868	982044565	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044565	18950464	Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.	1.25
1449269868	1449190810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190810	29432897	Allele T is not associated with likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-2.25
1449269868	982044597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044597	18950464	Genotypes AC + CC are not associated with risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype AA.	-0.25
1449269868	827814788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814788	21148049	Allele C is not associated with bleeding events when treated with acenocoumarol or warfarin.	-1.5
1449269868	1449190803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190803	29432897	Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele A.	3.25
1449269868	1449269136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449269136	29577257	Allele C is associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to allele A.	3.5
1449269868	1444703983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444703983	25858232	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin in people with Alcoholism as compared to CYP2C9 *1.	0.0
1449269868	1444706532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706532	23113310	CYP2C9 *1/*2 + *3/*3 + *2/*3 + *1/*3 + *2/*2 are not associated with increased risk of Hemorrhage when treated with acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	-1.25
1449269868	1444707161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707161	16699986	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.75
1449269868	1444707240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707240	15213846	CYP2C9 *1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449269868	1444707430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707430	12876643	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with acenocoumarol and indomethacin as compared to CYP2C9 *1/*1.	0.25
1449269868	1444707481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707481	12414349	CYP2C9 *1/*3 + *3/*3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.75
1449269868	1447519366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519366	21148049	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	-1.5
1449269868	1448602404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602404	28033245	CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1449269868	1448602417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602417	28033245	CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1450929851	PA166161955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161955		Annotation of CPIC Guideline for tropisetron and CYP2D6	100
1450929851	981954714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954714	12065557	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.	3.25
1451244700	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451244700	827827170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827170	17015053	Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.	-0.125
1451244700	1450823509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823509	30989645	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.	2.0
1449747595	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747595	1449733363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733363	12709367	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747595	1449747515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449747515	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183617103	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1183617103	PA166104954	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104954		Annotation of DPWG Guideline for imipramine and CYP2C19	100
1183617103	1183684364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684364	7965806	CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	1.0
1183617103	1183684391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684391	1988236	CYP2C19 poor metabolizers are associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446902332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902332	8835703	CYP2C19 poor metabolizers are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446902590	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902590	8835703	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446905415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905415	1988236	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1183622249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622249	19884907	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to CYP2C19 *1/*1.	2.5
1183617103	1183622781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622781	9316174	CYP2C19 *2/*3 + *2/*2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
1183617103	1446902041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902041	17667959	CYP2C19 *2 is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.5
1183617103	1446902544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902544	9316174	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
1184997207	1184349250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349250	9109770	HLA-B *59:01:01:01 is associated with Stevens-Johnson Syndrome when treated with methazolamide in people with Glaucoma.	0.25
1184997207	1184415386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184415386	20504258	HLA-B *59:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.	3.25
1184997207	1444706649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706649	25918017	HLA-B *59:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	3.75
1184997207	1444709192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709192	25970075	HLA-B *59:01:01:01 is associated with Epidermal Necrolysis, Toxic when treated with methazolamide in people with Glaucoma.	0.25
1184997207	1448530438	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530438	26458485	HLA-B *59:01:01:01 is associated with Epidermal Necrolysis, Toxic when treated with methazolamide in women with Glaucoma.	0.25
1184997207	1450397876	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397876	30242287	HLA-B *59:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.	1.0
1183617651	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1183617651	PA166104982	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104982		Annotation of DPWG Guideline for amitriptyline and CYP2D6	100
1183617651	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183617651	1446901072	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901072	7159207	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183617651	1446901646	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901646	3571939	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in people with Depression as compared to CYP2D6 normal metabolizers.	0.0625
1183617651	827777562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777562	15205367	CYP2D6 *4 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	827777575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777575	15205367	CYP2D6 *10 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	827777570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777570	15205367	CYP2D6 *41 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	1183615357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615357	17764479	CYP2D6 *4/*4 is associated with increased amitriptyline + nortriptyline plasma concentration in one CYP2D6 PM when treated with amitriptyline.	0.125
1183617651	1183615381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615381	17764479	CYP2D6 *4/*4 is associated with increased nortriptyline/(E)-10-OH-NT ratio when treated with amitriptyline as compared to CYP2D6 *1.	1.5
1183617651	1183615397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615397	17764479	CYP2D6 *4/*4 is associated with increased amitriptyline/(E)-10- OH-AT ratio when treated with amitriptyline as compared to CYP2D6 *1.	1.0
1183617651	1183617193	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617193	12172336	CYP2D6 *2/*5 + *1/*10 is not associated with differences in the ratio of nortriptyline and its metabolite when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	-0.5
1183617651	1183617206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617206	12172336	CYP2D6 *5/*10 + *10/*10 is associated with increased ratio of nortriptyline and its metabolite (NT/EHNT) when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	0.0
1183617651	1183623082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623082	16024198	CYP2D6 *4/*4 is associated with decreased clearance of amitriptyline in one suicide case.	0.25
1183617651	1446902725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902725	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	1.0
1183617651	1446903079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903079	20531370	CYP2D6 *3 + *4 + *5 + *6 are associated with increased concentrations of nortriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.0
1183617651	1446903324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903324	21614669	CYP2D6 *4/*4 is associated with increased concentrations of amitriptyline.	0.125
1183617651	1446903345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903345	16024198	CYP2D6 *4/*5 + *4/*4 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.	2.5
1183617651	1446903489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903489	17764479	CYP2D6 *4/*4 is not associated with metabolism of amitriptyline as compared to CYP2D6 normal metabolizers.	-0.125
1444608367	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444608367	1184510147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510147	15841390	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials in children as compared to allele A.	0.25
1444608367	1444696929	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696929	8285309	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444696981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696981	9111378	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697028	9490575	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697082	10633132	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697167	15917167	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697205	16458854	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697262	17999439	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697273	18790089	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697435	20111055	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697456	21162657	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697475	21504270	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697482	21725156	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697673	25744662	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697690	25515069	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	1.5
1444608367	1444697282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697282	18820594	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1449732298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732298	29805548	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.0
1444608367	1444697089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697089	11857751	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1444608367	1444697179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697179	16168391	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele A.	0.25
1444608367	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1444608367	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1444608367	1444697495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697495	22475488	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1444608367	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1444608367	1451437874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437874	19835846	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1444608367	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1444608367	1451439920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451439920	21777984	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials.	0.0
1444608367	1451440060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440060	22879993	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials.	0.25
1444608367	1451440086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440086	23256547	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1444608367	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1183619004	PA166127639	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127639		Annotation of CPIC Guideline for sertraline and CYP2C19	100
1183619004	PA166104980	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104980		Annotation of DPWG Guideline for sertraline and CYP2C19	100
1183619004	1183617538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617538	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with sertraline in people with Depressive Disorder, Major.	0.125
1183619004	1183698918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698918	11452243	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased clearance of sertraline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer phenotype) .	1.0
1183619004	1183699890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699890	18677622	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 are associated with increased mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.25
1183619004	1183699907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699907	18677622	CYP2C19 *1/*17 + *17/*17 are not associated with differences in mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-0.75
1183619004	1447950096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447950096	26830411	CYP2C19 *2 + *17 are not associated with metabolism of sertraline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-2.0
1183619004	1450933318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933318	31649299	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1183619004	1450933348	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933348	31649299	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1183619004	1450933341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933341	31649299	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451241420	1447944425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944425	26616266	NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with isoniazid in people with Tuberculosis as compared to NAT2 intermediate and rapid acetylators.	1.75
1451241420	1451308025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451308025	33165168	NAT2 slow acetylator is associated with increased adverse events when treated with isoniazid in healthy individuals as compared to NAT2 rapid acetylator.	0.125
1451241420	1448994962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994962	28799976	NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.	1.625
1451241420	981344330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344330	19686464	Genotype CT is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women with Tuberculosis.	0.25
1451241420	981240117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240117	19891553	Allele A is associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.5
1451241420	981861770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861770	11595069	Allele A is not associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele G.	-1.25
1451241420	981939788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939788	19891553	Allele A is not associated with risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
1451241420	1449002647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002647	29036176	Allele A is not associated with risk of drug-induced liver injury when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele G.	-2.5
1451241420	981862352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862352	19761367	NAT2 *4/*4 is not associated with likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis.	-1.5
1451241420	981936611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936611	22506592	NAT2 *6A/*7B is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981939951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939951	21753138	NAT2 *5B is not associated with likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis.	-1.5
1451241420	981952688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981952688	21856096	NAT2 *4 is associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.	2.25
1451241420	1183702608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702608	23875638	NAT2 *4 (assigned as rapid acetylator phenotype) is associated with decreased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.0
1451241420	1447962939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447962939	18330759	NAT2 *6A is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.25
1451241420	1451241480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451241480	18421452	NAT2 *5A/*5A + *5A/*6A + *5A/*7A + *6A/*6A + *7A/*7A are associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.25
1451241420	981344312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344312	17950035	NAT2 *5B/*7B + *6A/*6A + *6A/*7B + *7B/*7B are associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981476263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476263	20392357	NAT2 *5D + *6B + *7A are associated with increased risk of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.5
1451241420	981934211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934211	21261721	NAT2 *6B/*7A is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981862026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862026	16677176	NAT2 *7A + *6B + *5A (assigned as slow acetylator phenotype) is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis.	-1.5
1451241420	1451435599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451435599	33135175	NAT2 *6B + *7A (assigned as slow acetylator phenotype) are associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis.	1.75
1451241420	981862092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862092	16770646	NAT2 *4/*5A + *4/*6B + *4/*7A + *4/*14A + *5A/*5A + *5A/*6B + *5A/*7A + *6B/*6B + *6B/*7A is not associated with increased likelihood of Toxic liver disease when treated with isoniazid and pyridoxal phosphate in people with Tuberculosis as compared to NAT2 *4/*4.	-1.25
1451241420	1183702528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702528	24188272	NAT2 *5D/*7A + *6B/*7A (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5D + *4/*7A.	2.25
1451241420	981934428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934428	22020825	NAT2 *6B + *7A (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934449	22020825	NAT2 *5A (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	This annotation is not used for clinical annotation scoring. Ambiguous genotyping for identification of *5 allele
1451241420	981934405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934405	22283902	NAT2 *6B + *7A + *5A (assigned as slow acetylator phenotype) is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	-1.5
1451241420	981934399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934399	21047300	NAT2 *5A + *6B + *7A (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.0
1451241420	1451797500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451797500	24888881	NAT2 *5A/*5A + *5A/*6B + *5A/*7A + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with increased risk of drug-induced liver injury when exposed to isoniazid as compared to NAT2 *4/*4 + *4/*5A + *4/*6B + *4/*7A (assigned as rapid acetylator phenotype) .	2.5
1451241420	981861818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861818	11915035	NAT2 *6B/*6B + *6B/*7A (assigned as slow acetylator phenotype) are associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.	2.5
1451241420	981861841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861841	12668988	NAT2 *5A + *6B + *7A (assigned as slow acetylator phenotype) are associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4 (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934205	21261721	NAT2 *5A/*7A is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	This annotation is not used for clinical annotation scoring. This paper also has other haplotypes contributing to same CA
1451241420	981934195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934195	21261721	NAT2 *5A/*4 is associated with decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	-2.5
1451241420	1183702632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702632	23394127	NAT2 *5D/*5D + *5D/*6B + *5D/*7A + *6B/*6B + *6B/*7A (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	2.75
1451241420	981862142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862142	18023090	NAT2 *6A is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.	2.75
1451241420	981862039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862039	16246623	NAT2 *5B/*7B + *6A/*6A + *6A/*7B (assigned as slow acetylator phenotype) is associated with increased risk of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*12A (assigned as rapid acetylator phenotype) .	2.0
1451241420	981953978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953978	22788240	NAT2 *5B + *5G + *6A + *6B + *5C + *17 + *5D + *7B + *6E + *6D + *6C + *14B + *5J + *5E + *5A + *14A is associated with increased likelihood of adverse reactions when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4 + *12A + *13A +*11A + *12C + *12B (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934348	22012226	NAT2 *5A + *5B + *6A + *7B +*14B +*5C (assigned as slow acetylator phenotype) is associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis as compared to NAT2 *4 + *12A + *13A.	1.5
1451241420	981851624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851624	23190413	NAT2 *5D + *6B + *7A + *14A (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1448635217	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1448635217	PA166184613	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184613		Annotation of DPWG Guideline for mercaptopurine and NUDT15	100
1448635217	1447945037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945037	26878724	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .	1.625
1448635217	1448576430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576430	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1448635217	1448624581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624581	28445187	NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.25
1448635217	1448624596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624596	28445187	NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1448635217	1448635204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635204	28659275	NUDT15 *1/*2 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	0.25
1448635217	1449750346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750346	29967377	NUDT15 *1/*3 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 + *1/*5 + *1/*6 + *1/*2.	0.0
1448635217	1449750363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750363	29967377	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.	0.0
1451703980	1444929357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929357	26086150	HLA-C *06:02:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	2.5
1451703980	1444929367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929367	26086150	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	2.5
1451703980	1451348845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348845	32452529	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	3.0
1451703980	1451348900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348900	32452529	HLA-C *07:27:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	2.5
1451237240	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1451237240	1184174063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174063	20136357	TPMT poor metabolizer phenotype is associated with increased risk of myelotoxicity when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1451237240	1184174068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174068	20136357	TPMT intermediate metabolizer phenotype is associated with increased risk of mild leukopenia when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1451237240	1184233739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233739	20308917	TPMT intermediate metabolizer phenotype is associated with decreased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT poor metabolizer phenotype.	1.0
1451237240	1184349913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349913	18616518	TPMT intermediate metabolizer genotype is associated with increased likelihood of adverse effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.5
1451237240	1184407184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407184	16543290	TPMT intermediate metabolizers is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1451237240	1184414133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184414133	12269967	TPMT intermediate metabolizer phenotype is associated with increased likelihood of intolerable side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT normal metabolizer phenotype.	1.5
1451237240	1448266607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266607	26674571	TPMT poor metabolizers are associated with increased likelihood of Leukopenia and Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.	1.375
1451237240	1451237464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451237464	31024313	Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.	-1.5
1451237240	1449750678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750678	29867468	Genotype CT is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic and Sjogren's Syndrome as compared to genotype TT.	-1.25
1451237240	1184134111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134111	16202677	TPMT *1/*2 + *1/*3A is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184134311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134311	10376773	TPMT *1/*3A is associated with hepatic toxicity when treated with azathioprine, mercaptopurine or purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237240	1184136197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136197	15792824	TPMT *1/*3A + *1/*3C is associated with increased likelihood of haematological toxicity or hepatotoxicity when treated with azathioprine in people with neurological problems as compared to TPMT *1/*1.	2.0
1451237240	1184173900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173900	9841604	TPMT *1/*3A is associated with increased risk of low leukocyte counts when treated with azathioprine in people with Rheumatic Diseases as compared to TPMT *1/*1.	1.25
1451237240	1184174715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174715	12172211	TPMT *3A/*3A is associated with increased severity of myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases.	0.25
1451237240	1184175442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184175442	16611274	TPMT *1/*3A + *1/*3C is not associated with likelihood of Leukopenia, malaise and Pancreatitis when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184233233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233233	16044099	TPMT *1/*2 + *1/*3A + *1/*3C is associated with increased likelihood of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation as compared to TPMT *1/*1.	2.0
1451237240	1184233329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233329	16044099	TPMT *3A/*3C is associated with severity of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation.	1.5
1451237240	1184233545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233545	19695401	TPMT *1/*3C is associated with increased likelihood of myelosuppression when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	3.0
1451237240	1184233570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233570	19682195	TPMT *1/*3C is not associated with increased likelihood of severe adverse reactions when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.5
1451237240	1184233729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233729	20308917	TPMT *1/*3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.75
1451237240	1184233750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233750	16396707	TPMT *1/*3C + *1/*6 is not associated with likelihood of adverse events when treated with azathioprine in people with Lupus Erythematosus, Systemic as compared to TPMT *1/*1.	-1.25
1451237240	1184233780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233780	17241387	TPMT *3C/*3C is associated with increased risk of severe myelosuppression when treated with azathioprine in people with Hepatitis, Autoimmune as compared to TPMT *1/*1.	0.25
1451237240	1184233799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233799	18827410	TPMT *1/*3C is not associated with myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184272572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184272572	19048245	TPMT *1/*3C is not associated with risk of hematotoxicity or hepatotoxicity when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	-0.25
1451237240	1184348490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348490	17176368	TPMT *1/*3C is associated with increased likelihood of haematopoietic toxicity when treated with azathioprine in people with Kidney Transplantation.	2.5
1451237240	1184348908	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348908	21712851	TPMT *3A/*3A is associated with severe myelosuppression when treated with azathioprine in people with Kidney Transplantation.	0.25
1451237240	1184349269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349269	10798786	TPMT *1/*3A + *1/*3C is associated with decreased leukocytes and neutrophils when treated with azathioprine in people with heart transplantation as compared to TPMT *1/*1.	1.5
1451237240	1184349305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349305	15476481	TPMT *1/*3A + *1/*3B + *1/*3C is associated with decreased hematological indices when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	1.5
1451237240	1184349431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349431	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1451237240	1184407209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407209	17439508	TPMT *1/*3A + *1/*3C is not associated with increased likelihood of myelosuppression or any other side effect when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.5
1451237240	1184467185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467185	16431304	TPMT *1/*3A + *1/*3C + *3A/*3A is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	3.25
1451237240	1447682889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682889	26735160	TPMT *1/*3C is associated with Leukopenia when treated with azathioprine in children with Crohn Disease.	0.0
1451237240	1447983088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447983088	27082580	TPMT *1/*3C is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	0.0
1451237240	1448261284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261284	27604507	TPMT *1/*3C is not associated with risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to TPMT *1/*1.	-1.75
1451237240	1448268166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268166	18662289	TPMT *3A + *3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1451237240	1448268960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268960	22535280	TPMT *3A + *3B + *3C is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	3.0
1451237240	1449161615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161615	29210335	TPMT *6 is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.5
1451237240	1449161632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161632	29210335	TPMT *3C is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-2.5
1451237240	1184174686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174686	12172211	TPMT *1/*3A + *3A/*3A is not associated with risk of Gastrointestinal side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184133979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184133979	20175817	TPMT *2 + *3A + *3B + *3C is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.25
1451237240	1184174663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174663	14560161	TPMT *3A/*3A is associated with increased severity of bone marrow suppression when treated with azathioprine in people with Colitis, Ulcerative.	0.25
1451237240	1451905428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905428	34582038	TPMT *1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of discontinuation and Myelosuppression when treated with azathioprine in people with Inflammation as compared to TPMT *1/*1 (assigned as normal metabolizer phenotype) .	3.5
1451274090	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274090	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274090	1450932303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932303	31486738	Genotype AT is associated with increased severity of Drug Toxicity and Death when treated with capecitabine.	0.25
1451274090	982006241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006241	23603345	Allele A is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
1451274090	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451274090	1184000471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000471	24590654	Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	4.0
1451274090	1184471966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471966	24167597	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	3.25
1451274090	1449731731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731731	30114658	Genotype AT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	4.0
1451274090	1447945538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945538	26099996	Genotype AT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.0
1451274090	1447959064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959064	24923815	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
1451274090	1447988411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988411	19795123	Allele A is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274090	1447991648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991648	19104657	Allele A is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.0
1451274090	1448123106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123106	20819423	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	-1.25
1451274090	1448123303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123303	21498394	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	3.0
1451274090	1448124229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124229	23736036	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451274090	1448124799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124799	24647007	Genotype AT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-3.0
1451274090	1448125409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125409	25677447	Genotype AT is associated with increased severity of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype TT.	1.75
1451274090	1448255009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255009	21077799	Genotype AT is associated with risk of Death, Drug Toxicity and Ectropion when treated with capecitabine in people with Rectal Neoplasms.	0.25
1451274090	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451274090	1448568497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568497	27995989	Genotype AT is associated with increased risk of hand-foot syndrome when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype TT.	2.5
1451274090	1448605513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448605513	27454530	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype TT.	2.5
1451274090	1448994811	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994811	28481884	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	2.5
1451274090	1449161738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161738	28427087	Genotype TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AA + AT.	-2.0
1451274090	1449162090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162090	29065426	Genotype AT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451274090	1449716901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716901	29889674	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine in men with Colonic Neoplasms.	0.25
1451274090	1449732118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732118	29846282	Genotype AT is associated with Drug Toxicity when treated with capecitabine in men with Colonic Neoplasms.	0.25
1451274090	1449732196	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732196	29998006	Genotype AT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
1451274090	1450371932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371932	30723313	Genotypes AA + AT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.5
1451274090	1450372255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372255	30858516	Genotypes AA + AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.25
1451274090	1450373060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373060	30485432	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	0.25
1451266120	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266120	827810959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810959	21410976	Genotype AT is associated with risk of Diarrhea when treated with tegafur in people with Rectal Neoplasms.	0.25
1451266120	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451266120	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451288269	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451288269	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451288269	1451313980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451313980	33410339	Genotype CT is not associated with increased likelihood of Drug Toxicity or treatment modification when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	-2.0
1451288269	827823468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823468	19530960	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	2.0
1451288269	1448123285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123285	21498394	Genotypes CT + TT are associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.0
1451288269	1448124454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124454	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1451288269	1448124654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124654	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451288269	1448124852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124852	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-3.0
1451288269	1448255378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255378	26603945	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451288269	1448262687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262687	24923815	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451288269	1448568395	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568395	27995989	Genotype CC is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.	-1.5
1451288269	1448994769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994769	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451288269	1450373074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373074	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1451704000	1444929346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929346	26086150	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	3.0
1451704000	1451348840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348840	32452529	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	3.0
1451704000	1451348850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348850	32452529	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfamethoxazole / trimethoprim.	3.0
1451704000	1451348861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348861	32452529	HLA-B *38:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	2.5
827843617	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
827843617	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
827843617	769176388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176388	20819423	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1450950682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950682	19104657	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
827843617	981352322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352322	15017333	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	0.0
827843617	981352338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352338	18443386	Genotype CT is associated with Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms.	1.75
827843617	981352346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352346	19858398	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	-2.0
827843617	981390716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981390716	19473056	Genotype CT is associated with increased likelihood of mucositis when treated with fluorouracil in women with Neoplasms as compared to genotype CC.	3.0
827843617	981394390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981394390	19473056	Genotype CT is associated with increased likelihood of Thrombocytopenia when treated with fluorouracil in women with Neoplasms as compared to genotype CC.	2.25
827843617	982006233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006233	23603345	Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
827843617	982010242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010242	23585145	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
827843617	827810976	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810976	20809970	Genotype CT is associated with risk of Drug Toxicity when treated with fluorouracil in people with Gastrointestinal Neoplasms.	0.25
827843617	827814910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814910	11555601	Genotypes CT + TT is associated with Death and Myelosuppression when treated with fluorouracil in people with Drug Toxicity as compared to genotype CC.	0.25
827843617	827823452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823452	19530960	Genotype CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
827843617	827824695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824695	17700593	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	2.25
827843617	827825029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825029	17335544	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.0
827843617	827825042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825042	17165084	Genotype CT is associated with Death when treated with fluorouracil in people with Pancreatic Neoplasms.	0.25
827843617	827892654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892654	17064846	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.75
827843617	827892773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892773	17121937	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
827843617	769171393	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171393	18299612	Genotype CT is associated with increased risk of Drug Toxicity, Leukopenia and mucositis when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
827843617	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
827843617	1184471962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471962	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
827843617	1184473549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473549	24817302	Genotypes CT + TT is associated with increased severity of Myelosuppression when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473554	24817302	Genotypes CT + TT is associated with increased severity of hand-foot syndrome when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473558	24817302	Genotypes CT + TT is associated with increased severity of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473562	24817302	Genotypes CT + TT is not associated with severity of mucositis when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.25
827843617	1184473566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473566	24817302	Genotypes CT + TT is not associated with severity of gastrointestinal toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.25
827843617	1450945020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450945020	9472650	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in men with Colorectal Neoplasms as compared to genotype CC.	0.25
827843617	1450949820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450949820	30898145	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Pancreatic Neoplasms as compared to genotype CC.	0.25
827843617	1450950640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950640	11953843	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	0.25
827843617	1450951027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951027	23481061	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Head and Neck Neoplasms as compared to allele C.	-0.25
827843617	1450951200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951200	24700034	Allele T is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Pancreatic Neoplasms as compared to allele C.	0.25
827843617	1450951260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951260	9470816	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in women with Breast Neoplasms as compared to genotype CC.	0.25
827843617	1450951303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951303	25381393	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
827843617	1450951481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951481	29134491	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.0
827843617	1450951510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951510	8698850	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in men with Neoplasms.	0.25
827843617	1450951600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951600	27738344	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.25
827843617	1450951660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951660	30775324	Allele T is associated with increased risk of Death when treated with fluorouracil in men with Carcinoma, Squamous Cell.	0.25
827843617	1450952760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952760	11156223	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to genotype CC.	0.25
827843617	1450952800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952800	11350878	Genotype TT is associated with increased risk of Drug Toxicity and Death when treated with fluorouracil in women with Rectal Neoplasms.	0.25
827843617	1450952860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952860	12360106	Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.0
827843617	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
827843617	1450953460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953460	16361556	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450953940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953940	18299612	Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil.	3.5
827843617	1450954786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954786	20385995	Genotype CT is associated with increased likelihood of Neutropenia when treated with fluorouracil, FOLFIRI or FOLFOX in people with Colorectal Neoplasms as compared to genotype CC.	0.0
827843617	1450955720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955720	20803296	Genotype CT is associated with decreased activity of DPYD.	0.0
827843617	1450955734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450955734	20803296	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450956264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450956264	23736036	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450960760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960760	9439663	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
827843617	1447945371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945371	26846104	Genotype CT is associated with increased Infection and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.0
827843617	1447945531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945531	26099996	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	4.0
827843617	1447959056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959056	24923815	Allele T is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
827843617	1447988372	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988372	12209976	Genotypes CT + TT is associated with risk of Neutropenia when treated with fluorouracil in people with Neoplasms.	0.25
827843617	1447988460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988460	19795123	Allele T is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
827843617	1448124202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124202	23736036	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
827843617	1448126243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126243	26794347	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele C.	-1.75
827843617	1449162076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162076	29065426	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	0.0
827843617	1449165558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165558	26967565	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.75
827843617	1449731693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731693	30114658	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	4.0
827843617	1449732176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732176	29998006	Genotype CT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
827843617	1450371900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371900	30723313	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
827843617	1450373052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373052	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1184986174	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1184986174	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1184986174	1183681878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681878	23736036	Genotype CG is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.	-1.75
1184986174	1184471970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471970	24167597	Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1184986174	1447676529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676529	26658227	Allele C is not associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele G.	-2.0
1184986174	1447954949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954949	24923815	Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	3.75
1184986174	1447988987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988987	20803296	Allele C is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele G.	2.0
1184986174	1448126287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126287	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele G.	-2.0
1184986174	1448997537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997537	28614820	Genotype CG is associated with Drug Toxicity when treated with fluorouracil.	0.25
1184986174	1449161752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161752	28427087	Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.	-2.0
1184986174	1449162097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162097	29065426	Genotype CG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype GG.	-2.0
1449575645	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575645	1449575556	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575556	29769267	Allele T is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele G.	0.0
982035703	982035636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035636	18030307	Genotype CC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.	1.75
982035703	982037919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037919	20072124	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.0
982035703	982044357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044357	16611750	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.25
982035703	1183704687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704687	24019055	Genotype AA is associated with increased dose of warfarin as compared to genotype AC.	2.5
982035703	1450980580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980580	18322281	Genotype CC is associated with decreased dose of warfarin as compared to genotype AA.	2.75
1449575662	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575662	1448125721	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125721	24648345	Allele T is not associated with activity of DPYD when assayed with fluorouracil as compared to allele C.	-0.0
1449575662	1449575540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575540	29769267	Allele T is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.	0.0
1451448820	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451448820	PA166184613	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184613		Annotation of DPWG Guideline for mercaptopurine and NUDT15	100
1451448820	1448576467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448576467	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451448820	1451133189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451133189	32308129	NUDT15 *1/*2 + *1/*3 + *1/*6 + *2/*2 is associated with increased Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.75
1451448820	1449575788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449575788	29923122	NUDT15 *2 + *3 + *4 + *5 + *6 are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to NUDT15 *1.	3.5
982029857	PA166176068	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176068		Annotation of CPIC Guideline for tamoxifen and CYP2D6	100
982029857	1444935629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935629	21430657	CYP2D6 poor metabolizers are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	1.25
982029857	1444935672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935672	21430657	CYP2D6 poor metabolizers are not associated with increased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.75
982029857	1449170911	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170911	29436156	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.	-0.0625
982029857	1444708801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708801	15632378	CYP2D6 *3 + *4 + *5 + *6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.75
982029857	1444709550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444709550	20124171	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	2.25
982029857	1444710685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710685	21480951	CYP2D6 *10 + *5 is not associated with concentrations of 4-hydroxytamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.25
982029857	1444710781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710781	21480951	CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.25
982029857	1444710805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710805	21480951	CYP2D6 *41 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-0.125
982029857	1444712023	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712023	16815318	CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *2xN/*4 + *1/*1xN + *2/*1xN + *1/*2xN.	2.0
982029857	1444712210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712210	16815318	CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10.	2.0
982029857	1444930474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930474	23476897	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.	-1.0
982029857	1444930553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930553	18407954	CYP2D6 *10/*10 is associated with decreased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	1.0
982029857	1444930567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930567	18407954	CYP2D6 *10/*10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.125
982029857	1444935054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935054	23922954	CYP2D6 *3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 + *1/*17 + *1/*41.	-1.0
982029857	1444936127	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936127	17761971	CYP2D6 *10/*10 + *5/*5 are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	2.0
982029857	1444936241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936241	17761971	CYP2D6 *10/*10 + *5/*5 are not associated with decreased concentrations of n-desmethyltamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-1.0
982029857	1445401203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401203	20565970	CYP2D6 *4/*4 + *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.	2.25
982029857	1448112207	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448112207	27109434	CYP2D6 *2 + *10 + *87 + *90 + *91 + *93 + *95 + *98 are associated with decreased clearance of tamoxifen as compared to CYP2D6 *1.	0.0
1451215020	981747419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981747419	19299905	Genotypes AA + AG are associated with increased severity of Diarrhea when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.	2.5
1451215020	981794265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794265	18221820	Genotype AA is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.5
1451215020	981794523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794523	16636344	Genotype AA is not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.25
1451215020	1448617817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617817	28367249	Allele A is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to allele G.	2.0
1451215020	1448617936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617936	28502040	Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG.	3.5
1451215020	1447959787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959787	26125934	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with cisplatin and irinotecan in women with Ovarian Neoplasms as compared to UGT1A1 *1/*1.	3.25
1451215020	1448422688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422688	26857783	UGT1A1 *6 + *28 are not associated with risk of Diarrhea when treated with irinotecan in people with Neoplasms.	-1.5
1451215020	1448422767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422767	27160286	UGT1A1 *6 + *28 are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms.	3.0
1451215020	1451204620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204620	20335017	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451206340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206340	15280927	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451206467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206467	16456808	UGT1A1 *1/*28 + *28/*28 are associated with increased risk of Diarrhea when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.75
1451215020	1451206751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206751	18594531	UGT1A1 *1/*28 + *28/*28 are not associated with Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451215020	1451207680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207680	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451215020	1451208420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208420	17577039	UGT1A1 *28/*28 is not associated with increased risk of Diarrhea or Neutropenia when treated with irinotecan in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	-1.25
1451215020	1451208821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208821	17185998	UGT1A1 *1/*28 + *28/*28 are not associated with Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451215020	1451208880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208880	16951398	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.25
1451215020	1451209203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209203	11990381	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	0.375
1451215020	1451209840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209840	16636344	UGT1A1 *1/*28 is not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451215020	1451210040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210040	23529007	UGT1A1 *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.75
1451215020	1451210050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210050	23529007	UGT1A1 *1/*28 is not associated with risk of Diarrhea when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.0
1451215020	1451212320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451212320	15297419	UGT1A1 *28 is not associated with increased likelihood of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.25
1451215020	1451213400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213400	28367249	UGT1A1 *1/*1 + *1/*28 is associated with decreased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.	1.75
1451215020	1451213590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213590	19450125	UGT1A1 *28/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.25
1451215020	1451213621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213621	24815493	UGT1A1 *1/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451213837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213837	18221820	UGT1A1 *1/*28 is not associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.5
1451215020	1451214007	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214007	25285015	UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Diarrhea when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	3.0
1451215020	1451214200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214200	28502040	UGT1A1 *1/*1 + *1/*28 is associated with decreased severity of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.	1.25
1451215020	1451214800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214800	29504153	UGT1A1 *28/*28 + *28/*37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.25
1451215020	1447945258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945258	26862009	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28.	0.0
655384621	981502824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502824	20215968	Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin in people with prior vascular disease as compared to genotype AA.	2.0
655384621	769146469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146469	18222353	Genotypes AG + GG are associated with decreased risk of Myocardial Infarction when treated with pravastatin.	3.0
655384621	981482129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981482129	20886236	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.	3.5
655384621	981565085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981565085	18222353	Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin.	This annotation is not used for clinical annotation scoring. other VA from the same publication already counted in the scoring
655384621	981962878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981962878	20403483	Genotypes AG + GG are associated with increased response to pravastatin in people with Myocardial Infarction as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The study included patients from CARE study which already been published previously (PMID:18222353, 20886236) and used for scoring.
1451243216	1184514962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514962	22309416	Genotype CT are not associated with dose of tacrolimus in people with liver transplantation as compared to genotype CC.	-1.25
1451243216	1184998539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998539	23738951	Genotypes CT + TT is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.	1.5
1451243216	1185011784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185011784	25310192	Genotype CC is associated with decreased dose of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.	2.75
1451243216	1444694003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694003	21886016	Genotypes CT + TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	1.125
1451243216	1184514971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514971	19289993	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.25
1451243216	1447946859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946859	26856709	CYP3A5 *1/*1 is not associated with dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.125
1451243216	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451243216	1449748555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748555	29621122	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451243216	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1451241700	982046274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046274	23837476	Genotypes CT + TT are associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.	2.5
1451241700	982046278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046278	23837476	Genotypes CT + TT are associated with increased time to reach stable dose of tacrolimus in children with Transplantation as compared to genotype CC.	2.0
1451241700	1183491645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491645	23900887	Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241700	1183533905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533905	21359536	Allele C is associated with decreased dose of tacrolimus in people with liver transplantation as compared to allele T.	1.75
1451241700	1184512384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512384	22422348	Genotype TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	0.0
1451241700	1184514968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514968	16628701	Genotype CC is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.5
1451241700	1446899553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899553	26271661	Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1451241700	1184514988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514988	19289993	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451241700	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241700	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1183621000	PA166119846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166119846		Annotation of CPIC Guideline for rasburicase and G6PD	100
1183621000	1183685142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685142	22190578	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Burkitt Lymphoma.	0.125
1183621000	1183685166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685166	22015451	G6PD deficiency is associated with Hemolysis when treated with methylene blue and rasburicase in people with Neoplasms.	0.125
1183621000	1183685176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685176	18561168	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Hyperuricemia.	0.125
1183621000	1183685188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685188	16204390	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Kidney Failure, Acute.	0.125
1183621000	1183685208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685208	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685218	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Neoplasms.	0.125
1183621000	1183685222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685222	9369411	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183685227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685227	12075750	G6PD deficiency is associated with Hemolysis when treated with rasburicase in people with Neoplasms.	0.0
1183621000	1183685232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685232	22573495	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685242	17387701	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Burkitt Lymphoma.	0.125
1183621000	1183685251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685251	12942574	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Neoplasms.	0.0
1183621000	1183685257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685257	23860572	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Leukemia, Lymphoid.	0.125
1183621000	1184169040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169040	24750455	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in women with Tumor Lysis Syndrome.	0.125
1183621000	1184515920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515920	25115783	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Leukemia.	0.125
1183621000	1444710866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710866	25988058	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase.	0.125
1183621000	1444713834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713834	26033222	G6PD deficiency is associated with Anemia, Hemolytic and Methemoglobinemia when treated with methylene blue and rasburicase.	0.125
1183621000	1448634792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634792	28370399	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Tumor Lysis Syndrome.	0.125
1183621000	1449161310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161310	29290749	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183620431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620431	20196170	G6PD A-202A_376G is associated with Hemolysis when exposed to rasburicase in men with Burkitt Lymphoma.	0.25
1183621000	1184515977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515977	23209099	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with Hemolysis and subsequent death when treated with rasburicase in children with Hyperuricemia.	0.25
1183621000	1184515983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515983	19654083	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with adverse reaction due to rasburicase in men with Neoplasms.	0.25
1183621000	1444699847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699847	23989394	G6PD A- 202A_376G (assigned as deficiency phenotype) is associated with Methemoglobinemia when treated with rasburicase in infants with Kidney Failure, Acute.	0.25
1183621261	PA166127636	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127636		Annotation of CPIC Guideline for paroxetine and CYP2D6	100
1183621261	PA166104976	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104976		Annotation of DPWG Guideline for paroxetine and CYP2D6	100
1183621261	1183695918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183695918	1531950	CYP2D6 poor metabolizers are associated with increased median AUC, plasma half-life and steady-state plasma concentrations of paroxetine when exposed to paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183621261	1184137305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137305	10434486	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.	1.0
1183621261	1184137318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137318	1531950	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183621261	1184165939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165939	16319918	CYP2D6 poor metabolizers is associated with increased steady-state Cmax and AUC(0-24) and the lowest clearance when treated with paroxetine in children with Depressive Disorder, Major.	0.0625
1183621261	1184169696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169696	1531951	CYP2D6 poor metabolizers are associated with increased paroxetine plasma concentration when treated with paroxetine in people with Diabetic Neuropathies as compared to CYP2D6 normal metabolizers.	0.0625
1183621261	982047439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047439	16319918	CYP2D6 *1/*1 is associated with increased clearance of paroxetine in children with Depressive Disorder, Major.	0.0
1183621261	1183615301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615301	16669849	CYP2D6 *5 is associated with decreased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183621261	1183619689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619689	16319918	CYP2D6 *2/*2 is associated with increased clearance of paroxetine in children with Depressive Disorder, Major.	0.0
1183621261	1183620613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620613	14639062	CYP2D6 *3/*4 + *4/*4 + *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	1.5
1183621261	1183620621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620621	14639062	CYP2D6 *3/*4 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
1183621261	1183620631	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620631	14639062	CYP2D6 *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
1183621261	1183620639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620639	14639062	CYP2D6 *2/*2xN is associated with undetectable paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major.	1.5
1183621261	1183620645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620645	19743889	CYP2D6 *1/*4 + *1/*5 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.	1.75
1183621261	1183620663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620663	19743889	CYP2D6 *4/*4 + *3/*4 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.	1.75
1183621261	1183620727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620727	16633156	CYP2D6 *1/*2xN is associated with low or undetectable paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1183620762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620762	20174590	CYP2D6 *1/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
1183621261	1183620875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620875	20174590	CYP2D6 *4/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
1183621261	1183620950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620950	12173784	CYP2D6 *9/*2xN is associated with undetectable paroxetine plasma concentration when treated with paroxetine in healthy individuals.	0.125
1183621261	1183621057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621057	18641553	CYP2D6 *1/*1xN is associated with undetectable paroxetine serum concentration when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1183621076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621076	18641553	CYP2D6 *1/*1xN is associated with decreased paroxetine serum concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
1183621261	1183621104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621104	15349705	CYP2D6 *10/*10 + *1/*10 is not associated with differences in plasma paroxetine concentrations at administered dose above 10mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.25
1183621261	1183621118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621118	15349705	CYP2D6 *10/*10 + *1/*10 are associated with increased plasma paroxetine concentrations at administered dose of 10mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183621261	1183621133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621133	16423440	CYP2D6 *1/*10 + *1/*5 is associated with increased paroxetine plasma concentration at an administered dose of 30mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183621261	1183621153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621153	16423440	CYP2D6 *1/*10 + *1/*5 is not associated with differences in paroxetine plasma concentration when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.25
1183621261	1183701674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701674	10505591	CYP2D6 *1/*3 + *1/*4 + *1/*5 is associated with increased median paroxetine steady-state plasma concentration when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
1183621261	1183701701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701701	16534507	CYP2D6 *10 + *5 is not associated with differences in paroxetine daily dose, plasma concentrations or nausea when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1.	-0.75
1183621261	1184137325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137325	10824636	CYP2D6 *10/*10 is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1183621261	1184165575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165575	16633156	CYP2D6 *1/*2xN is associated with undetectable or low paroxetine serum concentrations when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1184169844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169844	17256449	CYP2D6 *1/*4 is associated with increased paroxetine serum concentrations (Cmin) when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*41.	1.0
1183621261	1184468801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468801	15544025	CYP2D6 *1/*5 is associated with increased plasma concentration when treated with paroxetine.	0.125
1183621261	1444712725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712725	25967538	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .	2.0
1183621261	1444712755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712755	25967538	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .	1.5
1183621261	1448108691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108691	27187662	CYP2D6 *10/*10 is not associated with metabolism of paroxetine as compared to CYP2D6 *10/*41 + *41/*41 + *1/*10 + *1/*41 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.	-1.0
1183621261	1449310381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310381	28933337	CYP2D6 *5/*10 + *10/*10 + *10/*14 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.	0.125
1183621261	1183615266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615266	16669849	CYP2D6 *4/*5 is associated with decreased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183621261	1183615309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615309	16669849	CYP2D6 *2xN is associated with increased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183629373	1450806633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806633	7648764	CYP2C19 poor metabolizers are associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183629373	1183618419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618419	11380317	CYP2C19 *2/*2 + *3/*3 is associated with decreased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	2.0
1183629373	1183620365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620365	15470328	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629373	1183622261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622261	16937451	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	1.0
1183629373	1183622290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622290	16937451	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	-0.25
1183629373	1183622300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622300	16937451	CYP2C19 *1/*2 + *1/*3 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	-0.25
1183629373	1183622935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622935	17725594	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1183629373	1183622953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622953	17725594	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1183629373	1183622965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622965	17725594	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	-0.125
1183629373	1183624311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624311	19552744	CYP2C19 *2/*2 + *2/*3 is associated with decreased clearance of rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1183629373	1183679290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679290	22324425	CYP2C19 *1/*2 is not associated with clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1.	-0.125
1183629373	1450809654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809654	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.125
1183629373	1183620224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620224	15470328	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	2.0
1183629373	1451253680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253680	15715938	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183629373	1451253733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253733	20838991	CYP2C19 *1/*1 is associated with increased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	0.125
1183629373	1451253720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253720	15715938	CYP2C19 *1/*2 + *1/*3 are not associated with metabolism of rabeprazole as compared to CYP2C19 *1/*1.	-0.125
1183629796	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183629796	PA166104987	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104987		Annotation of DPWG Guideline for lansoprazole and CYP2C19	100
1183629796	1184754961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754961	24996380	CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizers and intermediate metabolizers.	0.75
1183629796	1184754980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754980	24996380	CYP2C19 intermediate metabolizers is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizer.	0.75
1183629796	1184754990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754990	24996380	CYP2C19 intermediate metabolizers is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizers.	0.75
1183629796	1183617346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617346	11012469	CYP2C19 *1/*1 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183617370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617370	11012469	CYP2C19 *1/*2 + *1/*3 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183617444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617444	11240980	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183618465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618465	11929404	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183618478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618478	11929404	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*3 + *2/*2.	2.0
1183629796	1183618644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618644	12121503	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.25
1183629796	1183618781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618781	12386647	CYP2C19 *2/*2 + *2/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.75
1183629796	1183618795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618795	12386647	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.25
1183629796	1183619140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619140	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-1.5
1183629796	1183619151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619151	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183619401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619401	12656699	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183619415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619415	12656699	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183620883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620883	15963082	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629796	1183620899	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620899	15963082	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629796	1183621246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621246	16863547	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.75
1183629796	1183621366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621366	16863547	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-0.875
1183629796	1183621387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621387	16863547	CYP2C19 *1/*2 + *1/*3 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.75
1183629796	1183622712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622712	17215846	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183622726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622726	17215846	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-0.5
1183629796	1183622809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622809	17295875	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.25
1183629796	1183622820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622820	17295875	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623444	18241283	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.25
1183629796	1183623799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623799	19166419	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623810	19166419	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.25
1183629796	1183623820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623820	19166419	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183624062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624062	19259653	CYP2C19 *1/*2 + *1/*3 is associated with decreased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.5
1183629796	1183624077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624077	19259653	CYP2C19 *1/*1 is associated with increased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183679442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679442	23646118	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183629796	1183679456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679456	23646118	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.25
1183629796	1183679469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679469	23646118	CYP2C19 *1/*2 + *1/*3 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183679635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679635	12662378	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.25
1183629796	1183679931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679931	15710002	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183679942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679942	15710002	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183679983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679983	15952098	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	3.0
1183629796	1183679996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679996	15952098	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	3.0
1183629796	1183680085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680085	20559522	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.5
1183629796	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183679880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679880	14638340	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183679894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679894	14638340	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183617822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617822	11240980	CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.75
1183629796	1183680006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680006	16815316	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183680019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680019	16815316	CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183621166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621166	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183621202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621202	16863547	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183621191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621191	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183629796	1183622736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622736	17215846	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183679954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679954	15710002	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.25
1451244800	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1451244800	1451163180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451163180	32128760	Allele C is associated with increased exposure to atorvastatin as compared to allele T.	0.0
1451244800	1451164960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451164960	31594719	Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	1.5
1451244800	1451230062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230062	29442027	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	2.0
1451244800	769171454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171454	19374892	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.	This annotation is not used for clinical annotation scoring. drug drug interaction
1451244800	1451352820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352820	29039339	Genotypes CC + CT are associated with increased concentrations of atorvastatin as compared to genotype TT.	1.25
1451244800	1451352866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352866	26857559	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	1.75
1451244800	1451352940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352940	26373210	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	0.125
1451244800	981758554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758554	23361102	Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.	0.125
1451244800	827827481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827481	17473846	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.	1.0
1451244800	1184169609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169609	23876492	Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.	1.5
1451244800	1447990018	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447990018	25673568	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	0.125
1451244800	1451226420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226420	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1451244800	1451448741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451448741	33805706	SLCO1B1 *1/*5 + *5/*5 are associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	2.0
1451244800	1451352842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352842	28435225	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1451244800	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1451244800	1184989241	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989241	15970799	SLCO1B1 *5 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1451244800	1451533063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451533063	20040338	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	1.75
1451244800	1451165020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451165020	31594719	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1451244800	1451905600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905600	35034348	SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.	2.5
1183621866	PA166105001	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105001		Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6	100
1183621866	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183621866	1446901896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901896	10774635	CYP2D6 poor metabolizers are associated with decreased metabolism of trimipramine in people with Schizophrenia as compared to CYP2D6 normal metabolizers.	0.0625
1183621866	1183621485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621485	14520122	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183621866	1446901759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901759	14520122	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1183621866	1446901830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901830	14646691	CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizers phenotype) are associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN + *1/*1.	1.5
1183621866	1446901857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901857	14646691	CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.	2.0
1183621987	PA166105001	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105001		Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6	100
1183621987	1446901990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901990	10774635	CYP2C19 poor metabolizers are associated with decreased metabolism of trimipramine in people with Schizophrenia as compared to CYP2C19 normal metabolizers.	0.0625
1183621987	1183621560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621560	14520122	CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183621987	1446901738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901738	14520122	CYP2C19 *2 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1445400172	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400172	1185234581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185234581	10823104	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to allele C.	0.0
1445400172	1185235523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235523	22030266	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine in people with Myopathy, Central Core as compared to allele C.	0.25
1445400172	1445117584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445117584	25086907	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400172	1449160984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160984	12059893	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1445400172	1449160992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160992	14985404	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to as compared to allele C.	0.0
1445400172	1449161010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161010	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1451244720	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451244720	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451244720	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1183617714	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1183617714	827808349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808349	16044105	Genotype AA is associated with increased log metabolic ratio of amitriptyline/nortriptyline when treated with amitriptyline as compared to genotype GG.	1.75
1183617714	1183617143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617143	12172336	CYP2C19 *2/*2 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1183617161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617161	12172336	CYP2C19 *2/*3 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.0
1183617714	1183617173	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617173	12172336	CYP2C19 *1/*2 + *2/*2 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.0
1183617714	1183617183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617183	12172336	CYP2C19 *1/*3 + *2/*3 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.0
1183617714	1183617529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617529	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with amitriptyline in people with Depressive Disorder, Major.	0.125
1183617714	1183623160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623160	16024198	CYP2C19 *2/*2 + *1/*2 is associated with decreased metabolism of amitriptyline in postmortem toxicology cases as compared to CYP2C19 *1/*1.	2.0
1183617714	1446901519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901519	12012142	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.0
1183617714	1446901546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901546	12012142	CYP2C19 *2/*2 + *2/*3 are associated with decreased concentrations of nortriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.5
1183617714	1446901561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901561	12012142	CYP2C19 *2/*2 + *2/*3 are not associated with clearance of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	-0.125
1183617714	1446902626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902626	16044105	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.25
1183617714	1446902958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902958	20531370	CYP2C19 *17 + *2 are not associated with concentrations of nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183617714	1446902977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902977	20531370	CYP2C19 *17 is associated with increased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	0.0
1183617714	1446903003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903003	20531370	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1446903025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903025	20531370	CYP2C19 *2/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1446903873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903873	15590749	CYP2C19 *1/*2 + *2/*2 are associated with increased concentrations of amitriptyline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.0
1183617714	1446903892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903892	20531370	CYP2C19 *17 + *2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183617714	1446903928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903928	15205367	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-0.125
1183617714	1448615842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615842	28296334	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased exposure to amitriptyline in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183617714	1450664831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664831	15205367	CYP2C19 *1/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.0
1183617714	1450664844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664844	15205367	CYP2C19 *1/*2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	0.125
1451282740	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1451282740	PA166104975	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104975		Annotation of DPWG Guideline for escitalopram and CYP2C19	100
1451282740	1183698879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698879	24257813	CYP2C19 poor metabolizers are associated with decreased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1451282740	1183698912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698912	24257813	CYP2C19 ultrarapid metabolizer phenotype is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.	0.75
1451282740	1184137275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137275	19404631	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.	1.0
1451282740	655387725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387725	17625515	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	2.5
1451282740	655387729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387729	17625515	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	2.5
1451282740	655387735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387735	17625515	Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.	2.5
1451282740	655387732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387732	17625515	Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.	2.5
1451282740	1183618316	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618316	18654768	CYP2C19 *17/*17 is associated with increased clearance of escitalopram in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1451282740	1183619481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619481	20350136	CYP2C19 *2/*2 + *2/*3 is associated with increased S-CIT serum concentrations when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*2.	1.25
1451282740	1183619732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619732	16418702	CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1451282740	1183619741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619741	17625515	CYP2C19 *2 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619754	17625515	CYP2C19 *3 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619762	17625515	CYP2C19 *17/*17 is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619790	21926427	CYP2C19 *2/*2 + *2/*3 are associated with increased mean escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.0
1451282740	1183619821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619821	21926427	CYP2C19 *17/*17 is associated with decreased mean logarithm escitalopram concentration and higher mean metabolic ratio when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.0
1451282740	1183699996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699996	19841156	CYP2C19 *1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased clearance of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.0
1451282740	1183700031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700031	19773541	CYP2C19 *2/*2 is associated with increased relative dose-adjusted serum concentrations of escitalopram and lower relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite when treated with escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1.	0.125
1451282740	1183700043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700043	19773541	CYP2C19 *17/*17 is associated with lower relative dose-adjusted serum concentrations of escitalopram and higher relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite when treated with escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1.	0.125
1451282740	1183700055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700055	19404631	CYP2C19 *2/*2 + *2/*4 (assigned as poor metabolizer phenotype) is associated with increased area under the time-plasma concentration curve (AUC(0-24)) when treated with escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1451282740	1184137240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137240	21926427	CYP2C19 *1/*17 is associated with decreased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
1451282740	1184748190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748190	25154506	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282740	1184748315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748315	25154506	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1451282740	1184748329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748329	25154506	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282740	1184748337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748337	25154506	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1451282740	1449163468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163468	29325448	CYP2C19 *2 + *3 + *4 are associated with increased exposure to escitalopram as compared to CYP2C19 *1/*1.	2.5
1451282740	1449163487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163487	29325448	CYP2C19 *1/*17 + *17/*17 are associated with decreased exposure to escitalopram as compared to CYP2C19 *1/*1.	2.5
1183620386	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1183620386	PA166104977	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104977		Annotation of DPWG Guideline for citalopram and CYP2C19	100
1183620386	1183701599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701599	8451774	CYP2C19 poor metabolizer is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2C19 normal metabolizer.	0.75
1183620386	1183701639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701639	8835706	CYP2C19 poor metabolizer is associated with increased plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	0.875
1183620386	1451715780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451715780	33608663	Genotype AG is associated with increased concentrations of citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.	2.0
1183620386	982029840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029840	20531370	Genotype TT is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to genotype CC.	1.75
1183620386	982029829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029829	20531370	Genotype AA is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to genotype GG.	1.75
1183620386	982046981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046981	11802100	CYP2C19 *1/*2 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-0.125
1183620386	1183619572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619572	12968986	CYP2C19 *2/*2 + *2/*3 are associated with increased AUC of the S-enantiomer of citalopram (no effect on R-CT) when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183620386	1183619684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619684	12975335	CYP2C19 *2/*2 + *2/*3 is associated with decreased oral clearance of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	0.5
1183620386	1183619708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619708	12975335	CYP2C19 *2/*2 + *2/*3 is associated with increased citalopram AUC and terminal elimination half-life when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.5
1183620386	1183619732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619732	16418702	CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1183620386	1183619883	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619883	16855453	CYP2C19 *2 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.25
1183620386	1183619898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619898	16855453	CYP2C19 *3 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1183620386	1183701537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701537	23981149	CYP2C19 *1/*2 is not associated with clearance of citalopram in healthy individuals as compared to CYP2C19 *1/*1.	-0.125
1183620386	1183847009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183847009	19840783	CYP2C19 *1/*2 + *2/*2 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183620386	1184137222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137222	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with plasma concentrations when treated with citalopram in people with Depressive Disorder, Major.	0.125
1183620386	1184137230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137230	20531370	CYP2C19 *2/*2 is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to CYP2C19 *1/*1.	1.75
1183620386	1184137250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137250	20531370	CYP2C19 *1/*17 is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to CYP2C19 *1/*1.	1.75
1183620386	1184748190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748190	25154506	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1183620386	1184748315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748315	25154506	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1183620386	1184748329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748329	25154506	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1183620386	1184748337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748337	25154506	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1183620386	1446908220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908220	26343256	CYP2C19 *2 is associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.0
1183620386	1446908239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908239	26343256	CYP2C19 *1/*17 is not associated with metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-0.5
1451147720	PA166265421	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265421		Annotation of DPWG Guideline for quetiapine and CYP3A4	100
1451147720	1451147640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147640	32331352	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	0.0
1451147720	1451648462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451648462	24525658	CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.	2.0
1451155125	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451155125	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451155125	1183618106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618106	18713907	CYP2D6 *1xN is associated with Respiratory Insufficiency when treated with tramadol as compared to CYP2D6 *1/*1.	0.25
1451155125	1183618150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618150	21691803	CYP2D6 *1/*1xN is associated with increased risk of severe cardiotoxicity (refractory cardiac arrest) when treated with tramadol as compared to CYP2D6 *1/*1.	0.25
1451155125	1444694442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444694442	25647677	CYP2D6 *2/*2xN is associated with increased risk of Respiratory Insufficiency when treated with tramadol.	0.25
1451163884	PA166128738	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166128738		Annotation of CPIC Guideline for atazanavir and UGT1A1	100
1451163884	1183863801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863801	24557078	Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele C.	0.0
1451163884	1183863806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863806	24557078	Genotype TT is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to genotype CC.	0.0
1451163884	1445296945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296945	26180834	Genotype TT is associated with increased discontinuation of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	3.25
1451163884	1449154881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154881	29117017	Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.	3.0
1451163884	1449154902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154902	29117017	Genotype CT is not associated with increased discontinuation of atazanavir as compared to genotype CC.	-1.75
1451163884	1184747361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747361	20504240	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV.	3.0
1451163884	1184747406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747406	20504240	UGT1A1 *6 is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV.	-1.5
1451163884	1184747517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747517	24516079	UGT1A1 *28 is associated with Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV.	1.5
1451163884	1184747549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747549	21317582	UGT1A1 *28/*28 + *1/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV as compared to UGT1A1 *1/*1.	1.75
1451163884	1184998649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998649	19710077	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in healthy individuals.	1.0
1451163884	1184998662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998662	19710077	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in healthy individuals.	1.0
1451163884	1184999159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184999159	23548653	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV.	0.0
1451163884	1184999665	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184999665	21348813	UGT1A1 *28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV as compared to UGT1A1 *1.	1.5
1451163884	1185000885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000885	17058217	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV.	3.5
1451163884	1451163820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163820	16170755	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir or indinavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28.	2.25
1451163884	1451163920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163920	23148286	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.	3.5
1451163884	1451163981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163981	23148286	UGT1A1 *28/*28 is associated with increased likelihood of Jaundice when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 +*1/*36 + *36/*36.	3.5
1451163884	1451164100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164100	22661571	UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.	2.75
1451163884	1451164185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164185	17148966	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.	3.0
1451163884	1451164300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164300	22179231	UGT1A1 *1/*28 is associated with increased Hyperbilirubinemia and Jaundice when treated with atazanavir in men with Acquired Immunodeficiency Syndrome.	0.25
1451163884	1451165241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451165241	25622064	UGT1A1 *1/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to UGT1A1 *1/*1.	1.75
1451163884	1451213520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213520	23782005	UGT1A1 *1/*36 + *28/*36 + *36/*37 + *1/*1 are associated with decreased severity of Hyperbilirubinemia when treated with atazanavir / ritonavir, lamivudine and zidovudine in women with HIV Infections and Pregnancy as compared to UGT1A1 *1/*28 + *1/*37 + *28/*28 + *28/*37.	2.0
1184996903	PA166176623	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176623		Annotation of CPIC Guideline for oxcarbazepine and HLA-B	100
1184996903	PA166265201	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265201		Annotation of DPWG Guideline for oxcarbazepine and HLA-B	100
1184996903	PA166105213	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166105213		Annotation of FDA Label for oxcarbazepine and HLA-B	100
1184996903	981859082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859082	20235791	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine in Epilepsy.	2.75
1184996903	1184469071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469071	24496695	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	2.5
1184996903	1184988799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988799	18785891	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in men with Seizures.	0.25
1184996903	1184988858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988858	22429379	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	0.25
981203719	PA166124619	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166124619		Annotation of CPIC Guideline for tacrolimus and CYP3A5	100
981203719	PA166104983	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104983		Annotation of DPWG Guideline for tacrolimus and CYP3A5	100
981203719	981858954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858954	23073468	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	827699040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827699040	19258929	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.25
981203719	827813802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813802	21770725	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	827830139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830139	12966368	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	2.25
981203719	769166529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166529	21047202	Genotype TT is associated with risk of being underdosed when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1183532526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183532526	22871995	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1183533900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533900	23837477	Genotype CC is associated with decreased dose of tacrolimus in children with Transplantation as compared to genotypes CT + TT.	2.25
981203719	1183533922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533922	21711429	Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1183684248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684248	24120259	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1183684255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684255	24120259	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1183684260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684260	24120259	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.25
981203719	1184468834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468834	21047202	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	2.25
981203719	1184514549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514549	12694072	Genotype CT is associated with increased dose of tacrolimus in children with heart transplantation as compared to genotype CC.	1.25
981203719	1184514552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514552	14578760	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1184514558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514558	15167702	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
981203719	1184514564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514564	15808586	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
981203719	1184514687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514687	23991193	Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	1.75
981203719	1184514784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514784	21047202	Genotype TT is associated with higher stable dose levels of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	0.0
981203719	1184514793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514793	22101623	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	1184514796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514796	21851254	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1184514802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514802	22469198	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.5
981203719	1184514808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514808	23146466	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514811	24024898	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514817	21480817	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.75
981203719	1184514826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514826	21671989	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	0.0
981203719	1184514829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514829	21566507	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514832	21677300	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
981203719	1184514838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514838	16753004	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514850	16146556	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
981203719	1184514853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514853	16249748	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1184514859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514859	17430486	Genotypes CT + TT are associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
981203719	1184514862	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514862	18334918	Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514865	19067682	Genotype TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514868	19125240	Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514871	21273673	Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1184514874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514874	21331500	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	3.0
981203719	1184998300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998300	22304537	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.5
981203719	1184998312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998312	22704849	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.75
981203719	1184998369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998369	21922127	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
981203719	1184998398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998398	22369694	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184998408	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998408	22310591	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1185011784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185011784	25310192	Genotype CC is associated with decreased dose of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.	2.75
981203719	1444694034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694034	24739669	Genotypes CT + TT is associated with increased dose of tacrolimus in people with heart transplantation as compared to genotype CC.	2.25
981203719	1444694293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694293	25594874	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.0
981203719	1448597107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448597107	27977332	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	1449147673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147673	29113387	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1449732574	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732574	29393157	Genotype CC is associated with decreased dose of tacrolimus in people with Colitis, Ulcerative as compared to genotypes CT + TT.	2.0
981203719	827698530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698530	21206424	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
981203719	827785547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827785547	20818295	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.5
981203719	1183697996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697996	23149441	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	827784291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784291	21886016	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1183697400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697400	22183771	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1183959864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959864	20383212	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to CYP3A5 *3/*3.	-0.25
981203719	1184470735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470735	24656015	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184470804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470804	24655974	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	3.0
981203719	1184470883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470883	24528196	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1184471318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471318	24444408	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	3.0
981203719	1184471382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471382	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184471393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471393	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184471403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471403	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	1.75
981203719	1184514597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514597	19343327	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1184514634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514634	23146479	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	2.75
981203719	1184514878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514878	19343327	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1184514887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514887	19545678	CYP3A5 *1/*3 + *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	2.25
981203719	1184514893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514893	20041908	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1184514901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514901	21528942	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1184514907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514907	21930396	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1184514921	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514921	23666583	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1184514927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514927	24089074	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
981203719	1184514946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514946	24033383	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	2.0
981203719	1184989793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989793	25322286	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1445164685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164685	26177012	CYP3A5 *3/*3 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-0.25
981203719	1445297499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297499	25817604	CYP3A5 *3/*3 is not associated with dose of tacrolimus in people with Arthritis, Rheumatoid as compared to CYP3A5 *1/*1 + *1/*3.	-1.25
981203719	1447520665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520665	26227094	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1447520826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520826	26543771	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1447673635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447673635	26114223	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
981203719	1447946747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946747	26823971	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1447946767	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946767	26823971	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1447947417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947417	26915847	CYP3A5 *1/*1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	2.0
981203719	1448255771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255771	26518946	CYP3A5 *1/*3 + *3/*3 are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.75
981203719	1448267453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267453	26714287	CYP3A5 *3 is not associated with dose of tacrolimus in people with Kidney Transplantation.	-1.5
981203719	1448267466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267466	26990694	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1448285878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285878	27225724	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
981203719	1448423892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423892	26450467	CYP3A5 *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1448427616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448427616	27217047	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1448530690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530690	28030534	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1448640957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640957	26924289	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
981203719	1448819466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819466	28540692	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.75
981203719	1448819488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819488	28605053	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	3.0
981203719	1449170393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170393	27138785	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1449171185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171185	29162334	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	2.0
981203719	1449172013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172013	28401703	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1449172236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172236	29375701	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with Autoimmune Diseases as compared to CYP3A5 *3/*3.	-0.125
981203719	1449183103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449183103	29161757	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	2.5
981203719	1449747633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747633	29535109	CYP3A5 *1/*3 is not associated with dose of tacrolimus in children with henoch-schonlein purpura nephritis as compared to CYP3A5 *3/*3.	-0.125
981203719	1449747930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747930	29539600	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
981203719	1449748855	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748855	29691732	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	1.25
981203719	1449748938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748938	29731062	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
981203719	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
981203719	1449750413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750413	29920880	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.	0.75
981203719	1450373276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373276	30704156	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Arthritis, Rheumatoid or Colitis, Ulcerative as compared to CYP3A5 *3/*3.	1.5
981203719	1448276612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276612	27266721	CYP3A5 *3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation.	0.0
981203719	1447674199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674199	26635230	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1451554440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451554440	32848803	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981238501	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
981238501	PA166104984	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104984		Annotation of DPWG Guideline for phenytoin and CYP2C9	100
981238501	1451151749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151749	32457604	Allele T is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele C.	2.25
981238501	1451151730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151730	32457604	Allele C is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele A.	2.25
981238501	769250046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250046	19617466	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype CC.	0.0
981238501	769248937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248937	21068649	Allele T is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele C.	3.0
981238501	769259087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769259087	21537551	Allele T is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele C.	-1.0
981238501	1448614798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614798	28391407	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele C.	3.5
981238501	1448614807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614807	28391407	Allele T is not associated with drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele C.	-1.5
981238501	769259088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769259088	21537551	Allele C is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele A.	-1.0
981238501	769248932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248932	21068649	Allele C is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele A.	3.0
981238501	769250049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250049	19617466	Genotype AC is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype AA.	0.0
981238501	827921686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921686	22641027	CYP2C9 *2/*2 is associated with Drug Toxicity when treated with diazepam and phenytoin in children with Epilepsy.	0.25
981238501	981858881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858881	20390258	CYP2C9 *1/*3 is associated with increased risk of phenytoin toxicity when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	3.25
981238501	981858886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858886	15024534	CYP2C9 *1/*3 is associated with increased likelihood of diphenylhydantoin-induced skin rash when exposed to phenytoin in neurological patients as compared to CYP2C9 *1/*1.	2.0
981238501	981859027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859027	11673755	CYP2C9 *3/*3 is associated with increased toxicity when treated with phenytoin.	0.0
981238501	981859041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859041	12707459	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	0.0
981238501	981859044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859044	21338443	CYP2C9 *1/*2 + *1/*3 is associated with increased adverse drug reactions when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	2.5
981238501	981859058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859058	19030785	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	0.0
981238501	981859061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859061	10774639	CYP2C9 *1/*3 is associated with increased toxicity when treated with phenytoin.	0.0
981238501	1184989037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989037	25096692	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	4.0
981238501	1184989132	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989132	25096692	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	3.75
981238501	1184989143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989143	25096692	CYP2C9 *3 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	3.5
981238501	1184989152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989152	25096692	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.	3.0
981238501	1447948974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948974	26928377	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin as compared to CYP2C9 *1.	2.5
981238501	1449565339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565339	25994870	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions due to phenytoin in children with Epilepsy.	3.25
981238501	1449565877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565877	27179628	CYP2C9 *1/*3 + *2/*3 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1 + *1/*2.	-1.25
981238501	1449565892	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565892	27179628	CYP2C9 *1/*2 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1.	-1.25
981238501	1450376288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376288	29288229	CYP2C9 *3 is not associated with risk of Maculopapular Exanthema due to phenytoin.	-2.0
981238501	1450806480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806480	30270535	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with phenytoin as compared to CYP2C9 *1/*1.	3.5
981238501	1450969260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450969260	31461080	CYP2C9 *1/*2 is not associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	-1.5
981238501	1450969282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450969282	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	3.25
981238501	1451117820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451117820	31646624	CYP2C9 *3 is associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C9 *1/*1.	4.0
981201962	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201962	1447987416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987416	22490566	Genotypes CC + CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
981201962	1447945633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945633	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201962	769169854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169854	17848752	Genotype CC is associated with increased likelihood of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	1.75
981201962	827892939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892939	14635116	Genotype CT is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	-1.5
981201962	769169871	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169871	17848752	Genotype CC is associated with decreased clearance of fluorouracil as compared to genotype TT.	0.0
981201962	769169847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169847	17848752	Genotype CC is associated with increased likelihood of Nausea and Vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	2.25
981201962	1450952700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952700	11156223	Allele C is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to allele T.	0.25
981201962	1450954520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954520	19473056	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	-1.5
981201962	1450954700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954700	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.5
981201962	1450954820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954820	23942539	Allele C is not associated with Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-0.25
981201962	1450954900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954900	18299612	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
981201962	1448126219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126219	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms or Colorectal Neoplasms as compared to allele T.	-1.75
981201962	1448262704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262704	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201962	1449162048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162048	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981201962	1449732013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732013	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
655385102	981499254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981499254	16772309	Genotype AA is associated with increased risk of asthma exacerbations when exposed to salmeterol in children with Asthma as compared to genotype GG.	2.25
655385102	981499270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981499270	19800676	Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG.	3.25
655385102	699639135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639135	16322642	Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG.	2.25
655385102	1183700310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700310	24279851	Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG.	3.5
655385102	1184169941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169941	24681963	Genotype GG is not associated with influence on differential bronchodilator effects when treated with montelukast or salmeterol in people with Asthma as compared to genotype AA.	-1.25
655385102	1451341440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451341440	30425908	Allele G is associated with increased response to salmeterol in children Asthma as compared to allele A.	1.75
655385102	981499235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981499235	23126384	Genotype AA is associated with decreased response to salmeterol in children with Asthma.	This annotation is not used for clinical annotation scoring. The variant annotation is on treatment comparison rather than genotype comparison.
655385028	1451340124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340124	31869433	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	1.0
655385028	1451589737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589737	31114289	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385028	982035663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035663	18030307	Allele G is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.	2.25
655385028	982038182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038182	20203262	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.0
655385028	982043538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043538	16493479	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.25
655385028	982043645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043645	17456829	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.75
655385028	982044365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044365	16611750	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.25
655385028	982046155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046155	19874474	Allele G is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
655385028	769160740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769160740	16270629	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
655385028	1183704889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704889	24019055	Genotype CC is associated with increased dose of warfarin as compared to genotypes CG + GG.	2.5
655385028	1450980643	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980643	18322281	Genotype GG is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385028	1447519677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519677	18466099	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385307	751539632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751539632	11710708	Genotypes AA + AG are associated with increased risk of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.5
655385307	1451618382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451618382	33794950	Genotypes AA + AG are associated with increased likelihood of Drug Toxicity due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	2.0
655385307	981934235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934235	23095111	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.25
655385307	827774221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827774221	21931346	Allele A is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
655385307	748441277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748441277	18381794	Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.5
655385307	608431516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431516	20863444	Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.0
655385307	769170642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170642	20472929	Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Arthritis, Psoriatic as compared to genotypes AG + GG.	2.75
655385307	769170659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170659	20595278	Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	2.75
655385307	769170688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170688	20514079	Allele A is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
655385307	1448592699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448592699	27992285	Allele A is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	1.25
655385307	1449164930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164930	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.75
655385307	1449270267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270267	29589488	Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	0.5
1447673015	1447222974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222974	18574025	Allele T is associated with decreased time in therapeutic range when treated with warfarin as compared to allele C.	0.0
1447673015	1447223056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223056	18690342	Allele T is not associated with time in therapeutic range when treated with warfarin as compared to allele C.	-1.5
1447673015	1447521498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521498	22130800	Allele T is not associated with time in therapeutic range when treated with warfarin in children as compared to allele C.	-1.25
1447673015	1184473602	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473602	25001883	Allele T is associated with increased propertion of the first 6 months' treatment time spent within the target INR range (PTIR) when treated with warfarin in children as compared to allele C.	2.25
1447673015	1184510000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510000	22592842	Genotypes CT + TT is associated with increased number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to genotype CC.	2.0
1447673015	1450980720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980720	18322281	Genotypes CT + TT is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.	3.75
1447673015	1451122100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451122100	31720756	Genotype TT is associated with increased time in therapeutic range when treated with warfarin as compared to genotypes CC + CT.	2.25
1447673015	1448257403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257403	27511999	Allele T is not associated with time in therapeutic range when treated with warfarin as compared to allele C.	-1.5
1447673015	1449170748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170748	29396738	Allele T is associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to allele C.	3.0
1451092460	PA166192341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192341		Annotation of CPIC Guideline for tenoxicam and CYP2C9	100
1451092460	1183702710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702710	18992346	CYP2C9 *3 is associated with increased AUC and half-life time (t1/2) when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1 + *2.	1.5
1451092460	1183702721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702721	15229460	CYP2C9 *1/*3 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092460	1183702730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702730	15229460	CYP2C9 *1/*2 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1183704228	981238818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981238818	22920394	Allele A is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
1183704228	981934126	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934126	16815313	Genotype GG is associated with increased dose of acenocoumarol as compared to genotypes AA + AG.	1.5
1183704228	1043737589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737589	16201835	Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.	1.75
1183704228	1043818101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818101	20020283	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	3.0
1183704228	655388351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388351	19270263	Genotype AA is associated with decreased dose requirement of acenocoumarol as compared to genotypes AG + GG.	2.0
1183704228	1450979500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450979500	18781852	Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.	0.0
1183704228	1450415284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415284	30983536	Genotype AA is associated with decreased dose of acenocoumarol.	0.25
1183704228	1444706973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706973	19225451	Genotypes AA + AG are associated with decreased dose of acenocoumarol as compared to genotype GG.	3.0
1183704228	1444707128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707128	17596133	Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.	2.25
1451204660	PA166104951	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104951		Annotation of DPWG Guideline for irinotecan and UGT1A1	100
1451204660	PA166104831	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104831		Annotation of FDA Label for irinotecan and UGT1A1	100
1451204660	1184483423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483423	24308720	UGT1A1 *28 is not associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	-1.0
1451204660	1184483429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483429	24308720	UGT1A1 *6 + *28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	1.0
1451204660	1184483709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483709	24519753	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28 + *1/*1.	1.25
1451204660	1448422676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422676	26857783	UGT1A1 *6 + *28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.	2.5
1451204660	1448422855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422855	27385990	UGT1A1 *1/*28 + *6/*28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	1.0
1451204660	1448427979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427979	25869015	UGT1A1 *28 is not associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1.	-1.25
1451204660	1448519703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448519703	20530282	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.5
1451204660	1451204842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204842	20562211	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	2.0
1451204660	1451205308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205308	17728214	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.625
1451204660	1451205360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205360	19390945	UGT1A1 *1/*28 + *28/*28 are not associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451205440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205440	17510208	UGT1A1 *28/*28 is associated with increased likelihood of Anemia, Leukopenia, Neutropenia or Thrombocytopenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451204660	1451205620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205620	17510208	UGT1A1 *28/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451204660	1451206354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206354	15280927	UGT1A1 *1/*28 + *28/*28 are not associated with Anemia, mucositis, Nausea, Neutropenia or Thrombocytopenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451206444	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206444	16456808	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451206820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206820	18594531	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	3.0
1451204660	1451207040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207040	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451204660	1451207282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207282	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451204660	1451208420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208420	17577039	UGT1A1 *28/*28 is not associated with increased risk of Diarrhea or Neutropenia when treated with irinotecan in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	-1.25
1451204660	1451208752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208752	17185998	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451208889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208889	16951398	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-0.25
1451204660	1451209004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209004	15007088	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.	2.75
1451204660	1451209203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209203	11990381	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	0.375
1451204660	1451209760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209760	16636344	UGT1A1 *1/*28 is not associated with Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451209900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209900	23529007	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451204660	1451209909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209909	23529007	UGT1A1 *1/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451204660	1451210000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210000	23529007	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	2.0
1451204660	1451210158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210158	26229432	UGT1A1 *28/*28 + *6/*6 + *1/*6 + *1/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451204660	1451211761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211761	26830078	UGT1A1 *28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	2.0
1451204660	1451211808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211808	18797458	UGT1A1 *1/*28 + *28/*28 are associated with increased Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451204660	1451211900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211900	23386248	UGT1A1 *28 is not associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451204660	1451212280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451212280	15297419	UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.75
1451204660	1451213421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213421	28367249	UGT1A1 *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1.	-1.0
1451204660	1451213580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213580	19450125	UGT1A1 *28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms.	-1.25
1451204660	1451213606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213606	24815493	UGT1A1 *1/*28 is not associated with increased likelihood of Anemia, Leukopenia, Neutropenia, Thrombocytopenia or Vomiting when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451213905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213905	18221820	UGT1A1 *1/*28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451214002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214002	25285015	UGT1A1 *28 is not associated with increased risk of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451204660	1451214143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214143	28502040	UGT1A1 *1/*28 + *28/*28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	-0.5
1451204660	1451214800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214800	29504153	UGT1A1 *28/*28 + *28/*37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.25
982033279	827814765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814765	21148049	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.	-1.5
982033279	827814749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814749	21148049	Allele C is associated with decreased dose of acenocoumarol as compared to allele A.	0.0
982033279	981934149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934149	16815313	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	1.5
982033279	981934157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934157	16815313	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	1.5
982033279	981934182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934182	12414349	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.75
982033279	981934227	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934227	12414349	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981940067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940067	19018719	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	-1.25
982033279	981940074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940074	19018719	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981954438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954438	22629463	CYP2C9 *1 is not associated with increased dose of acenocoumarol as compared to CYP2C9 *2 + *3.	-1.5
982033279	982006745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006745	23159639	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.75
982033279	982006752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006752	23159639	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	-1.75
982033279	982010010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010010	22486182	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	2.5
982033279	982010082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010082	22486182	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	2.5
982033279	982010090	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010090	22486182	CYP2C9 *1/*2 is not associated with dose of acenocoumarol.	-1.5
982033279	982010097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010097	22486182	CYP2C9 *1/*3 is not associated with dose of acenocoumarol.	-1.5
982033279	982015075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015075	23473641	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.5
982033279	982015087	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015087	23473641	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	982031268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031268	23651023	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	982032876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032876	23651023	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1183680067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680067	24108193	CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	2.5
982033279	1184511592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511592	25042728	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1.	-2.75
982033279	1184754650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754650	23774941	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	0.0
982033279	1184996788	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184996788	18781852	CYP2C9 *1/*2 + *2/*2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	0.0
982033279	1184996801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184996801	18781852	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	0.0
982033279	1444699553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699553	25519826	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	3.0
982033279	1444705544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705544	23481074	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1444705555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705555	23481074	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1444705825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705825	24956252	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.	3.0
982033279	1444705930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705930	24530212	CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.	3.25
982033279	1444705951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705951	24530212	CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.	3.25
982033279	1444706944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706944	19277427	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	1444706957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706957	19277427	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol.	-1.5
982033279	1444706981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706981	19225451	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	3.0
982033279	1444707113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707113	18021343	CYP2C9 *1/*3 + *2/*3 + *2/*2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.25
982033279	1444707144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707144	16699986	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.75
982033279	1444707400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707400	14521618	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.25
982033279	1444707419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707419	14521618	CYP2C9 *1/*2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.25
982033279	1444707494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707494	12123234	CYP2C9 *2 + *3 are not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1444707507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707507	12010835	CYP2C9 *3 + *2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.0
982033279	1444707543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707543	11186138	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	1.5
982033279	1444707558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707558	11186138	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol.	-0.25
982033279	1447678179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678179	15116052	CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
982033279	1447678195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678195	15116052	CYP2C9 *2 is not associated with time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1447678231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678231	24956252	CYP2C9 *2 + *3 is not associated with decreased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-2.0
982033279	1447678809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678809	16815313	CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	1447678821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678821	16815313	CYP2C9 *2 is not associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1447681848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681848	26781925	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	1.75
982033279	1448255545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255545	27335128	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to CYP2C9 *1/*1.	2.5
982033279	1448259338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259338	22911785	CYP2C9 *2 + *3 is associated with dose of acenocoumarol.	2.5
982033279	1448259384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259384	25089947	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1/*1.	2.0
982033279	1449188252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188252	29479633	CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.	3.0
982033279	1449188274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188274	29479633	CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.	3.0
982033279	1450415269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415269	30983536	CYP2C9 *3/*3 is associated with decreased dose of acenocoumarol.	0.25
982033279	981934319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934319	15128048	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1043818082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818082	20020283	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981420009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981420009	22920394	CYP2C9 *2 is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
982033279	981420013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981420013	22920394	CYP2C9 *3 is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
1183622099	PA166105002	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105002		Annotation of CPIC Guideline for desipramine and CYP2D6	100
1183622099	1183682189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682189	3769385	CYP2D6 poor metabolizers is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183622099	1183684001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684001	6488689	CYP2D6 poor metabolizers is associated with increased desipramine to hydroxy-desipramine ratio when treated with desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183622099	1446900203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900203	3816019	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900238	3816019	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900251	3621781	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900258	3621781	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446904957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904957	9049581	CYP2D6 poor metabolizers are associated with increased concentrations of desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1183622099	1446905111	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905111	3356084	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1448126229	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448126229	27440861	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in human liver microsomes as compared to CYP2D6 normal metabolizers.	0.0
1183622099	1183621911	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621911	10895986	CYP2D6 *10/*10 + *5/*10 is associated with increased steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	1.5
1183622099	1183621960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621960	10895986	CYP2D6 *10/*10 + *5/*10 is associated with increased desipramine/2-hydroxy-desipramine ratio when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183622099	1183621995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621995	15115913	CYP2D6 *6/*9 is associated with increased elimination half-life and drug exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1183622099	1183622026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622026	15115913	CYP2D6 *1/*1 + *1/*2 is associated with decreased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*4 + *1/*41.	1.5
1183622099	1183622080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622080	1346258	CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4 + *3.	2.0
1183622099	1183622215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622215	11417443	CYP2D6 *1/*2xN + *5/*2xN is associated with a trend towards increased clearance of desipramine when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
1183622099	1183623304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623304	1346258	CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4/*4 + *4/*5.	2.0
1183622099	1446902165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902165	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	2.5
1043858794	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1043858794	PA166104956	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104956		Annotation of DPWG Guideline for clopidogrel and CYP2C19	100
1043858794	982028906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028906	19106084	Allele A is associated with decreased plasma exposure to the active metabolite of clopidogrel when exposed to clopidogrel in healthy individuals as compared to allele G.	2.0
1043858794	982032776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032776	17900275	Allele A is associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to allele G.	1.75
1043858794	982042060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042060	23809542	CYP2C19 *2 is associated with decreased clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	3.0
1043858794	982042087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042087	23809542	CYP2C19 *17 is not associated with clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	-2.0
1043858794	1183697338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697338	24214141	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased Cmax and AUC of thiol metabolite when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1043858794	1184348998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348998	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.	1.0
1043858794	1184349010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349010	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*17 + *17/*17.	0.125
1043858794	1184469857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469857	19429918	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	2.0
1043858794	1184472453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472453	22428615	CYP2C19 *2/*2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	0.125
1043858794	1184472493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472493	21716274	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	0.125
1043858794	1184516457	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516457	25001882	CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.	0.0
1043858794	1184989861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989861	25008027	CYP2C19 *1/*2 + *1/*8 + *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.0
1043858794	1444607027	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607027	25542807	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1043858794	1444704559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704559	24402637	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.25
1043858794	1446907223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907223	26426352	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.	2.0
1043858794	1447359923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447359923	26524713	CYP2C19 *1/*2 + *2/*17 + *2/*2 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.	0.0
1043858794	1448101486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101486	26071277	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.	2.5
1043858794	1448624865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624865	27981573	CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	0.0
1043858794	1450664694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664694	21689142	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	0.0
655385012	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
655385012	PA166182841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182841		Annotation of DPWG Guideline for warfarin and VKORC1	100
655385012	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
655385012	1184748906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748906	25084205	Allele T is associated with decreased dose of warfarin.	2.0
655385012	1185235716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235716	24601977	Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.	2.25
655385012	1444666236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666236	25312789	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1444694721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694721	25594941	Genotype TT is associated with decreased dose of warfarin in people with as compared to genotype CT.	2.5
655385012	827864542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864542	20833980	Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.	1.75
655385012	1183689393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689393	22990331	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.0
655385012	981754840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754840	23061746	Allele T is associated with decreased dose of warfarin.	2.5
655385012	1183700756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700756	20375999	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	1449192273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192273	28049362	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.25
655385012	1451409502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409502	31902949	Genotypes CC + CT is associated with increased dose of warfarin in people with Heart Failure as compared to genotype TT.	2.0
655385012	1451589723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589723	31114289	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	982045983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045983	19582440	Allele T is associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to allele C.	2.5
655385012	982038234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038234	21176721	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.5
655385012	1445296652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296652	26024874	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	3.5
655385012	1445401042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401042	20615525	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	0.0
655385012	1446847493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446847493	26219158	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	1447519319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519319	23602689	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	1447520009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520009	26445138	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1447520074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520074	26433837	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	1.375
655385012	1447586694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447586694	20386359	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	1447586762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447586762	20339978	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	1447680544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680544	26739746	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	0.0
655385012	1447682688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682688	26745506	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	3.25
655385012	981483977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483977	20653676	Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to genotypes CC + CT.	2.5
655385012	981502435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502435	19875892	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	2.25
655385012	981505306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505306	21185752	Genotypes CT + TT are associated with lower warfarin dose requirement when treated with warfarin as compared to genotype CC.	2.0
655385012	982033139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033139	20833655	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	982035645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035645	18030307	Allele T is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.	2.25
655385012	982036670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036670	18542936	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	982036934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036934	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	982037894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037894	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	982040695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982040695	19135231	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.75
655385012	982043014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043014	17510308	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.25
655385012	982043949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043949	15947090	Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.	2.75
655385012	982044388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044388	16890578	Genotype TT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CT.	2.5
655385012	982045585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045585	18855533	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	0.0
655385012	982046164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046164	19874474	Allele T is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
655385012	982046752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046752	22010099	Genotype CC is associated with increased dose of warfarin in children as compared to genotypes CT + TT.	2.5
655385012	982047897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047897	22130800	Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.	2.25
655385012	608431774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431774	19794411	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.75
655385012	827567282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567282	15883587	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	827567361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567361	15888487	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.5
655385012	827601694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827601694	18305455	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	827603022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827603022	15930419	Allele T is associated with decreased dose of warfarin.	2.5
655385012	827664180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827664180	16580898	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	827783301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783301	22040439	Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation.	0.25
655385012	827783799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783799	21174619	Genotype CC is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to genotype TT.	2.75
655385012	827814719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814719	21148049	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655385012	827823796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823796	21110192	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	2.5
655385012	827826043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827826043	21747589	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	827925119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925119	22528326	Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.	2.5
655385012	978614455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614455	22676192	Allele T is associated with dose of warfarin.	0.0
655385012	637879838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879838	20203262	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655385012	637880256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880256	18535201	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	637880237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880237	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	637880240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880240	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	637880249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880249	19228618	Allele T is associated with decreased dose of warfarin.	2.0
655385012	769277920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277920	17049586	Genotype TT is associated with decreased dose of warfarin as compared to genotype CT.	2.25
655385012	827864552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864552	21228733	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1183697213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697213	22349464	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.75
655385012	1183697690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697690	23990957	Genotype TT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotypes CC + CT.	2.75
655385012	1183701155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701155	18574025	Allele T is associated with decreased dose of warfarin.	2.5
655385012	1183701305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701305	19679631	Allele C is associated with increased dose of warfarin as compared to allele T.	2.0
655385012	1183701524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701524	20421126	Allele T is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele C.	2.5
655385012	1183704858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704858	24019055	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	3.0
655385012	1184472424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472424	20128861	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1184472851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472851	24474498	Genotype TT is associated with decreased dose of warfarin in children as compared to genotypes CC + CT.	2.25
655385012	1184473132	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473132	22158446	Genotype CC is associated with increased likelihood of having warfarin Dose greater than 7.5 mg/day when treated with warfarin as compared to genotypes CT + TT.	1.25
655385012	1184473580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473580	25001883	Allele T is associated with decreased dose of warfarin in children as compared to allele C.	1.75
655385012	1184482753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482753	23949431	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	1184483809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483809	23104259	Genotypes CC + CT is associated with increased dose of warfarin as compared to genotype TT.	2.75
655385012	1184509863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509863	22854539	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.0
655385012	1184509986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509986	22592842	Allele T is associated with decreased warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.	2.5
655385012	1184510015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510015	22571356	Genotypes CT + TT is associated with decreased stable warfarin dose when treated with warfarin as compared to genotype CC.	3.0
655385012	1184510103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510103	22274142	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1184510339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510339	21320153	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	1184511552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511552	25042728	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1184511950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511950	24029542	Genotype CC is associated with increased dose of warfarin in healthy individuals as compared to genotypes CT + TT.	1.5
655385012	1184654330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654330	24330000	Genotype CC is associated with increased dose of warfarin in children with Heart Diseases as compared to genotype TT.	1.5
655385012	982037339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037339	19745563	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.5
655385012	1451120169	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451120169	31395958	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.75
655385012	1448615516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615516	28429387	Genotype TT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.	3.0
655385012	1448624157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624157	28550460	Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.	2.5
655385012	1449165091	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165091	28382498	Allele C is associated with increased dose of warfarin as compared to allele T.	1.75
655385012	1449260681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449260681	27617219	Allele T is associated with decreased dose of warfarin as compared to allele C.	1.75
655385012	1449262642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449262642	29568565	Allele T is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.0
655385012	1449577174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577174	29781049	Genotype CT is associated with increased dose of warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.	2.5
1183624499	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183624499	PA166104958	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104958		Annotation of DPWG Guideline for pantoprazole and CYP2C19	100
1183624499	827789173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827789173	19785625	CYP2C19 *1/*2 is associated with increased response to pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183624499	1183620957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620957	15976989	CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183624499	1183621536	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621536	16912869	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.	2.5
1183624499	1183622885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622885	17645482	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624499	1183622896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622896	17645482	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624499	1183623682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623682	18637061	CYP2C19 *1/*1 is not associated with response to pantoprazole in people with Helicobacter Infections.	-1.5
1183624499	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183624499	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183624499	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183624499	1183623652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623652	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183624499	1183623663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623663	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	2.25
1043880701	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1043880701	1451228580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228580	29950617	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.0
1043880701	1451358200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358200	31981411	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.	1.5
1043880701	1451358660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358660	27557342	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	1.75
1043880701	827827497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827497	17473846	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.	1.5
1043880701	1183631263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631263	23930675	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	2.25
1043880701	1184169599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169599	23876492	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.	2.0
1043880701	1444693880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693880	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.	0.0
1043880701	1451124180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124180	31857620	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.125
1043880701	1451141460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141460	32361904	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.	2.25
1043880701	1447989994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989994	25673568	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	0.125
1043880701	1449733005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449733005	16198652	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	1.5
1043880701	1451226461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226461	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1043880701	1184746588	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746588	16697742	SLCO1B1 *14 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746570	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746570	16697742	SLCO1B1 *9 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746579	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746579	16697742	SLCO1B1 *15 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746561	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746561	16697742	SLCO1B1 *5 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	982043808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043808	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1043880701	982043792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043792	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1043880701	982043801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043801	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1183679833	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183679833	769176398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176398	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1183679833	1184473513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473513	23942539	Allele G is associated with increased risk of Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele A.	2.0
1183679833	1447945640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945640	26099996	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.75
1183679833	1448108454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108454	14635116	Genotype AG is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.0
1183679833	1448119107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119107	18299612	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
1183679833	1448120824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448120824	19473056	Genotype AG is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.5
1183679833	1448122765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122765	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1183679833	1448124027	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124027	23588312	Genotype AG is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype AA.	-0.0
1183679833	1448124372	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448124372	23942539	Genotypes AG + GG is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.0
1183679833	1448126296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126296	26794347	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele A.	-2.0
1183679833	1448262714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262714	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1183679833	1449162083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162083	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1183630664	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183630664	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1183630664	1447959040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959040	24923815	Allele C is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Article designed about c.11295923C>G as additional risk variant and not to detect association with toxicity and c.1679T>G In the conclusion the authors state: "....c.11295923C>G DPYD variant as a predictive marker of earlyonset FP toxicity in a realworld clinical setting. We estimate that fewer than 50 patients need to be screened prior to therapy for this variant and for c.1905+1G>A, c.1679T>G and c.2846A>T in order to prevent one case of severe FP toxicity."
1183630664	1444607122	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607122	25381393	Genotype AC is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population (only 4 patients with the AC genotype). No significant increase in risk of experiencing grade 3 or higher adverse events, either 5-fluorouracil-related adverse events or overall adverse events.
1183630664	1447945597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945597	26099996	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population Only two patients carried the varian and both had toxicities.
1183630664	1447991202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991202	19530960	Genotype AC is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population. Only 1 heterozygote variant carrier, which experienced grade 0-2 toxicity
1183630664	1450372235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372235	30858516	Genotypes AC + CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. c.1679T>G was present in 2 of the cases group, but were absent in the controls group. 2 patients developed Grade >=3 toxicity. Non-significance likely due to sample size.
1183630664	1448126314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126314	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele A.	This annotation is not used for clinical annotation scoring. "Although our data set was relatively large and the power was good enough to detect AE variants with relatively large effects, the power may have been too low to detect variants with low allele frequency (including DPYD*2A and I560S) and/or smaller effect sizes."
1183630664	827892788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892788	17121937	Genotype AC is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	2.75
1183630664	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1183630664	1446440411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446440411	26265035	Genotype AC is associated with increased risk of Death when treated with fluorouracil in women with Intestinal Neoplasms.	0.25
1183630664	1447988419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988419	19795123	Allele C is associated with risk of Neutropenia when treated with fluorouracil in people with Neoplasms.	0.25
1183630664	1448124253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124253	23736036	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1183630664	1449161870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161870	28427087	Genotype AA is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AC + CC.	-2.0
1183630664	1450373067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373067	30485432	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	0.25
1183960766	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960766	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960766	1449190712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190712	28947035	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
1183960766	1449191837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191837	25266159	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960766	1449192458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192458	26474553	Allele C is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960766	1183960690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960690	22293084	Allele C is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183617979	1183684630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684630	19281600	CYP2D6 poor metabolizer phenotype is associated with decreased plasma oxymorphone/oxycodone ratio when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.75
1183617979	1449003184	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003184	20590587	CYP2D6 poor metabolizer genotype is associated with increased exposure to oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.5
1183617979	1451153660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153660	11207001	CYP2D6 poor metabolizer phenotype is associated with increased concentrations of noroxycodone and oxycodone in women with Neoplasms and Pain as compared to CYP2D6 normal metabolizer phenotype.	0.0625
1183617979	1451405702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451405702	33799050	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased concentrations of noroxycodone or oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	1.0
1183617979	1451647381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647381	34480108	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	1.25
1183617979	1183621778	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621778	21735164	CYP2D6 *4/*4 + *3/*4 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	2.25
1183617979	1183621795	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621795	21735164	CYP2D6 *4/*4 + *4/*6 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	2.25
1183617979	1183621831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621831	19719813	CYP2D6 *4/*4 + *3/*4 is associated with mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio when treated with oxycodone as compared to CYP2D6 *1/*1.	2.25
1183617979	1184473395	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473395	23555934	CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7 (assigned as poor metabolizer phenotype) is associated with decreased Mean oxymophone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .	2.0
1183617979	1451155460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155460	12422998	CYP2D6 *4 is associated with increased concentrations of oxycodone.	This annotation is not used for clinical annotation scoring.
1183617979	1451159180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159180	19755414	CYP2D6 *1/*1xN is associated with decreased exposure to oxycodone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41.	0.125
1451141882	PA166228121	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228121		Annotation of CPIC Guideline for hydrocodone and CYP2D6	100
1451141882	1183683979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683979	7693389	CYP2D6 normal metabolizer phenotype is associated with increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizer phenotype.	0.0625
1451141882	1445117515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445117515	24269714	CYP2D6 poor metabolizer is associated with decreased metabolism of hydrocodone as compared to CYP2D6 ultrarapid metabolizer phenotype.	0.0
1451141882	1447948869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447948869	25621429	CYP2D6 poor metabolizers are associated with decreased metabolism of hydrocodone in healthy individuals as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	1.0
1451141882	1449189944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449189944	20837591	CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.	0.125
1451141882	1451141840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141840	31969823	CYP2D6 *5/*17 is associated with decreased concentrations of hydromorphone in women.	0.125
1451141882	1451155490	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451155490	14998425	CYP2D6 *4/*4 is associated with decreased concentrations of hydromorphone in human liver microsome as compared to CYP2D6 *1/*1 + *1/*4.	0.0
1451236700	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1451236700	PA166104843	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104843		Annotation of FDA Label for celecoxib and CYP2C9	100
1451236700	827826389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826389	11337938	Allele T is associated with decreased metabolism of celecoxib.	0.0
1451236700	827826410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826410	11337938	Allele T is not associated with increased AUC of celecoxib when treated with celecoxib.	-0.125
1451236700	827826458	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826458	16401468	Genotype CT is associated with higher plasma concentrations of celecoxib when exposed to celecoxib in healthy individuals as compared to genotype CC.	1.5
1451236700	1183690922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690922	12893985	Allele T is not associated with clearance of celecoxib in healthy individuals as compared to allele C.	-0.125
1451236700	827826380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826380	11337938	Allele C is associated with decreased metabolism of celecoxib.	0.0
1451236700	827826398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826398	11337938	Allele C is associated with increased AUC of celecoxib when treated with celecoxib as compared to allele A.	0.125
1451236700	1183690913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690913	16153401	Genotype CC is associated with decreased metabolism of celecoxib in children as compared to genotype AA.	0.5
1451236700	1183690931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690931	12893985	Genotype CC is associated with decreased clearance of celecoxib in healthy individuals as compared to genotype AA.	1.0
1451236700	1183680709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680709	23996211	CYP2C9 *1/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451236700	1183680725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680725	23996211	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451236700	1183680733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680733	23996211	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*3.	1.0
1451236700	1183680745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680745	23996211	CYP2C9 *1/*2 is associated with increased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	-1.0
1451236700	1448431851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431851	27864660	CYP2C9 *1/*3 + *1/*13 + *3/*3 are associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.75
1451236700	1449171322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171322	26360837	CYP2C9 *1/*3 is associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.25
1043880520	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1043880520	1451226263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226263	30549267	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.	1.0
1043880520	1451451120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451120	26744986	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.	1.75
1043880520	827827514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827514	19776292	SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.	1.75
1043880520	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1043880520	1451451060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451060	17047488	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1043880520	982043980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043980	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA on rs4149056.
1043880520	982043959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043959	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1043880520	982043998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043998	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1043880520	982044004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044004	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
981419266	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
981419266	PA166264881	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166264881		Annotation of DPWG Guideline for phenytoin and HLA-B	100
981419266	PA166104860	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104860		Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B	100
981419266	981349390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349390	18637831	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	2.75
981419266	981859069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859069	20235791	HLA-B *15:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	3.0
981419266	981859108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859108	21216202	HLA-B *15:02:01 + *46:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	0.0
981419266	981859117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859117	22500513	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	0.25
981419266	1183680863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680863	23692434	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	-2.25
981419266	1183680889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680889	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	1.5
981419266	1184987970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987970	23551241	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin in children.	-0.25
981419266	1184988734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988734	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	1.25
981419266	1184988858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988858	22429379	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	0.25
981419266	1184989223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989223	25096692	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	2.5
981419266	1446902370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902370	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	2.25
981419266	1447948964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948964	26928377	HLA-B *15:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	-1.5
981419266	1447949133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949133	26927288	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	3.75
981419266	1448614858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614858	28391407	HLA-B *15:02:01 is not associated with likelihood of drug reaction with eosinophilia and systemic symptoms or Stevens-Johnson Syndrome when exposed to phenytoin as compared to HLA-B *07:02:01.	-2.0
981419266	1450806464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806464	30270535	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	3.5
981419266	1449566048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566048	28476759	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	-1.25
981419266	1184755407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755407	19018717	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	This annotation is not used for clinical annotation scoring. No patients had the allele.
981419266	1451271980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451271980	28476759	HLA-B *15:02:01 is associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.	3.5
981419266	1185003437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003437	25305458	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	This annotation is not used for clinical annotation scoring. Allele not found in the study population
981419266	1451783740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451783740	34175889	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.	-1.5
1183689558	PA166104955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104955		Annotation of DPWG Guideline for hormonal contraceptives for systemic use and F5	100
1183689558	1183685452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685452	7968118	Genotypes CT + TT are associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	0.0
1183689558	1183689235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689235	12069454	Genotype CT is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	3.5
1183689558	1183689367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689367	15208046	Genotypes CT + TT is not associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	-1.75
1183689558	1183689500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689500	16769590	Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	1.75
1183689558	1448993770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993770	28750087	Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.	3.5
1183689558	1183689466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689466	15946211	Genotypes CT + TT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	0.0
1183703296	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1183703296	1183703229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703229	16182270	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1183703296	1183703238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703238	15764711	CYP2C9 *1/*3 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703250	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703250	15764711	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703257	15764711	CYP2C9 *1/*13 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703264	15764711	CYP2C9 *1/*13 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703784	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183703784	1183703775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703775	24037119	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
1183703784	1447954574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954574	24388031	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
1183705759	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705759	1447673466	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673466	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1183705759	1447674721	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674721	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705759	1444667790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667790	17122579	Genotype CT is associated with Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	2.5
1183705759	1444697806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697806	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1444697935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697935	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1444698070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698070	23159934	Allele T is associated with increased response to halothane as compared to allele C.	1.5
1183705759	1445124430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124430	21455645	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1445400784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400784	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447644283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644283	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447653270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447653270	16732084	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447672403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672403	12059893	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447672529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672529	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447672779	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672779	8220423	Allele T is associated with increased risk of Myopathy, Central Core and Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447673813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673813	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447673984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673984	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705759	1447674167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674167	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447674310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674310	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447675026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675026	12151923	Allele T is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to allele C.	0.0
1183705759	1447675781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675781	7889656	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447947748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947748	21965348	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447949930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949930	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447952044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952044	8592342	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447960578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960578	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447960912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960912	7547049	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine or volatile anesthetics as compared to allele C.	0.0
1183705759	1447960955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960955	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447987298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987298	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1451206982	PA166104951	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104951		Annotation of DPWG Guideline for irinotecan and UGT1A1	100
1451206982	PA166104831	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104831		Annotation of FDA Label for irinotecan and UGT1A1	100
1451206982	1447945228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945228	26862009	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with decreased dose of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*28 + *1/*6.	2.75
1451206982	1448261674	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261674	20038727	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451206982	1448261782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261782	21654688	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451206982	1448261806	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261806	26739304	UGT1A1 *28/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	0.25
1451206982	1448281118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448281118	27507617	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.25
1451206982	1451206740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206740	18594531	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451206982	1451207688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207688	18300238	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451206982	1451209847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451209847	16636344	UGT1A1 *1/*28 is not associated with dose of irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451206982	1451214640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451214640	28493308	UGT1A1 *28 is associated with decreased dose of irinotecan in people with Adenocarcinoma and Gastrointestinal Neoplasms as compared to UGT1A1 *1.	0.25
1451206982	1451294486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451294486	33203301	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in women with Colorectal Neoplasms.	0.25
1183680546	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183680546	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
1183680546	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183680546	981240127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240127	22626609	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
1183680546	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1183680546	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183680546	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183705764	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705764	1447673490	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673490	9334205	Allele A is associated with increased sensitivity to caffeine or halothane as compared to allele G.	0.0
1183705764	1447674728	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674728	9497245	Genotype AG is associated with sensitivity to caffeine or halothane in muscle as compared to genotype GG.	0.0
1183705764	1447952306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952306	8012359	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1445124435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124435	21455645	Genotype AG are associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1184510534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510534	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705764	1444697974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697974	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1445296836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296836	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705764	1445400815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400815	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447644623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644623	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447672272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672272	16732084	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447672423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672423	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype AA.	0.0
1183705764	1447672565	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672565	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705764	1447673948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673948	12411788	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype GG.	0.25
1183705764	1447674225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674225	10051009	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447675255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675255	12151923	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447675304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675304	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447675406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675406	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447675632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675632	8828983	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447944085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944085	9543323	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447944096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944096	9543323	Genotype AG is associated with increased creatine kinase as compared to genotype GG.	0.0
1183705764	1447952011	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952011	8902717	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.0
1183705764	1447952297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952297	9106529	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to genotype GG.	0.25
1183705764	1447952360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952360	8825043	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype GG.	0.25
1183705764	1447952470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952470	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447952476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952476	16163667	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447960676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960676	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447987336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987336	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1449157608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157608	29101530	Allele A is associated with risk of Malignant Hyperthermia when treated with sevoflurane as compared to allele G.	0.25
1183705764	1449160111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160111	25268394	Allele A is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele G.	0.25
1183960775	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960775	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960775	1449191843	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191843	25266159	Allele G is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960775	1449192465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192465	26474553	Allele G is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960775	1183960694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960694	22293084	Allele G is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1451242500	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1451242500	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1451242500	1448107499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107499	26196596	Genotype GG is associated with increased dose of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	0.0
1451242500	1184511673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511673	20441246	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.	0.25
1451242500	1184987905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987905	24956253	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.	0.0
1451242500	1448261257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261257	17918089	CYP2B6 *1/*26 + *6/*6 + *6/*26 is associated with decreased dose of efavirenz in people with HIV.	0.25
1183630036	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183630036	PA166104957	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104957		Annotation of DPWG Guideline for omeprazole and CYP2C19	100
1183630036	1184754946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754946	24996380	CYP2C19 normal metabolizers is associated with decreased intragastric ph when exposed to omeprazole in healthy individuals as compared to CYP2C19 poor metabolizer and intermediate metabolizer genotypes.	0.75
1183630036	1183617218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617218	10982760	CYP2C19 *1/*2 is associated with increased intragastric pH when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.	2.0
1183630036	1183617232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617232	10982760	CYP2C19 *1/*2 is associated with increased meal-stimulated plasma gastrin concentrations when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.	2.0
1183630036	1183617444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617444	11240980	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183618651	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618651	12121503	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.25
1183630036	1183619427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619427	12809821	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183619521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619521	14653835	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183619532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619532	14653835	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183619942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619942	15447734	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	-0.25
1183630036	1183620822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620822	15932363	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	-2.0
1183630036	1183620957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620957	15976989	CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183630036	1183621225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621225	16863547	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183630036	1183621319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621319	16863547	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183621329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621329	16863547	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.375
1183630036	1183622382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622382	17112810	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183622397	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622397	17112810	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.5
1183630036	1183623283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623283	17934830	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183623301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623301	17934830	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	0.375
1183630036	1183623444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623444	18241283	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.25
1183630036	1183623842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623842	19166419	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183623852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623852	19166419	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183623865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623865	19166419	CYP2C19 *1/*2 + *1/*3 is not associated with response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183679160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679160	20633187	CYP2C19 *1/*1 is associated with decreased response to omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183679177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679177	21361732	CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183679211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183679211	21361732	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with decreased intragastric ph when treated with omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183679401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679401	23646118	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.625
1183630036	1183679411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679411	23646118	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183630036	1183679423	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679423	23646118	CYP2C19 *1/*2 + *1/*3 is not associated with response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183679579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679579	10579481	CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183679601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679601	11446878	CYP2C19 *1/*1 is not associated with response to omeprazole or rabeprazole in people with Helicobacter Infections.	-1.5
1183630036	1183679613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679613	11785712	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.25
1183630036	1183680115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680115	21054464	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.5
1183630036	1450807430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807430	9867757	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1450807446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807446	9867757	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	2.25
1183630036	1450807458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807458	9867757	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	1.75
1183630036	1450807761	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807761	10340921	CYP2C19 *1/*2 + *1/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183630036	1450807773	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807773	10340921	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.5
1183630036	1450807784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807784	10340921	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.0
1183630036	1450808566	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808566	11069321	CYP2C19 *1/*2 + *1/*3 are associated with increased response to omeprazole in people with Esophagitis and Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	1.75
1183630036	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630036	1183679880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679880	14638340	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183679894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679894	14638340	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183630036	1183617822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617822	11240980	CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.75
1183630036	1183680006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680006	16815316	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183680019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680019	16815316	CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183621166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621166	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183621202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621202	16863547	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183621191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621191	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630036	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183630036	1451343133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343133	16911680	CYP2C19 *1/*1 + *1/*2 are not associated with response to omeprazole in people with Peptic Ulcer as compared to CYP2C19 *2/*2.	-1.25
1183630036	1183623314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623314	17934830	CYP2C19 *1/*2 + *1/*3 are not associated with response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.375
655384799	1444668176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668176	12759288	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.0
655384799	1444668552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668552	18050183	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG.	2.5
655384799	1444668728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668728	18713756	Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA.	3.25
655384799	699638591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638591	19365401	Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.5
655384799	1451243060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451243060	16909270	Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.375
655384799	1444668429	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668429	16720636	Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.25
655384799	1183703414	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703414	22760475	Genotypes AG + GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotype AA.	1.75
1183888959	981483879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483879	21246582	Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
1183888959	827814618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814618	21628662	Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT.	2.25
1183888959	1183888942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888942	24117654	Genotype TT is associated with higher rate of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
1183888959	1184136354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136354	24362944	Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
1183888959	1444665876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665876	25393304	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.25
1183888959	1444704847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704847	20648473	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT.	2.25
1451245360	769170794	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170794	19827168	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	1.75
1451245360	981239954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239954	15677700	Genotypes CC + CT are associated with increased severity of Arthritis, Rheumatoid when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	1.5
1451245360	827863341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863341	22450926	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.75
1451245360	655386407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386407	15457444	Genotype TT is associated with decreased disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	3.0
1451245360	769171231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171231	18322994	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.	2.75
1451245360	769171199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171199	17325736	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	2.0
1451245360	769171198	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171198	17325736	Genotype TT is associated with increased likelihood of remission when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
1451245360	1451110120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451110120	31099054	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
1451245360	1447674478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674478	26616421	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
1451245360	1448576460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576460	27992285	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	1.375
1183960780	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960780	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960780	1449191796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191796	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960780	1183960698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960698	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1451526333	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1451526333	PA166182844	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182844		Annotation of DPWG Guideline for simvastatin and SLCO1B1	100
1451526333	1451231960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451231960	29242847	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.	2.25
1451526333	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1451526333	655386692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386692	18650507	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.	3.5
1451526333	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451526333	1451390520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390520	26376374	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.75
1451526333	1451463080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451463080	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	3.5
1451526333	1451479840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479840	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.5
1451526333	1451480140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480140	33150478	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.75
1451526333	981420028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420028	18650507	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.	0.0
1451526333	769164512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164512	21243006	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.	1.75
1451526333	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451526333	1183699306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699306	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	2.5
1451526333	1183699611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699611	24263182	Genotype CC is not associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	-1.75
1451526333	1183699615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699615	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	0.0
1451526333	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451526333	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1451526333	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1183705773	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705773	1444667782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667782	16284304	Genotype AC is associated with Malignant Hyperthermia when exposed to caffeine or isoflurane as compared to genotype AA.	2.0
1183705773	1447522117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522117	19020143	Genotype AC is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to genotype AA.	0.0
1183705773	1447952235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952235	7829078	Genotype AC is associated with increased risk of Malignant Hyperthermia as compared to genotype AA.	0.25
1183705773	1447952485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952485	16163667	Genotype AC is associated with increased risk of Malignant Hyperthermia as compared to genotype AA.	0.25
1183705778	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705778	1444697990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697990	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1445124445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124445	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1445400837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400837	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447644750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644750	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447673835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673835	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447674232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674232	12208234	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447674497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674497	9497245	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1183705778	1447949860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949860	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705778	1447952723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952723	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1183705778	1447952967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952967	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447960606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960606	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447987466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987466	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1449296086	1449713987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713987	23557865	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	-1.5
1449296086	1449716420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716420	21128989	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	-1.25
1449296086	1449715317	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715317	23313934	CYP3A4 *18/*18 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	1.75
1449296086	1449715329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715329	23313934	CYP3A4 *18 is not associated with dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1.	-1.25
1449296086	1450823962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823962	19784640	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1449716539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716539	21223952	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1450823212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823212	25794200	CYP3A4 *36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	1.375
1449296086	1449716742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716742	29601950	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1449296077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296077	21535061	CYP3A4 *36 is associated with decreased dose of fentanyl in women with Pain, Postoperative.	1.75
1449296086	1449716632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716632	21513075	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1183705698	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705698	1447673611	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673611	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1183705698	1447674761	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674761	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705698	981419447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419447	1774074	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.0
1183705698	1184510571	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510571	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705698	1444697819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697819	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1445124440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124440	21455645	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1445297022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297022	20681998	Allele T is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele C.	0.25
1183705698	1445400825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400825	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1446900676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900676	25658027	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447626893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447626893	18502356	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447635001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635001	17081152	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447649391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447649391	14500992	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447651288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447651288	12237752	Allele T is associated with Malignant Hyperthermia when exposed to sevoflurane and succinylcholine as compared to allele C.	0.0
1183705698	1447672415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672415	12059893	Genotypes CT + TT are associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447672484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672484	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447672514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672514	24195946	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447672572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672572	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447672846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672846	11668625	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447673042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673042	11553045	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447673095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673095	11493496	Genotypes CT + TT are associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447673643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673643	12434264	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447673651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673651	12434264	Genotype TT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447673826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673826	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447673922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673922	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.25
1183705698	1447673940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673940	12411788	Genotypes CT + TT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705698	1447673982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673982	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447674291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674291	10051009	Allele T is associated with increased risk of Malignant Hyperthermia and multi-core congenital myopathy as compared to allele C.	0.0
1183705698	1447674357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674357	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447674400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674400	11448278	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to genotype CC.	0.25
1183705698	1447675262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675262	12151923	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447675366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675366	17710899	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447675373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675373	9389851	Genotypes CT + TT are associated with increased risk of Malignant Hyperthermia when exposed to enflurane, halothane, isoflurane or succinylcholine as compared to genotype CC.	0.0
1183705698	1447675432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675432	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia, Myopathy, Central Core and Rhabdomyolysis as compared to genotype CC.	0.0
1183705698	1447675649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675649	8602662	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447675654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675654	7586638	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447675666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675666	7751854	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447944035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944035	10352931	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447948514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948514	17667581	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.0
1183705698	1447951935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447951935	9520251	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447951942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447951942	9520251	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447952206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952206	7762556	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705698	1447952426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952426	7633940	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447952494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952494	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447952704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952704	26951757	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to allele C.	0.0
1183705698	1447952756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952756	1510267	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to genotype CC.	0.25
1183705698	1447960695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960695	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447960905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960905	7547049	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine or volatile anesthetics as compared to allele C.	0.0
1183705698	1447960967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960967	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447961035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961035	14985404	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele C.	0.0
1183705698	1447961271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961271	19191333	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447987407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987407	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1449158220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449158220	27646467	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1449160118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160118	25268394	Allele T is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele C.	0.25
1183705698	1449160141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160141	27382027	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.25
1447673005	1444697569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697569	25769357	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.	3.0
1447673005	1447223035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223035	18690342	Genotype TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	1.5
1447673005	1447223093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223093	23104259	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.75
1447673005	1447519274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519274	23602689	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	2.5
1447673005	1447519425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519425	25244877	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.5
1447673005	1447520024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520024	26445138	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	2.0
1447673005	1447520306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520306	19794411	Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	3.25
1447673005	1447521449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521449	22990331	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.5
1447673005	1447521736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521736	23279643	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin in children as compared to genotypes CC + CT.	0.0
1447673005	1447586730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586730	21318593	Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	3.5
1447673005	1447680569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680569	26739746	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	0.0
1447673005	982046164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046164	19874474	Allele T is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
1447673005	978616277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978616277	22571356	Genotypes CT + TT are associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to genotype CC.	3.5
1447673005	1183701243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701243	18574025	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin.	3.5
1447673005	1184483167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483167	23932037	Genotypes CT + TT is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to genotype CC.	1.5
1447673005	1448602391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602391	28033245	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	2.0
1447673005	1449192296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192296	28049362	Allele T is associated with increased Blood Coagulation Disorders when treated with warfarin as compared to allele C.	2.75
1447672998	1447222981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222981	18574025	Allele T is not associated with time to therapeutic inr when treated with warfarin as compared to allele C.	-2.0
1447672998	1447223148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223148	22571356	Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.	3.0
1447672998	1447520283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520283	19794411	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	2.75
1447672998	1447586687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586687	20386359	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	0.0
1447672998	1447586712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586712	21318593	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	3.5
1447672998	1447586784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586784	20339978	Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.	2.25
1447672998	1447586823	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586823	23279643	Allele T is not associated with time to therapeutic inr when treated with warfarin in children as compared to allele C.	-1.25
1447672998	1184472895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472895	24474498	Genotype TT is associated with shorter time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to genotypes CC + CT.	1.75
1447672998	1184510004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510004	22571356	Genotypes CT + TT is associated with decreased time to therapeutic INR>=2 when treated with warfarin as compared to genotype CC.	3.0
1447672998	1450980720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980720	18322281	Genotypes CT + TT is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.	3.75
1447672998	1449165055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165055	28382498	Allele T is not associated with international normalized ratio variability (inr-var) when treated with warfarin as compared to allele C.	-1.25
1447672998	1449190958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190958	29432897	Allele T is associated with increased time to therapeutic inr when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	2.25
1449556772	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1449556772	1446896983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896983	26164721	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.	2.5
1449556772	1451249860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451249860	17108811	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.	1.5
1449556772	1184754854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754854	24598718	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.	0.0
1449556772	1447983120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983120	25446771	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	0.5
1449556772	1451352480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352480	26774055	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	1.5
1449556772	1451352500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352500	25673568	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.	0.125
1449556772	1446907580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907580	26367500	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	2.0
1449556772	1448612369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612369	28350522	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.	1.0
1449556772	1449556752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449556752	29469964	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.	1.5
1183705812	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705812	1184510587	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510587	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705812	1444697856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697856	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1444698005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698005	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1445124455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124455	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1445297009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297009	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1445400843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400843	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447521525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521525	23628358	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447629867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447629867	18502356	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype GG.	0.0
1183705812	1447634830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634830	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447636459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447636459	16732128	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447645250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645250	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447672435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672435	10793526	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447672455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672455	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447672504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672504	25735680	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447672586	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672586	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447672852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672852	11668625	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447673858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673858	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447674051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674051	10484775	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447674253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674253	12208234	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447674378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674378	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447675269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675269	12151923	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447675467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675467	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia and Rhabdomyolysis as compared to genotype GG.	0.0
1183705812	1447947731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947731	21965348	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447949853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949853	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447952530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952530	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447952792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952792	10700782	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447960466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960466	18945287	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447960643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960643	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447987523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987523	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1449157794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157794	28326467	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449157801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157801	28063098	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449158213	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449158213	27646467	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449160088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160088	26994242	Allele A is associated with Malignant Hyperthermia and Rhabdomyolysis as compared to allele G.	0.25
1183705812	1449160104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160104	25268394	Allele A is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele G.	0.25
1183705812	1449160127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160127	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1183689079	PA166181885	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166181885		Annotation of CPIC Guideline for atomoxetine and CYP2D6	100
1183689079	PA166104989	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104989		Annotation of DPWG Guideline for atomoxetine and CYP2D6	100
1183689079	1447679997	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447679997	11854152	CYP2D6 poor metabolizers are associated with decreased clearance of atomoxetine in human microsomes.	0.0
1183689079	1447680051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680051	12485958	CYP2D6 poor metabolizers are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183689079	1183678529	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678529	17470523	CYP2D6 *10 is associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.	0.0
1183689079	1183678537	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678537	17470523	CYP2D6 *17 is associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.	0.0
1183689079	1183688850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688850	17224704	CYP2D6 *4/*5 is associated with increased atomoxetine and methylphenidateplasma concentration after overdose when exposed to atomoxetine and methylphenidate.	0.125
1183689079	1183688880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688880	21543662	CYP2D6 *10/*10 is associated with increased area under the plasma concentration-time curve values when treated with atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.	0.125
1183689079	1183688895	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688895	21543662	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.	1.5
1183689079	1447813900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813900	17610534	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.	1.5
1183689079	1447814409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814409	26254792	CYP2D6 *10/*10 + *1/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.	2.25
1183689079	1447814438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814438	26254792	CYP2D6 *10/*10 + *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.	2.25
1183689079	1447943783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447943783	26660002	CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.	2.0
1183689079	1447943838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447943838	26660002	CYP2D6 *4/*4xN + *4/*4 are associated with decreased clearance of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29.	1.0
1183689079	1447943944	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447943944	26666748	CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 when assayed with atomoxetine in microsomes from insect cells Sf21 as compared to CYP2D6 *1.	0.0
1445401793	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1445401793	1450952420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952420	10803677	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1445401793	982009850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009850	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype CC.	1.25
1445401793	1450953041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953041	16115930	Genotype CT is not associated with decreased catalytic activity of DPYD as compared to genotype CC.	-0.0
1445401793	1450955300	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955300	26265035	Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1445401793	1450951685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951685	26804652	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1445401793	1447987720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987720	23328581	Genotype TT is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype CC.	-0.0
1183705783	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705783	1447681102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447681102	11063719	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype AA.	0.0
1183960785	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960785	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960785	1449191825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191825	25266159	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960785	1183960710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960710	22293084	Allele C is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
827862764	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
827862764	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
827862764	1446904199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904199	26339796	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	4.0
827862764	981483523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483523	20964522	Genotypes CT + TT are associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	0.0
827862764	1444843642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843642	26032235	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.5
827862764	1444706410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706410	23712427	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	This annotation is not used for clinical annotation scoring. Direction of association changes depending on the type of analysis carried out.
827862764	1448594952	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448594952	28186161	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.75
827862764	981848148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848148	23383658	Genotype CC is associated with higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	0.0
827862764	981240111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240111	22863269	Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	981344129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344129	22345656	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotypes CT + TT.	-0.25
827862764	981352182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352182	22438096	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.75
827862764	981352188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352188	22438096	Genotype CC is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.25
827862764	981419782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419782	21374656	Genotype CC is associated with rapid virological response (rvr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	981419793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419793	21374656	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.75
827862764	981419910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419910	21145807	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.25
827862764	981419925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419925	21145807	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	981419938	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419938	21068134	Genotype CC is associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981478958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478958	21606533	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	2.25
827862764	981478966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478966	21606533	Genotypes CC + CT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	2.0
827862764	981478976	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478976	21505315	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	981481472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481472	20804372	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981481534	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481534	20931559	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	981481546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481546	21447862	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.25
827862764	981483535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483535	21157362	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	981501267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501267	20176026	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981501273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501273	20176026	Allele C is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele T.	-1.25
827862764	981501391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501391	20389235	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.5
827862764	981934499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934499	23142377	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	1.0
827862764	982031571	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031571	21390311	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	1444705303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705303	21911885	Genotype CC is associated with decreased severity of Hepatitis C when treated with peginterferon alfa-2b and ribavirin as compared to genotypes CT + TT.	0.0
827862764	769251002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769251002	19684573	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	0.0
827862764	827789030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827789030	21993426	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	827813726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813726	21726252	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.	1.0
827862764	827820480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820480	21254158	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	2.5
827862764	827864105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827864105	21951981	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1183888950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888950	24117654	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1183888954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888954	23321318	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	-2.0
827862764	1184136155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136155	23291588	Genotype CC is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.5
827862764	1184136375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136375	24308755	Genotype CC is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.25
827862764	1184136394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136394	24072198	Genotype TT is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype CC.	3.5
827862764	1184985914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184985914	24748394	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.75
827862764	1444668491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668491	24102823	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1444668546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668546	24768758	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.5
827862764	1444698141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698141	25705565	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotype TT.	0.25
827862764	1444705048	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705048	22368681	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	1444705100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705100	22328925	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.	3.0
827862764	1444705124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705124	21466653	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	1444705141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705141	21466653	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
827862764	1444705288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705288	21911885	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.5
827862764	1444705484	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705484	21346780	Genotypes CT + TT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
827862764	1444705756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705756	20621700	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	2.75
827862764	1444705763	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705763	20621700	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	3.25
827862764	1444705777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705777	20621700	Genotypes CC + CT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	-1.75
827862764	1444705790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705790	20621700	Genotypes CC + CT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	-1.75
827862764	1444705804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705804	21987611	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
827862764	1444706036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706036	20728570	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.25
827862764	1444706170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706170	21537116	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.	2.75
827862764	1444706370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706370	21112657	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.25
827862764	1444706626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706626	24073221	Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	3.0
827862764	1444706715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706715	20578254	Genotype CC is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-3.0
827862764	1444706722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706722	20399780	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.5
827862764	1444706780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706780	21572301	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes CT + TT.	3.0
827862764	1444706841	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706841	21907615	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CT.	2.25
827862764	1444843627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843627	26098993	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1444843635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843635	26098993	Genotype CC is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.25
827862764	1445296829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296829	25278709	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.5
827862764	1447676759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676759	26284539	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	1447676885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676885	25958342	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.0
827862764	1447947784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947784	26902034	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1447948064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948064	26699619	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1447948081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948081	26699619	Genotype CC is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-2.0
827862764	1450934072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934072	31803800	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448107024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107024	23490377	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.0
827862764	1448107049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107049	23383658	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1448265190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265190	27514956	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.0
827862764	1448266019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266019	25918016	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes CT + TT.	1.25
827862764	1448266117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266117	27714501	Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448428352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428352	27833958	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	1448530766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530766	27498543	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.75
827862764	1448602915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602915	26911666	Genotypes CT + TT are associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.0
827862764	1448636081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636081	28703131	Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448996449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996449	28261910	Allele T is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	2.0
827862764	1448998952	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998952	28739427	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1448999231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999231	28739427	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1448999241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999241	28739427	Genotype CC is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1450342908	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342908	30450628	Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
1451237326	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1451237326	1184516561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184516561	15570193	TPMT low activity phenotype is associated with decreased dose of azathioprine as compared to TPMT high activity phenotype.	1.125
1451237326	1451237363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451237363	30987408	Genotype CT is associated with decreased dose of azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.5
1451237326	1184134029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134029	20175817	TPMT *2 + *3A + *3B + *3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	0.0
1451237326	1184134089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134089	16202677	TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.5
1451237326	1184174025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174025	12477776	TPMT *3A/*3A is associated with decreased dose of azathioprine in people with Crohn Disease as compared to TPMT *1/*1.	0.25
1451237326	1184174034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174034	12477776	TPMT *3A/*3C is associated with decreased dose of azathioprine in people with Crohn Disease as compared to TPMT *1/*1.	0.25
1451237326	1184175334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175334	15349717	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine in people with Transplantation as compared to TPMT *1/*1.	2.25
1451237326	1184521242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184521242	18467186	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.25
1451237326	1184548150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184548150	21819368	TPMT *1/*3C is not associated with dose of azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	-1.0
1451237326	1451237580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451237580	26072396	TPMT *1/*2 + *1/*3A + *1/*3C + *3A/*3A is associated with decreased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	0.0
1451809140	981859096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859096	17509004	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.	2.75
1451809140	981859101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859101	17509004	HLA-B *15:02:01 is not associated with increased risk of maculopapular exanthema when treated with antiepileptics or carbamazepine in Epilepsy.	-1.25
1451809140	1446902379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902379	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.	3.25
1451809140	1451507720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451507720	34488672	HLA-B *15:02:01 is associated with increased risk of Maculopapular Exanthema when treated with antiepileptics in people with Epilepsy.	2.5
1451809140	1451783980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451783980	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with antiepileptics.	4.0
1183960795	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960795	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960795	1449191776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191776	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960795	1183960702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960702	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183960800	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960800	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960800	1449191818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191818	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960800	1451160403	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451160403	27160424	Allele A is associated with increased activity of CFTR when exposed to ivacaftor.	0.0
1183960800	1183960706	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960706	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1451208740	981794068	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794068	18221820	Genotype AA is associated with increased concentrations of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1451208740	981747792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981747792	17627617	Genotype AA is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to genotype GG.	2.5
1451208740	981843914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981843914	16636344	Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.25
1451208740	1184747085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747085	15179405	UGT1A1 *6/*60 + *6/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	0.75
1451208740	1184747113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747113	15179405	UGT1A1 *6/*6 + *1/*6 is associated with decreased metabolism of SN-38 in people with Neoplasms.	1.25
1451208740	1184747123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747123	15179405	UGT1A1 *28/*28 + *1/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451208740	1185235188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235188	24958824	UGT1A1 *1/*28 + *28/*28 is associated with increased concentrations of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451208740	1185235470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235470	25427841	UGT1A1 *6 + *28 is associated with increased concentrations of SN-38 in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451208740	1451205300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205300	20562211	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.5
1451208740	1451208680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208680	17577039	UGT1A1 *28/*28 is associated with increased concentrations of SN-38 in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	0.0
1451208740	1451208780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208780	17185998	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451208740	1451208840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208840	16951398	UGT1A1 *1/*28 + *28/*28 are associated with decreased clearance of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451208740	1451208948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208948	15007088	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.25
1451208740	1451209187	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451209187	11990381	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451208740	1451211800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451211800	18797458	UGT1A1 *1/*28 + *28/*28 are not associated with metabolism of SN-38 in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-0.125
1451208740	1451213120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451213120	27116457	UGT1A1 *28 is associated with increased concentrations of SN-38 in people with Colonic Neoplasms as compared to UGT1A1 *1.	2.0
1451251080	827830235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830235	12966368	Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.	1.25
1451251080	1183683991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683991	21903774	Genotype GG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	3.0
1451251080	827815666	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815666	21902502	Genotype AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.5
1451251080	1184989819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989819	25322286	Genotypes AA + AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	0.0
1451251080	982046215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046215	23837477	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in children with Transplantation as compared to CYP3A4 *1/*1.	2.75
1451251080	1184471333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471333	24444408	CYP3A4 *1/*22 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-1.5
1451251080	1185234468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234468	25287072	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.75
1451251080	1449173523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173523	29469606	CYP3A4 *1/*20 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1183621997	PA166104943	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104943		Annotation of DPWG Guideline for risperidone and CYP2D6	100
1183621997	1183699383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699383	23609392	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .	2.0
1183621997	1183904079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183904079	24232129	CYP2D6 intermediate metabolizers is not associated with serum concentration of 9-hydroxyrisperidone or sum of risperidone and 9-hydroxyrisperidone when treated with risperidone as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6.	-1.0
1183621997	1184748530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748530	25042870	CYP2D6 poor metabolizer are associated with decreased clearance of risperidone in healthy individuals.	0.625
1183621997	1184754471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754471	24643635	CYP2D6 ultrarapid metabolizer is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 poor metabolizers.	0.0
1183621997	1184754478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754478	24643635	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	0.0
1183621997	1447682043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682043	26514968	CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	1.0
1183621997	1448266372	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266372	26129906	CYP2D6 poor metabolizer genotype is associated with increased exposure to risperidone in people with Bipolar Disorder, Depression, Psychotic Disorders or Substance-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.	1.0
1183621997	1448530802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530802	24828442	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in children as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.5
1183621997	1448993578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993578	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.125
1183621997	1451251823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451251823	24232129	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .	1.25
1183621997	1183619675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619675	10639689	CYP2D6 *1xN is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	0.25
1183621997	1183619945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619945	11791898	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.75
1183621997	1183620411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620411	15260906	CYP2D6 *4 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183621997	1183620517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620517	17715206	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	2.0
1183621997	1183620832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620832	16833023	CYP2D6 *10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1.	1.5
1183621997	1183621939	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621939	15729081	CYP2D6 *10 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	-0.125
1183621997	1183699417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699417	23609392	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.	2.0
1183621997	1296599629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599629	24589909	CYP2D6 *10 + *5 are associated with increased concentrations of risperidone in people with Schizophrenia.	1.75
1183621997	1447681693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681693	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*10 + *1/*41.	0.0
1183621997	1447681711	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681711	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*5 + *10/*10 + *10/*41.	0.0
1183621997	1448530382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530382	26944100	CYP2D6 *5/*10 + *4/*10 + *10/*10 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .	1.75
1183621997	1448530486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530486	26944100	CYP2D6 *4/*10 + *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1183621997	1448530511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530511	26944100	CYP2D6 *10/*10 + *10/*41 + *1/*4 + *1/*5 are not associated with metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	-0.125
1183621997	1448530601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530601	20814331	CYP2D6 *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183621997	1448530620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530620	20332423	CYP2D6 *10/*10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183621997	1447959180	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959180	26544071	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.	0.0
1183621997	1451099341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451099341	30870237	CYP2D6 *10 is not associated with concentrations of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.	-0.125
1183621997	1183702193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702193	24329187	CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	1.5
1183621997	1183619642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619642	10639689	CYP2D6 *4 + *5 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183621997	1183620333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620333	15089809	CYP2D6 *4 + *5 + *10 +*14 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.75
1183621997	1447681725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681725	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *4/*10 + *5/*10.	0.0
1183960805	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960805	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960805	1449191790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191790	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960805	1183960682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960682	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184133833	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1184133833	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1184133833	PA166105117	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166105117		Annotation of FDA Label for efavirenz and CYP2B6	100
1184133833	1184473249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473249	23399569	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	981478651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478651	22471906	Genotype GG is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1183491434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491434	23254426	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1447680752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680752	26779253	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1183491467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491467	23254426	Genotype AG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1184473253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473253	23399569	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997136	26107645	Genotypes AG + GG are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997456	20841522	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997270	22481606	Genotypes AG + GG are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448665077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448665077	28816644	Allele G is not associated with increased concentrations of efavirenz in children with HIV Infections as compared to allele A.	-0.75
1184133833	1184988315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988315	20952418	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.5
1184133833	827824895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824895	21659470	Allele G is associated with decreased metabolism of bupropion and efavirenz.	0.0
1184133833	1184349357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349357	20625352	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	-0.5
1184133833	1184473257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473257	23399569	Genotype GG is not associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AG.	-0.75
1184133833	1451112320	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451112320	21821736	Allele G is associated with increased metabolism of efavirenz as compared to allele A.	0.0
1184133833	981480742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981480742	22927450	Genotypes CC + CT are associated with increased exposure of efavirenz in women with HIV Infections as compared to genotype TT.	2.5
1184133833	982046519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046519	23080225	Allele C is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele T.	2.5
1184133833	827807683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807683	18281305	Allele C is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele T.	2.5
1184133833	769162986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162986	20860463	Genotype CT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	1.5
1184133833	769163091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163091	19779319	Genotype CT is not associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	-0.75
1184133833	769163497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163497	19371316	Genotype CT is not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	-0.75
1184133833	769170863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170863	16495778	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	0.125
1184133833	1183634164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634164	24080498	Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	2.25
1184133833	1184467538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467538	24729586	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	1.75
1184133833	1184471365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471365	19659438	Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) .	1.5
1184133833	1184473165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473165	24316028	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	1.25
1184133833	1446905210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905210	25611810	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	2.0
1184133833	1447680778	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680778	26779253	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	2.0
1184133833	1448636182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636182	28692529	Genotypes CC + CT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	0.0
1184133833	1448665545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448665545	28816644	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	1.25
1184133833	1448994431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994431	28886044	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.	-0.25
1184133833	1448997158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997158	25889207	Genotypes CC + CT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1184133833	1448997264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997264	22481606	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	1.75
1184133833	827787878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787878	21814190	CYP2B6 *1 is associated with decreased plasma concentration of efavirenz when treated with efavirenz in people with HIV.	2.0
1184133833	981417238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417238	15194512	CYP2B6 *6/*6 is associated with increased plasma concentration when treated with efavirenz in people with HIV.	2.0
1184133833	981419341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981419341	17559344	CYP2B6 *6 is associated with decreased metabolism of efavirenz in human liver microsomes as compared to CYP2B6 *1.	1.25
1184133833	982032006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032006	23778320	CYP2B6 *6/*6 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	982032013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032013	23778320	CYP2B6 *18/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	982032019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032019	23778320	CYP2B6 *1/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1183491475	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491475	23254426	CYP2B6 *1/*1 is associated with increased clearance of efavirenz in people with HIV.	1.5
1184133833	1183616504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616504	23254426	CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in people with HIV.	2.0
1184133833	1183764170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183764170	24497997	CYP2B6 *1/*1 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.	1.75
1184133833	1183771932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183771932	24497997	CYP2B6 *1/*6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.	0.0
1184133833	1183944291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944291	24497997	CYP2B6 *6 is associated with metabolism of efavirenz in people with HIV.	1.75
1184133833	1184165591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184165591	24142869	CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.	1.5
1184133833	1184473220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473220	23399569	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1184510497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510497	23846872	CYP2B6 *1/*1 + *1/*6 is not associated with clearance of efavirenz in healthy individuals as compared to CYP2B6 *6/*6.	-0.125
1184133833	1447962916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447962916	17235330	CYP2B6 *28 is associated with increased exposure to efavirenz in people with HIV as compared to CYP2B6 *1.	0.0
1184133833	1447984366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984366	27045425	CYP2B6 *6 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 *1.	0.0
1184133833	1448993987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993987	26655325	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448994001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994001	26655325	CYP2B6 *18 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1448994017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994017	21896912	CYP2B6 *1/*6 + *6/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.0
1184133833	1448995403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995403	28622951	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.0
1184133833	1448995845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995845	27333947	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.	1.25
1184133833	1448995859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995859	20881953	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448995871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995871	19916993	CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.	1.0
1184133833	1448995983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995983	17235330	CYP2B6 *6/*6 + *1/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1448996001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448996001	17235330	CYP2B6 *1/*4 are associated with decreased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448997246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997246	23734829	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.0
1184133833	1448997763	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997763	16495778	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.25
1184133833	1449156732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449156732	23640958	CYP2B6 *6 + *38 are associated with decreased clearance of efavirenz as compared to CYP2B6 *1/*1.	0.0
1184133833	1451112380	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451112380	21821736	CYP2B6 *6 is associated with decreased metabolism of efavirenz as compared to CYP2B6 *1.	0.0
1184133833	1448997750	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997750	16495778	CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.	1.75
1184133833	1184988354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988354	20952418	CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1184133833	1184988346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988346	20952418	CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1184133833	1184988338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988338	20952418	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1184514050	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1184514050	1451237500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451237500	31024313	Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.	3.0
1184514050	1184514014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514014	25108385	Genotype TT is associated with increased severity of Leukopenia when treated with azathioprine in people with Crohn Disease as compared to genotype CC.	3.25
1184514050	1184514055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514055	25108385	Allele T is associated with increased risk of Leukopenia when treated with azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	3.0
1184514050	1450934743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934743	30728528	Allele T is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele C.	2.5
1184514050	1447682680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682680	26076924	Allele T is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	3.5
1184514050	1447682810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682810	26590936	Genotypes CT + TT is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	3.5
1184514050	1447682869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682869	26735160	Genotypes CT + TT is associated with Alopecia and Leukopenia when treated with azathioprine in children with Crohn Disease as compared to genotype CC.	0.0
1184514050	1448124075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124075	27416873	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with azathioprine in people with Colitis, Ulcerative, Crohn Disease or Hepatitis, Autoimmune as compared to genotype CC.	2.25
1184514050	1448261270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261270	27604507	Genotypes CT + TT are associated with increased risk of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to genotype CC.	3.75
1184514050	1448276309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276309	27558924	Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.	2.75
1184514050	1448531616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531616	28088792	Allele T is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	1.75
1184514050	1449575757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449575757	29923122	Allele T is associated with increased likelihood of Alopecia, Digestive system anomalies NOS and Leukopenia when exposed to azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	4.0
1184514050	1449749352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749352	30048756	Allele T is associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Behcet Syndrome, Hepatitis, Autoimmune, Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	0.0
1184514050	1449750314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750314	30101994	Genotype TT is associated with Agranulocytosis, Alopecia, febrile neutropenia, Leukopenia, Neutropenia, Thrombocytopenia and Toxic liver disease when treated with azathioprine in people with Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Pemphigus, Polyarteritis nodosa NOS or Vasculitis.	0.25
1184514050	1449750334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750334	30035323	Genotype TT is associated with Infection and Pancytopenia when treated with azathioprine in women with Pemphigus.	0.25
1184514050	1449750643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750643	29867468	Allele T is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to allele C.	3.25
1184514050	1449750655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750655	29867468	Genotypes CT + TT is associated with increased likelihood of Neutropenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to genotype CC.	2.75
1184514050	1449750718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750718	29704867	Genotype TT is associated with Neutropenia when treated with azathioprine in women with Arthritis, Rheumatoid and Pemphigus.	0.25
1184514050	1449750757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750757	29702976	Genotype TT is associated with Leukopenia when treated with azathioprine in women with Sjogren's Syndrome.	0.25
1184996860	PA166182810	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182810		Annotation of DPWG Guideline for flucloxacillin and HLA-B	100
1184996860	1184407571	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407571	19483685	HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.	3.0
1184996860	1184407578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407578	19483685	HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.	2.75
1445400924	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400924	1447961043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961043	14985404	Allele A is not associated with risk of Malignant Hyperthermia as compared to allele G.	This annotation is not used for clinical annotation scoring. The variant is designated as MHS causative by EMHG group. IVCT test for the subject was negative. However, MH may still develop in connection with indicated drugs, so evidence is not counted as conflicting finding in CA.
1445400924	1444698017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698017	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400924	1447635058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635058	17081152	Allele A is associated with Malignant Hyperthermia and Myopathy, Central Core as compared to allele G.	0.0
1445400924	1447673794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673794	17226826	Allele A is associated with increased risk of Myopathy, Central Core as compared to allele G.	0.0
1445400924	1447961003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961003	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445401008	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445401008	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445401008	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445401008	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1445401008	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1447672658	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
1447672658	982033589	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033589	10961881	Allele T is not associated with likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy when treated with warfarin as compared to allele C.	-2.0
1447672658	982033570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033570	10961881	Allele C is not associated with likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy when treated with warfarin as compared to allele A.	-2.0
1447672658	1447519958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519958	19752777	Allele C is associated with risk of over-anticoagulation when treated with warfarin as compared to allele A.	2.75
1447672658	982046133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046133	19874474	CYP2C9 *2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	982046140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046140	19874474	CYP2C9 *3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	1183700149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700149	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Hemorrhage and over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672658	1184483140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483140	23932037	CYP2C9 *2 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.	1.5
1447672658	1184483159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483159	23932037	CYP2C9 *3 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	1184483894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483894	23104259	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	2.75
1447672658	1184510190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510190	22075505	CYP2C9 *1/*3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.75
1447672658	1444607544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607544	25246753	CYP2C9 *1/*3 is associated with increased risk of over-anticoagulation when treated with warfarin in people with Thyrotoxicosis as compared to CYP2C9 *1/*1.	0.25
1447672658	1444697555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697555	25769357	CYP2C9 *2/*3 + *3/*3 + *2/*2 are associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation.	3.0
1447672658	1444707455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707455	12634980	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1444708161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708161	24911077	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	2.75
1447672658	1447223022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223022	18690342	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
1447672658	1447223110	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223110	22571356	CYP2C9 *2 is not associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672658	1447223124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223124	22571356	CYP2C9 *3 is not associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672658	1447519168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519168	19297219	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672658	1447519284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519284	23602689	CYP2C9 *1/*2 + *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672658	1447519432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519432	25244877	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447519788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519788	18466099	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1447520234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520234	17226852	CYP2C9 *1/*2 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.	1.5
1447672658	1447520315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520315	19794411	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.25
1447672658	1447521386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521386	17989110	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672658	1447521410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521410	20354686	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.25
1447672658	1447521435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521435	22990331	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447521456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521456	15001971	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672658	1447521716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521716	23279643	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin in children as compared to CYP2C9 *1/*1.	0.0
1447672658	1447572186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447572186	19074728	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447680579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680579	26739746	CYP2C9 *3/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1447586719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586719	21318593	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.5
1447672658	1183701124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701124	18574025	CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with warfarin.	3.5
1447672658	1447521153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521153	17324110	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.75
1447672988	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
1447672988	PA166182842	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182842		Annotation of DPWG Guideline for warfarin and CYP2C9	100
1447672988	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
1447672988	1449190810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190810	29432897	Allele T is not associated with likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-2.25
1447672988	1183700629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700629	10509530	Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to genotypes AA + AC.	2.5
1447672988	1451113584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451113584	31186542	Allele C is not associated with risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.	-1.5
1447672988	1449190803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190803	29432897	Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele A.	3.25
1447672988	982044429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044429	17653141	CYP2C9 *3 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044454	17653141	CYP2C9 *2 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044460	17653141	CYP2C9 *5 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044466	17653141	CYP2C9 *6 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044472	17653141	CYP2C9 *11 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044636	18756910	CYP2C9 *3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	2.0
1447672988	1183685004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685004	24503627	CYP2C9 *3 is not associated with risk of Hemorrhage when treated with warfarin.	-2.0
1447672988	1183685010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685010	24503627	CYP2C9 *3 is not associated with risk of major bleeding when treated with warfarin.	-2.0
1447672988	1183700149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700149	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Hemorrhage and over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672988	1183700618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700618	10509530	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to CYP2C9 *1/*1 + *1/*3.	2.5
1447672988	1183701135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701135	18574025	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin.	0.0
1447672988	1183704584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704584	24503627	CYP2C9 *2 + *3 is not associated with Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	-2.0
1447672988	1183704604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704604	24503627	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	0.0
1447672988	1184472914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472914	24474498	CYP2C9 *1/*3 is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1/*1.	1.75
1447672988	1184473641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473641	25001883	CYP2C9 *2 is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1.	-1.25
1447672988	1184473649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473649	25001883	CYP2C9 *3 is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1.	-1.25
1447672988	1184483171	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483171	23932037	CYP2C9 *2 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	1.25
1447672988	1184483179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483179	23932037	CYP2C9 *3 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	1.5
1447672988	1184483255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483255	23774101	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672988	1184483817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483817	23104259	CYP2C9 *3 is associated with increased risk of all and minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	1184483861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483861	23104259	CYP2C9 *3 is not associated with increased risk of major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	-1.75
1447672988	1444607206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607206	25521356	CYP2C9 *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1444607233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607233	25521356	CYP2C9 *1/*2 + *2/*2 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1444608341	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444608341	24602049	CYP2C9 *1/*3 + *3/*3 is not associated with increased risk of Hemorrhage when treated with warfarin.	-1.5
1447672988	1444697514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697514	25769357	CYP2C9 *3/*3 + *3/*2 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation.	3.5
1447672988	1444703983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444703983	25858232	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin in people with Alcoholism as compared to CYP2C9 *1.	0.0
1447672988	1447024601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447024601	14676821	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672988	1447148295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447148295	17955230	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1447223001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223001	18690342	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
1447672988	1447223135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223135	22571356	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1447519142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519142	19297219	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1447519308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519308	23602689	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1447519366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519366	21148049	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672988	1447519410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519410	25244877	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672988	1447519466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519466	15714076	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.875
1447672988	1447519480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519480	23348161	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
1447672988	1447519505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519505	18570163	CYP2C9 *1/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672988	1447680520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680520	26777610	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672988	1448257304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257304	27488176	CYP2C9 *2 + *3 are not associated with risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1448262972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262972	27581200	CYP2C9 *1/*2 + *1/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1448602404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602404	28033245	CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1447672988	1448602417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602417	28033245	CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1447672988	1449005238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449005238	28689179	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.	3.0
1447979749	PA166152939	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166152939		Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	100
1447979749	1449192069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192069	29126871	Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	1.0
1447979749	1449192108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192108	28606620	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.5
1447979749	1449192508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192508	27898234	Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	3.0
1447979749	1449192520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192520	27898234	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	-1.5
1447979749	1449192588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192588	25981758	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1449192632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192632	27805836	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.75
1447979749	1449192645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192645	27805836	Genotype del/del is not associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	-1.25
1447979749	1449192689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192689	29327948	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.75
1447979749	1449192749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192749	29451946	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.	2.5
1447979749	1449191920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191920	28325531	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.25
1447979749	1449192352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192352	27334259	Allele del is associated with response to ivacaftor / lumacaftor.	0.25
1447979749	1446903870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903870	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.0
1447979749	1446903951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903951	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1446903975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903975	24973281	Genotype CTT/del is not associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	-0.375
1447979749	1448107229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107229	27298017	Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	2.5
1447989671	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989671	1450957700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957700	10071185	Allele del is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to allele G.	0.125
1447989671	1450960647	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960647	9439663	Genotypes G/del + del/del are associated with decreased activity of DPYD as compared to genotype GG.	0.0
1447989671	1448124998	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124998	24648345	Allele del is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1447989678	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989678	1450958000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450958000	10071185	Genotype del/del is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype ATGA/ATGA.	0.125
1447989678	1448125015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125015	24648345	Allele del is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele ATGA.	0.0
1447989706	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989706	1450957760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957760	10071185	Allele A is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to allele G.	0.125
1447989706	1450960680	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960680	9439663	Allele A is associated with decreased activity of DPYD as compared to allele G.	0.0
1447989706	1450960685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960685	9439663	Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.	0.0
1447989706	1444699974	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444699974	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1447989723	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989723	1450957900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957900	10071185	Genotype AA is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.125
1447989723	1444700075	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700075	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.	0.0
1448423861	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1448423861	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1448423861	1448423827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423827	27812499	Allele A is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele G.	1.5
1448423861	1449191118	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191118	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1448423861	1449191353	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191353	23891399	Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	-0.0
1448423861	1449192347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192347	27334259	Allele G is not associated with response to ivacaftor or lumacaftor in people with Cystic Fibrosis.	-0.25
1449154729	PA166179847	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166179847		Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	100
1449154729	1449154644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154644	29099344	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	3.5
1449154729	1449154699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154699	29099333	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	3.25
1449154729	1449192662	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192662	28930490	Genotype del/del is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	2.0
1449191379	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191379	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191379	1449191088	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191088	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191385	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191385	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191385	1449191034	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191034	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191401	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191401	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191401	1449191068	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191068	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191407	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191407	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191407	1449191078	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191078	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449310234	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310234	1449160978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160978	12059893	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1449310234	1449160998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160998	16163667	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1449310234	1449161004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161004	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1449310234	1449161022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161022	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1449310249	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310249	1449160887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160887	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449310265	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310265	1449160893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160893	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449563861	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449563861	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1449563861	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1449575656	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575656	1444700024	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700024	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1449575656	1449575546	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575546	29769267	Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.	0.0
1449747617	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747617	1449733380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733380	12883402	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747643	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747643	1449733354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733354	12709367	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747643	1449733370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733370	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1450929867	PA166161955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161955		Annotation of CPIC Guideline for tropisetron and CYP2D6	100
1450929867	981954738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954738	12065557	CYP2D6 *3/*3 is associated with decreased metabolism of tropisetron in people with Neoplasms.	1.5
1450929867	1447148415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447148415	12728290	CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1450929867	1447148428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447148428	12728290	CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1450929867	1447159547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447159547	12728290	CYP2D6 *1/*2xN (assigned as ultra-metabolizer genotype phenotype) is associated with increased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	0.0
1451092541	PA166192321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192321		Annotation of CPIC Guideline for piroxicam and CYP2C9	100
1451092541	1183702677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702677	16198655	CYP2C9 *1/*2 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092541	1183702686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702686	16198655	CYP2C9 *1/*3 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092541	1451092520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092520	17112811	CYP2C9 *1/*3 + *3/*3 are associated with decreased metabolism of piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	0.5
1451092677	PA166192301	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192301		Annotation of CPIC Guideline for meloxicam and CYP2C9	100
1451092677	PA166182753	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166182753		Annotation of FDA Label for meloxicam and CYP2C9	100
1451092677	1183702049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702049	24322170	CYP2C9 *3/*3 is associated with decreased clearance of meloxicam in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3.	1.0
1451092677	1451092564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092564	26774055	CYP2C9 *1/*3 + *2/*2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092677	1451092600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092600	24615047	CYP2C9 *1/*3 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451092677	1451092660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092660	29024493	CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092677	1451092671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092671	21395648	CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092720	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1451092720	981862003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862003	12152005	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	2.0
1451092720	981862010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862010	12152005	CYP2C9 *2 is not associated with clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	-0.125
1451092720	981862045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862045	15289789	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	2.5
1451092720	981862303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862303	15289789	CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	0.0
1451092720	1183702755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702755	18694831	CYP2C9 *1/*3 is associated with decreased racemic, S-ibuprofen and R-ibuprofen metabolism, with increase of AUC(0-infinity) and reduction of clearance when exposed to ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451092720	1447682551	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682551	26122864	CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092720	1447682561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682561	26122864	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092720	1450935257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935257	19480553	CYP2C9 *3 + *2 are associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1451137080	PA166219301	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219301		Annotation of CPIC Guideline for dexlansoprazole and CYP2C19	100
1451137080	1451137042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137042	22455762	CYP2C19 poor metabolizer is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 normal metabolizer.	0.0625
1451137080	1451136960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451136960	29018343	CYP2C19 *2/*2 is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1451137080	1451136980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451136980	29018343	CYP2C19 *1/*2 + *1/*3 are associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1451154980	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451154980	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451154980	1183617989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617989	8988065	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.	1.5
1451154980	1183684648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684648	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased pain threshold and pain tolerance when treated with tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.125
1451154980	1450376063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376063	30784356	CYP2D6 poor and ultrarapid metabolizers is associated with increased likelihood of discontinuation when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.625
1451154980	1450376074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376074	30784356	CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.25
1451154980	1451155685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155685	16129989	CYP2D6 poor metabolizer phenotype is associated with increased response to tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	1.0
1451154980	1451205845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205845	22428763	CYP2D6 poor metabolizer is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	0.0
1451154980	1451406280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406280	33812699	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	0.0
1451154980	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451154980	1183617913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617913	16631290	CYP2D6 *4/*6 is associated with intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief) when treated with oxycodone and tramadol.	0.25
1451154980	1183618035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618035	17361124	CYP2D6 *3/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618044	17361124	CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618052	17361124	CYP2D6 *4/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618060	14499440	CYP2D6 *4/*4 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618069	14499440	CYP2D6 *3/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618082	14499440	CYP2D6 *5/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618090	14499440	CYP2D6 *4/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618098	14499440	CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1446898050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898050	25948472	CYP2D6 *10/*10 is associated with increased severity of Pain when treated with tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.	2.5
1451154980	1451141860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141860	31969823	CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.	0.25
1451154980	1451638720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451638720	34246203	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.	2.0
1451289660	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451289660	1450953760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953760	17417073	Genotype AG is associated with increased likelihood of Drug Toxicity and Neutropenia when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	0.0
1451329460	981742607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981742607	19390945	Genotype AA is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.	2.5
1451329460	981743951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981743951	19390945	Genotype AG is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.	3.0
1451329460	981747378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981747378	19299905	Genotypes AA + AG are associated with increased severity of Neutropenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.	2.0
1451329460	981794141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794141	18221820	Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1451329460	981794502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794502	16636344	Genotype AA is associated with increased Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	1.75
1451329460	1445584988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445584988	26229432	Genotypes AA + AG is associated with increased risk of Neutropenia when treated with irinotecan in people with biliary tract neoplasms and Pancreatic Neoplasms as compared to genotype GG.	1.5
1451329460	1447814363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814363	26830078	Genotype AG is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	1.5
1451329460	1448617804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617804	28367249	Allele A is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to allele G.	2.0
1451329460	1448617936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617936	28502040	Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG.	3.5
1451329460	1184483416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483416	24308720	UGT1A1 *6 is not associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	-1.0
1451329460	1184483429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483429	24308720	UGT1A1 *6 + *28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	1.0
1451329460	1184483547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483547	24448639	UGT1A1 *1/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451329460	1184483574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483574	24448639	UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451329460	1184483688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483688	24519753	UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*6.	1.75
1451329460	1184483699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483699	24519753	UGT1A1 *1/*6 + *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451329460	1184483709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483709	24519753	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28 + *1/*1.	1.25
1451329460	1185235290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235290	25285015	UGT1A1 *6 is not associated with risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451329460	1448422676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422676	26857783	UGT1A1 *6 + *28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.	2.5
1451329460	1448422855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422855	27385990	UGT1A1 *1/*28 + *6/*28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	1.0
1451329460	1451210158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210158	26229432	UGT1A1 *28/*28 + *6/*6 + *1/*6 + *1/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451329460	1448820825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448820825	28585035	UGT1A1 *1/*6 + *6/*6 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451241780	1184470178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470178	24351870	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241780	1184514719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514719	16421475	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	0.75
1451241780	1184514722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514722	16628701	Genotypes CT + TT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.	1.0
1451241780	1184514725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514725	17568575	Genotypes CT + TT is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1184514748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514748	19384171	Genotypes CT + TT is associated with decreased concentration-to-adjusted dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1184515243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515243	17015051	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	1.75
1451241780	1184515246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515246	17875118	Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.25
1451241780	1184753650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753650	25141896	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	2.75
1451241780	1184754595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754595	24820765	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.25
1451241780	1444706064	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706064	25712187	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1448112500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112500	26518936	Genotype CC is associated with increased steady-state concentration of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1448569538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569538	28084894	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.5
1451241780	1448820454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820454	28685716	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241780	1449165670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165670	28941036	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1184998363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998363	21922127	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1446899545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899545	26271661	Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1451241780	1184469270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469270	24911663	CYP3A5 *1/*3 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241780	1184470918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470918	24526611	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451241780	1184471447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471447	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241780	1184514760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514760	22210422	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1451241780	1184514766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514766	19289993	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough levels of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1451241780	1184515125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515125	22210422	CYP3A5 *1/*1 + *1/*3 is not associated with blood concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1451241780	1448423903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423903	26450467	CYP3A5 *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	0.5
1451241780	1448568122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568122	28044353	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.25
1451241780	1447679054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679054	26521259	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451265448	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1451265448	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1451265448	1183683984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683984	2741190	CYP2D6 poor metabolizers is associated with side effects when treated with imipramine.	0.125
1451265448	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451265448	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1184136380	1444665886	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665886	25393304	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1444706391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706391	23712427	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.	0.0
1184136380	1444707026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707026	24205831	Genotype TT/TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.75
1184136380	1444707037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707037	24205831	Genotype TT/TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	-1.5
1184136380	1444843653	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843653	26032235	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	2.5
1184136380	1444843660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843660	26032235	Genotype TT/TT is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	-1.5
1184136380	1444843667	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843667	25548683	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	2.5
1184136380	1444843675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843675	25548683	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes G/TT + GG.	0.25
1184136380	1448594944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448594944	28186161	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1445205151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445205151	26186989	Genotypes G/TT + TT/TT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	2.5
1184136380	1447682460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682460	26670100	Allele TT is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.	3.25
1184136380	1184136144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136144	23291588	Genotype TT/TT is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.5
1184136380	1184136180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136180	24690180	Genotype TT/TT is associated with increased response (SVR rate) to HCV triple therapy (telaprevir (TVR), peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1184136185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136185	24355007	Genotypes G/TT + GG are associated with increased risk of treatment failure in Japanese patients with with chronic genotype 1 HCV infection when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.	2.0
1184136380	1184136349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136349	24362944	Genotype TT/TT is associated with increased likelihood of achieving SVR in older patients with genotype 1b chronic hepatitis C when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1184136358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136358	24308755	Genotype TT/TT is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.25
1184136380	1184136385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136385	24072198	Genotype GG is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype TT/TT.	3.5
1184136380	1184168705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168705	24748394	Genotype TT/TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	3.75
1184136380	1448123213	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123213	27180197	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C.	1.75
1184136380	1448264419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264419	27027531	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.25
1184136380	1448264449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264449	26820907	Genotype TT/TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.5
1184136380	1448427450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427450	27810523	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.0
1184136380	1448427467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427467	27810523	Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	1.75
1184136380	1448602991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602991	26916827	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.0
1184136380	1448636905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636905	28732143	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis B as compared to genotypes G/TT + GG.	2.0
1184136380	1448996483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996483	28261910	Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.	2.0
1184136380	1448998994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998994	28739427	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.0
1184136380	1448999052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999052	28739427	Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.5
1184136380	1448999280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999280	28739427	Genotype TT/TT is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184999911	1183491630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491630	23900887	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	1.75
1184999911	1183533917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533917	23894093	Genotype CT is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	-0.125
1184999911	1183684103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684103	23107770	Genotype TT is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes CC + CT.	2.5
1184999911	1184470178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470178	24351870	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1184999911	1184514710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514710	22309416	Genotype CT are not associated with clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	-0.75
1184999911	1184514713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514713	19384171	Genotype TT is not associated with concentration-to-adjusted dose ratio of tacrolimus in people with liver transplantation as compared to genotypes CC + CT.	-1.25
1184999911	1184515235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515235	18408564	Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.25
1184999911	1184753658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753658	25141896	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	2.75
1184999911	1184754595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754595	24820765	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.25
1184999911	1184998180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998180	21698374	Genotypes CT + TT are not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	-0.25
1184999911	1184998546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998546	23738951	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	0.125
1184999911	1448569538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569538	28084894	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.5
1184999911	1448820435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820435	28685716	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1184999911	1449165670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165670	28941036	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1184999911	1449747826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747826	29454235	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.75
1184999911	1184469290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469290	24911663	CYP3A5 *1/*1 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1184999911	1184470237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470237	24378577	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	0.75
1184999911	1184471437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471437	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1184514699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514699	22210422	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1184514728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514728	19289993	CYP3A5 *1/*1 + *1/*3 is not associated with dose-adjusted trough levels of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.125
1184999911	1184515131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515131	19289993	CYP3A5 *1/*1 + *1/*3 are not associated with trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1184999911	1184515148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515148	19289993	CYP3A5 *1/*1 + *1/*3 are not associated with trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1184999911	1444706133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706133	25869250	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1184999911	1447674129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674129	26634478	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1447946834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946834	26856709	CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1447946849	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946849	26856709	CYP3A5 *1/*1 is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1448358509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358509	27653228	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1449749518	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749518	29855074	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1184999911	1449749531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749531	29855074	CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1184999911	1447679054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679054	26521259	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
981202294	827861835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827861835	21441248	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	0.0
981202294	1448108757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108757	27195527	Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.	2.5
981202294	981240255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240255	22680342	Allele T is associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele G.	2.0
981202294	827784211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784211	21860339	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	0.0
981202294	827807692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807692	18281305	Allele T is associated with increased plasma concentration of nevirapine in people with HIV Infections as compared to allele G.	2.0
981202294	827823670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823670	22111602	Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	1.5
981202294	827848013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848013	22354160	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	0.0
981202294	827848956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848956	19228205	Genotype GT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.5
981202294	827848963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848963	19228205	Genotype TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.5
981202294	827849230	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827849230	21393201	Genotype TT is associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotypes GG + GT.	2.0
981202294	769163522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163522	15864119	Genotype TT is associated with increased plasma exposure of nevirapine in people with HIV Infections as compared to genotype GG.	1.75
981202294	1183491986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491986	23982262	Genotype TT is associated with increased nevirapine AUC0-6 h when treated with nevirapine in people with HIV Infections as compared to genotypes GG + GT.	0.125
981202294	1184349353	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349353	20625352	Genotypes GT + TT is not associated with metabolism of nevirapine in people with HIV Infections as compared to genotype GG.	-0.5
981202294	1296598965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598965	24217698	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.0
981202294	1448110402	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448110402	26348712	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	2.0
981202294	1448993707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993707	19218571	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	1.75
981202294	1449001754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449001754	28947469	Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	2.5
981345382	1451320594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451320594	31242253	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.	1.75
981345382	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
981345382	769162953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162953	21178985	Allele C is associated with increased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.	3.0
981345382	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
981345382	1450929840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450929840	31220337	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.	2.0
981345382	1450957388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957388	31967516	Genotype CC is associated with increased likelihood of discontinuation when treated with hmg coa reductase inhibitors in people with Acute coronary syndrome and Myocardial Infarction as compared to genotype TT.	3.5
981345382	1448531979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531979	27595674	Allele T is not associated with increased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors in people with familial hypercholesterolemia as compared to allele C.	-1.75
981345382	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
981345382	1449576182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576182	29785580	Genotypes CC + CT are not associated with likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.	-0.75
981345382	1449576215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576215	29785580	Genotypes CC + CT are associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.	1.0
982030836	1451155200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451155200	25869015	Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotypes AG + GG.	2.0
982030836	1451155287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451155287	20530282	Genotype AA is associated with increased risk of Neutropenia and Vomiting when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes AG + GG.	3.0
982030836	981785803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785803	17510208	Genotype AA is associated with increased Neutropenia when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.	2.75
982030836	981785904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785904	17510208	Genotype AA is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.	3.25
982030836	981792403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981792403	19450125	Genotype AA is not associated with Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	-1.25
982030836	982023184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023184	23386248	Allele A is not associated with risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms.	-1.5
982030836	827552106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827552106	15007088	Allele A is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele G.	1.25
982030836	1448531604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531604	27845419	Genotypes AA + AG are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	2.25
982030222	1448261868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261868	26491254	NAT2 slow acetylator is associated with decreased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 rapid acetylator.	1.0
982030222	1451308040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451308040	33165168	NAT2 slow acetylator is associated with increased concentrations of isoniazid in healthy individuals as compared to NAT2 rapid acetylator.	0.0625
982030222	1450807565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807565	30779340	Genotype AA is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes AG + GG.	2.0
982030222	981240165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981240165	19891553	Genotype AA is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype GG.	1.75
982030222	981848260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981848260	15855489	NAT2 *4 is associated with increased clearance of isoniazid in healthy individuals.	0.125
982030222	981851586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851586	16182272	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	1.5
982030222	981851591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851591	16182272	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	1.5
982030222	981939860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939860	21479500	NAT2 *4 is associated with increased metabolism of isoniazid in healthy individuals.	1.0
982030222	981939971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939971	21753138	NAT2 *4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	0.125
982030222	1184233189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233189	24533708	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .	2.0
982030222	1184233225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233225	24533708	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased clearance of isoniazid in children with Tuberculosis as compared to NAT2 *4/*5B + *4/*6A + *4/*5C + *4/*6O + *4/*7G + *5B/*12A + *6A/*13A (assigned as intermediate acetylator phenotype) .	1.5
982030222	981851608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851608	16531626	NAT2 *5A/*5A + *5A/*6A + *5A/*7A + *6B/*6B + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Lupus Erythematosus, Systemic as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	0.125
982030222	1183702439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702439	24383060	NAT2 *5A/*5A + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.0
982030222	981344548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344548	18544910	NAT2 *6A/*6A + *6A/*7B + *7B/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5B + *4/*6A + *4/*7B.	2.0
982030222	981476160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981476160	21558457	NAT2 *5A + *6B + *7A + *14A is associated with decreased clearance of isoniazid in children with HIV Infections as compared to NAT2 *4 + *12A + *13A.	0.0
982047862	982032925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032925	8806248	Genotype del/del is associated with increased resistance to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.0
982047862	982033131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033131	9069453	Genotype del/del is associated with decreased response to captopril in healthy individuals as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.5
982047862	982033238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033238	9551410	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.75
982047862	982033375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033375	9869506	Genotype del/del is associated with decreased response to captopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.5
982047862	982042579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042579	12832683	Genotype del/del is associated with decreased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.0
982047862	982042629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042629	12832683	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.0
982047862	982044530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044530	19286758	Genotype del/del is associated with decreased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.25
982047862	1183491329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491329	20830509	Genotype del/del is associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-1.5
1154221922	655388082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388082	20130569	Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.	2.75
1154221922	827807905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807905	20679960	Allele T is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.	2.75
1154221922	1183631259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631259	23930675	Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.	2.75
1154221922	1448107497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107497	20207952	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.	2.5
1183618159	1183682020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682020	19514130	CYP2D6 poor metabolizer genotype is associated with decreased dose of tramadol in people with Pain.	0.0
1183618159	1451155689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155689	16129989	CYP2D6 poor metabolizer phenotype is not associated with dose of amitriptyline or tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	-0.625
1183618159	1451205840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205840	22428763	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizers.	-0.75
1183618159	1183618035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618035	17361124	CYP2D6 *3/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618044	17361124	CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618052	17361124	CYP2D6 *4/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618060	14499440	CYP2D6 *4/*4 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618069	14499440	CYP2D6 *3/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618082	14499440	CYP2D6 *5/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618090	14499440	CYP2D6 *4/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618098	14499440	CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1446898032	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898032	25948472	CYP2D6 *10/*10 is associated with increased dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.	2.5
1183618159	1451157968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157968	18520597	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is not associated with dose of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .	-1.25
1183618159	1183960516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960516	16960721	CYP2D6 *10/*10 is associated with significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy when treated with tramadol as compared to CYP2D6 *1/*1 + *1/*10.	1.75
1183681792	1183681743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681743	24152261	HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.	4.0
1183681792	1184988608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988608	23604100	HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.	3.5
1183681792	1448994310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994310	28885988	HLA-B *13:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with dapsone.	4.0
1183681792	1448994375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994375	28885988	HLA-B *13:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with dapsone.	3.0
1183681792	1448994399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994399	28885988	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with dapsone.	4.0
1183681792	1449752292	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752292	29541744	HLA-B *13:01:01 is associated with increased risk of severe cutaneous adverse reactions due to dapsone.	0.0
1183681792	1449752371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752371	29512326	HLA-B *13:01:01 is associated with increased risk of Maculopapular Exanthema due to dapsone.	0.25
1183681792	1449752489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752489	29458119	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to dapsone in people with Skin Diseases.	3.5
1183693378	981349421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349421	16538176	HLA-B *40:01:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	3.0
1183693378	1183680916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680916	23692434	HLA-B *40:01:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
1183693378	1183702077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702077	24336023	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
1183693378	1184407446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407446	16981842	HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	-1.25
1183693378	1184468430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468430	24268988	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
1183693378	1451640980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451640980	34350628	HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
1444666386	982047669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047669	23774940	Allele C is associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele T.	3.0
1444666386	1296598592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598592	25147095	Genotypes CC + CT is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV Infections as compared to genotype TT.	4.0
1444666386	1448635501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635501	28689274	Allele C is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele T.	2.5
1444666386	1449155757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155757	28819312	Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and dress syndrome when treated with nevirapine in people with HIV Infections as compared to allele T.	0.0
1444686843	827815579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815579	22108237	Allele G is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele A.	2.25
1444686843	1184471061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471061	24465960	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	2.5
1444686843	1450928480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928480	31401678	Genotypes AA + AG are not associated with concentrations of tacrolimus in children with proteinuria as compared to genotype GG.	-1.25
1444686843	1448613208	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613208	28112181	Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	2.25
1444686843	1449163570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163570	29318894	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	3.0
1444686843	1449747816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747816	29454235	Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	1.75
1445421156	1451293140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451293140	33124517	Genotype GT is associated with decreased dose-adjusted trough concentrations of bupropion and hydroxybupropion in men with Depressive Disorder, Major.	0.125
1445421156	981786189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786189	23344581	CYP2B6 *6 is associated with decreased hydroxybupropion concentrations and hydroxybupropion/bupropion ratio when exposed to bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	981786255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786255	23344581	CYP2B6 *18 is associated with decreased hydroxybupropion concentrations when exposed to bupropion in healthy individuals.	1.0
1445421156	1043880685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880685	14515060	CYP2B6 *4 is associated with increased clearance of bupropion in healthy individuals.	1.5
1445421156	1445403153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445403153	23149928	CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.	1.5
1445421156	1445403174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445403174	23149928	CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.	2.5
1445421156	1445556633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556633	15083067	CYP2B6 *6 is associated with decreased metabolism of bupropion.	1.5
1445421156	1447521014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521014	26580670	CYP2B6 *6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	1447963480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963480	15722458	CYP2B6 *1/*22 is associated with increased metabolism of bupropion as compared to CYP2B6 *1/*1.	2.25
1445421156	1448257502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257502	27528039	CYP2B6 *6 is associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2B6 *1.	0.125
1445421156	1448257516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257516	27528039	CYP2B6 *6 is associated with increased steady-state concentration of bupropion in women with Pregnancy as compared to CYP2B6 *1.	0.125
1445421156	1449157219	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449157219	28181240	CYP2B6 *1/*30 is associated with decreased activity of CYP2B6 when exposed to bupropion as compared to CYP2B6 *1/*1.	0.0
1445421156	1449564017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449564017	29756345	CYP2B6 *6/*6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1445421156	1449564030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449564030	29756345	CYP2B6 *1/*4 + *4/*6 are associated with increased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	0.0
1445421156	1450820343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820343	23840296	CYP2B6 *1/*6 + *6/*6 are associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	1451350020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451350020	25565674	CYP2B6 *6/*6 is associated with decreased concentrations of hydroxybupropion as compared to CYP2B6 *1/*1 + *1/*6.	1.75
1447672600	827807404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807404	18322281	CYP2C9 *2 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	827807407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807407	18322281	CYP2C9 *3 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	982044562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044562	18322281	CYP2C9 *2 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.	2.25
1447672600	982044576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044576	18322281	CYP2C9 *3 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.	2.25
1447672600	982045771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045771	19077919	CYP2C9 *1/*3 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	982045784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045784	19077919	CYP2C9 *1/*13 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	982045790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045790	19077919	CYP2C9 *1/*14 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	1183700166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700166	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672600	1184472906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472906	24474498	CYP2C9 *2 is not associated with time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1447672600	1447148336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447148336	17955230	CYP2C9 *2 + *3 are not associated with decreased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672600	1447223063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223063	18690342	CYP2C9 *2 + *3 are associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672600	1447521135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521135	17324110	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	1447521743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521743	23279643	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1447672600	1447521763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521763	25504915	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	1449170693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170693	29396738	CYP2C9 *2 + *3 are associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1.	3.0
1449269910	1444607225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607225	25521356	Genotype TT is not associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	-2.0
1449269910	1448108311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108311	27262824	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to allele C.	-0.25
1449269910	1444697545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697545	25769357	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.	3.5
1449269910	1444705902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705902	24919870	Genotypes CT + TT is associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to genotype CC.	3.0
1449269910	1444707678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707678	23423913	Genotype TT is associated with increased likelihood of Hemorrhage when treated with phenprocoumon as compared to genotype CC.	0.0
1449269910	1447222942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222942	18574025	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1447223015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223015	18690342	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-1.5
1449269910	1447519301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519301	23602689	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.5
1449269910	1447519358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519358	21148049	Allele T is not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to allele C.	-1.5
1449269910	1447519399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519399	25244877	Allele T is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	0.0
1449269910	1447520016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520016	26445138	Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.0
1449269910	1447680512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680512	26777610	Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.5
1449269910	982044609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044609	18950464	Genotype TT is not associated with risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.	-1.25
1449269910	978616289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978616289	22571356	Genotype TT is associated with increased likelihood of Hemorrhage when treated with warfarin as compared to genotype CC.	3.0
1449269910	1184472922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472922	24474498	Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to genotype CC.	0.0
1449269910	1184473637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473637	25001883	Genotype CT is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to genotype CC.	2.75
1449269910	1184483191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483191	23932037	Genotypes CT + TT is not associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to genotype CC.	-1.0
1449269910	1184483278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483278	23774101	Genotype TT is not associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	-1.5
1449269910	1184483882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483882	23104259	Allele T is not associated with increased risk of all, major and minor hemorrhage as well as over anticoagulation when treated with warfarin as compared to allele C.	-1.75
1449269910	1184509978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509978	22592842	Allele T is not associated with increased risk of bleeding events during the 6-year follow up in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.	-1.5
1449269910	1448257297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257297	27488176	Allele T is not associated with risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1448262987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262987	27581200	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1448602391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602391	28033245	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	2.0
1449269910	1449005252	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449005252	28689179	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to genotype CC.	3.0
1449269910	1449190889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190889	29432897	Allele T is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	2.75
1449269910	1449269120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449269120	29577257	Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to genotype CC.	3.5
1448104189	1183702890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702890	16338275	CYP2B6 *6/*6 is associated with increased (S)-methadone plasma levels when treated with methadone as compared to CYP2B6 *1/*1 + *1/*6.	2.0
1448104189	1183702923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702923	17329992	CYP2B6 *6/*6 is associated with increased trough ( R , S )-methadone plasma concentrations when treated with methadone as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1448104189	1447944325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944325	26389554	CYP2B6 *1/*6 + *6/*6 is associated with decreased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1448104189	1447944355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944355	26389554	CYP2B6 *1/*4 + *4/*6 is associated with increased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1448104189	1448104418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104418	27286724	CYP2B6 *6 is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1.	2.0
1448104189	1449266547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266547	17178267	CYP2B6 *6/*6 is associated with increased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*6.	2.0
1448104189	1451156500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156500	17502774	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.	1.0
1448104189	1451156540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156540	17502774	CYP2B6 *6/*6 is not associated with concentrations of (R)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.	-0.125
1448104189	1451161580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161580	21589866	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.	0.0
1448104189	1451226268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226268	28723731	CYP2B6 *6/*6 is associated with increased concentrations of methadone as compared to CYP2B6 *1/*1.	2.25
1448104189	1451226300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226300	28723731	CYP2B6 *1/*6 is not associated with concentrations of methadone as compared to CYP2B6 *1/*1.	-0.75
1448104189	1451353463	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353463	32302325	CYP2B6 *1/*6 + *1/*18 + *6/*6 + *6/*18 are associated with decreased metabolism of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*5 + *1/*7.	1.25
1451243676	1444707678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707678	23423913	Genotype TT is associated with increased likelihood of Hemorrhage when treated with phenprocoumon as compared to genotype CC.	0.0
1451243676	1444707784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707784	23016521	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with phenprocoumon as compared to genotype CC.	3.0
1451243676	1447679579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447679579	21057703	Genotype TT is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CT.	2.25
1451243676	1447680482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680482	23016521	Genotype TT are associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CC.	3.0
1451244040	1043737589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737589	16201835	Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.	1.75
1451244040	1043818101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818101	20020283	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	3.0
1451244040	1449747466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747466	30207196	Allele A is associated with decreased dose of phenprocoumon in children as compared to allele G.	2.0
1451244040	1444707640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707640	24224579	Genotypes AA + AG are associated with decreased dose of phenprocoumon as compared to genotype GG.	2.5
1451261620	1451234500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451234500	16175507	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.	1.75
1451261620	1451234800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451234800	20625347	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain in men as compared to allele C.	3.5
1451261620	1451260720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451260720	21898657	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.	3.0
1451266065	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266065	827810951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810951	21410976	Genotype CT is associated with risk of Neutropenia when treated with tegafur in people with Rectal Neoplasms.	0.25
1451266065	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451266065	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
1451254525	981477722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477722	23111421	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype CC.	3.0
1451254525	981477735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477735	23111421	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.	2.25
1451254525	1444696319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444696319	25704243	Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.	1.5
981204902	981481971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481971	20840187	Genotype AA is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to genotypes AG + GG.	2.5
981204902	981482015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482015	21418140	Allele A is associated with increased severity of smoking when exposed to nicotine in people with smoking as compared to allele G.	1.5
981204902	981482036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482036	21418140	Allele A is not associated with increased risk of smoking when exposed to nicotine as compared to allele G.	-0.75
981204902	981482237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482237	20886544	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.0
981204902	981754805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754805	19706762	Allele A is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	3.5
981204902	981862067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862067	19132693	Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.	3.0
981204902	982022898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022898	20485328	Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.	0.0
981204902	769178836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769178836	18618000	Allele A is associated with increased risk of Tobacco Use Disorder.	2.0
981204902	827921955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921955	22648373	Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.	2.0
981204902	1184168936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168936	24733007	Genotypes AA + AG is not associated with likelihood of abstinance when treated with nicotine in smokers as compared to genotype GG.	-2.0
981204902	1450813499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813499	22046326	Allele A is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele G.	-1.5
981204902	1450813513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813513	22046326	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-1.5
981204902	1450928745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450928745	29621993	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-2.0
981204902	1450930789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450930789	29666375	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine in men as compared to allele G.	-2.5
981204902	1448261745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261745	27355804	Allele A is associated with increased likelihood of Tobacco Use Disorder as compared to allele G.	2.5
981204902	1449155955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155955	29196725	Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.75
981204902	1451120367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120367	31402126	Allele A is not associated with likelihood of cessation of nicotine in people with Lung Neoplasms as compared to allele G.	-1.5
981204902	1451135740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135740	31796940	Allele A is not associated with likelihood of cessation of nicotine in people with Tobacco Use Disorder as compared to allele G.	-1.5
981204902	1450112824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450112824	30453884	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	3.0
655386657	982046469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046469	22761669	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-0.875
655386657	827641636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641636	16875718	Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.	1.5
655386657	827817158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817158	22026922	Genotypes CT + TT are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	2.5
655386657	827817165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817165	22026922	Genotypes CT + TT are not associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	-1.5
655386657	827828058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828058	22188361	Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.25
655386657	827828226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828226	22188361	Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	0.0
655386657	769172568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172568	19362955	Genotype TT is associated with worse overall survival outcome when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
655386657	1184754301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754301	25025378	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	2.75
655386657	1184886873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886873	25232828	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele C.	-0.25
655386657	1296599089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599089	24446315	Genotypes CT + TT is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-2.25
655386657	1296599231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599231	24446315	Genotypes CT + TT is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-2.25
655386657	1444698493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698493	24224851	Genotypes CT + TT is associated with decreased response to Platinum compounds in people with Colorectal Neoplasms and Stomach Neoplasms as compared to genotype CC.	1.25
655386657	1448123553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123553	27248474	Genotypes CC + CT are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	1.75
655386657	1448263426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263426	27636246	Genotype TT is associated with decreased progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	1.125
655386657	1448522347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522347	20530282	Genotype CC is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	-2.0
655386657	1448617027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617027	28422153	Genotypes CT + TT are associated with decreased overall survival and progression-free survival when treated with cisplatin and gemcitabine in people with Mesothelioma as compared to genotype CC.	0.0
655386657	1448640030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640030	28743242	Genotypes CT + TT is associated with decreased response to platinum in people with Lung Neoplasms as compared to genotype CC.	1.75
655386657	1449752308	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752308	29662106	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.5
655386657	1449754452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449754452	21057378	Genotype CC is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	3.5
982030805	1444696308	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444696308	25704243	Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.	1.5
982030805	981477709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477709	23111421	Genotype CT is associated with increased levels of clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.	2.5
982030805	981802686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802686	23275066	Allele T is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel when exposed to clopidogrel as compared to allele C.	0.0
1183492249	982045529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045529	16103896	Genotype CT is associated with increased response to atorvastatin as compared to genotype CC.	3.0
1183492249	1043859215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859215	20031582	Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.	3.0
1183492249	827807830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807830	20031551	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.	3.0
1183492249	1450972880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450972880	17289397	Genotype CT is associated with increased likelihood of lipid response when treated with atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin as compared to genotype CC.	0.0
1183492249	1450973800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450973800	19667110	Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC.	3.5
1184654139	827919467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919467	21545408	HLA-C *03:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1184654139	1184747194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747194	21301380	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
1184654139	1184755032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755032	15743917	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1184654139	1184756728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756728	21393610	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
1184654139	1184756770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756770	21393610	HLA-C *03:02 is associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	3.25
1184654139	1184467894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467894	21912425	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1444608384	1184510363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510363	23505228	Genotype CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	3.5
1444608384	1447679904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679904	26167726	Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC.	2.25
1444608384	1450371570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371570	30457672	Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	2.25
1444666130	1184748707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748707	9179433	HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.	3.5
1444666130	1184748766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748766	15007363	HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.	3.5
1444666130	1185001852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001852	19392989	HLA-DPB1 *03:01:01 is associated with increased risk of Asthma when treated with aspirin.	4.0
1444699749	1184473890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473890	24911354	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.25
1444699749	1185001827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001827	18301070	HLA-DRB1 *01:01:01 is associated with increased risk of Exanthema when treated with efavirenz or nevirapine in people with HIV.	1.5
1444699749	1185002083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002083	21505298	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.	3.25
1444699749	1444697871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697871	25714001	HLA-DRB1 *01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.	1.0
1444699749	1444697890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697890	25714001	HLA-DRB1 *01:01:01 is associated with increased risk of Toxic liver disease when treated with nevirapine.	1.0
1444699749	1444699767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699767	15627041	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1444699749	1448926259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926259	28819312	HLA-DRB1 *01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1444706709	1184416003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184416003	20504258	HLA-C *01:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.	3.25
1444706709	1444706661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706661	25918017	HLA-C *01:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	3.75
1444706709	1450397888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397888	30242287	HLA-C *01:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	1.0
1446905691	981481580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481580	21274861	Allele A is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	2.5
1446905691	981483866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483866	21246582	Genotype CC is associated with increased risk of anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	1.75
1446905691	827815086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815086	21503919	Genotype CC is associated with decreased hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.0
1446905691	1444704997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704997	23707372	Genotype CC is associated with increased severity of Anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes AA + AC.	3.25
1446905691	1444706733	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706733	20173735	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	0.0
1446905691	1444706744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706744	20637204	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.	0.0
1446905691	1444707065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707065	23730840	Genotype AC is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CC.	1.75
1446905691	1444707727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707727	20547162	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	3.25
1446905691	1445297932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297932	26071337	Genotypes AA + AC is associated with decreased risk of Anemia when treated with peginterferon alfa-2b, protease inhibitors and ribavirin in people with Hepatitis C as compared to genotype CC.	2.5
1446905691	1446905487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446905487	26441325	Genotype CC is associated with increased risk of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AA + AC.	2.5
1446905691	1447682514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682514	26670100	Allele C is not associated with increased risk of Anemia when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with as compared to allele A.	-1.75
1446905691	1448532142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532142	26438033	Genotype CC is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AA + AC.	1.75
1446905691	1448602968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602968	26916827	Genotype CC is associated with increased risk of Anemia when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.5
1446905691	1448428382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428382	27833958	Genotype CC is associated with increased likelihood of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.0
1450810451	1450810440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810440	16679777	Genotype GG is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AA + AG.	2.5
1450810451	1450811230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811230	15902904	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	2.25
1451250540	1447673749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673749	15737014	Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.	0.25
1451250540	981417766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417766	18596266	Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	2.5
1451250540	981475217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475217	18992959	Genotype CT is associated with increased resistance when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype CC.	0.25
1451250540	981475231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475231	16912157	Allele T is associated with decreased response rate (RR) when treated with gefitinib in non-small-cell lung cancer patients as compared to allele C.	1.5
1451250540	981475241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475241	18093943	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475253	17085664	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475265	17020982	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in non-small cell lung cancer as compared to allele C.	0.25
1451250540	981475276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475276	18981003	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.25
1451250540	981475286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475286	20129249	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475298	19381876	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475309	19589612	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475337	21430269	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475352	22215752	Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
1451250540	981475378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475378	21248300	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.0
1451250540	981475801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475801	21921847	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.	0.25
1451250540	981477537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477537	16258541	Allele T is associated with increased acquired resistance to EGFR inhibitor when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.25
1043880630	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1043880630	769171454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171454	19374892	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.	This annotation is not used for clinical annotation scoring. drug drug interaction
1043880630	981758554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758554	23361102	Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.	0.125
1043880630	827827481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827481	17473846	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.	1.0
1043880630	1184169609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169609	23876492	Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.	1.5
1043880630	1451226420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226420	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1043880630	1451352842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352842	28435225	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1043880630	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1043880630	1451533063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451533063	20040338	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	1.75
1043880630	1451165020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451165020	31594719	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1183617478	PA166104992	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104992		Annotation of DPWG Guideline for zuclopenthixol and CYP2D6	100
1183617478	1447682070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682070	26514968	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.0625
1183617478	1451430400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451430400	12107620	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.	1.75
1183703748	1451589728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589728	31114289	Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.	2.25
1183703748	981239887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239887	22871975	Genotype AC is associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to genotype CC.	This annotation is not used for clinical annotation scoring. Cohort overlap with PMID 17110455
1183703748	1184510128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510128	22266406	Allele A is associated with increased dose of warfarin as compared to allele C.	2.0
1183703748	981862284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862284	23571513	Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.	2.0
1183703748	1184472416	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472416	20128861	Allele A is not associated with dose of warfarin as compared to allele C.	-1.5
1183703748	1448105757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105757	17110455	Allele A is associated with increased dose of warfarin as compared to allele C.	2.5
1450415170	PA166104995	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104995		Annotation of DPWG Guideline for metoprolol and CYP2D6	100
1450415170	1450415150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415150	31107373	CYP2D6 poor metabolizers are associated with decreased dose of metoprolol.	1.0
1450415170	1449717747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717747	28181117	CYP2D6 *4 is associated with decreased dose of metoprolol in people with Heart Failure.	2.0
1451266020	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266020	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1451266020	1448109214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109214	21410976	Genotype AC is associated with risk of Diarrhea when treated with tegafur in people with Rectal Neoplasms.	0.25
1451289700	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451289700	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451289700	1450964880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964880	31745289	Allele C is associated with decreased activity of DPYD as compared to allele G.	0.0
1451289700	1448261538	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448261538	27544765	Genotype CC is associated with decreased activity of DPYD.	0.0
1451289700	1448267561	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267561	25410891	Allele C is associated with decreased activity of DPYD.	0.0
1451289700	1448605284	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605284	28295243	Genotype CG is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype GG.	0.0
1183701224	PA166105008	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105008		Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B	100
1183701224	PA166265161	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265161		Annotation of DPWG Guideline for carbamazepine and HLA-A	100
1183701224	981482109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482109	23132554	HLA-A *31:01:02 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.	1.75
1183701224	992282434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/992282434	23588310	HLA-A *31:01:02 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.	2.5
1183701224	993813998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/993813998	23588310	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.	2.5
1183701224	993944301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/993944301	23588310	HLA-A *31:01:02 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	-1.5
1183701224	1183702064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702064	24336023	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
1183701224	1184466701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466701	21149285	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.75
1183701224	1184466909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466909	21428769	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	2.75
1183701224	1184466916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466916	21428769	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	3.25
1183701224	1184466922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466922	21428769	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
1183701224	1184467913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467913	21917426	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	4.0
1183701224	1184467926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467926	21917426	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	4.0
1183701224	1184467950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467950	21917426	HLA-A *31:01:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
1183701224	1184468310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468310	22348435	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.0
1183701224	1184468437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468437	24268988	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	3.5
1183701224	1184468448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468448	24268988	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.75
1183701224	1184469161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469161	24322785	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	4.0
1183701224	1184469204	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469204	24322785	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-3.5
1183701224	1184469261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469261	24322785	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	2.0
1183701224	1184469272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469272	24322785	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.0
1183701224	1184988697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988697	24897291	HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.25
1183701224	1296598666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598666	22211527	HLA-A *31:01:02 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	2.5
1183701224	1444935634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935634	25495410	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	0.625
1183701224	1448525723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525723	27888155	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	3.75
1183701224	1448612304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448612304	28340402	HLA-A *31:01:02 is associated with Exanthema when treated with carbamazepine in people with Epilepsy.	0.25
1183701224	1449295707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449295707	29610831	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Erythema multiforme NOS, Hypersensitivity and Maculopapular Exanthema when treated with carbamazepine in people with Bipolar Disorder, Epilepsy, Neuralgia or Schizophrenia.	0.0
1183701224	1450376254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376254	29288229	HLA-A *31:01:02 is not associated with risk of Maculopapular Exanthema due to carbamazepine.	-1.5
1183701224	1450376262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376262	29288229	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema due to carbamazepine.	0.0
